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Abstract 
 
The newly described cytokine Interleukin (IL) 31 has been shown to be expressed by murine 
activated T lymphocytes of a Th2 phenotype. Like IL-17 and IL-22, IL-31 is a tissue signalling cytokine 
whose receptor is mainly found on non-immune cells. An over-abundance of IL-31has been 
demonstrated in atopic diseases of the skin and transgenic mice engineered to over-express IL-
31develop the symptoms of atopic dermatitis (AD) such as pruritus, inflammation and alopecia. 
Allergic asthma and rhinitis share characteristics of AD such as pruritus and Th2 cell driven 
inflammation but the role IL-31 may play in these diseases is unknown. 
The aim of this thesis was threefold; firstly to investigate whether IL-31 is expressed in the airway 
and peripheral blood mononuclear cells (PBMC) derived from patients with allergic rhinitis. 
Secondly, this study explored the regulation of IL-31 expression from T-cells to understand the 
conditions under which IL-31 is expressed and investigate whether IL-31 is a Th2 cytokine like IL-4 
and IL-13. Finally we investigated the function of IL-31, with respect to its effect on normal human 
bronchial epithelial cells (NHBE). The influence of IL-31 on the gene expression of NHBE was 
comprehensively investigated with a single colour whole genome microarray.  
Basal IL-31 expression was higher in PBMC from atopic donors compared to healthy controls and 
very strongly up-regulated in response to allergen stimulation. IL-31 protein was also detected in 
skin and nasal biopsies by immunohistochemistry. IL-31 was expressed by Th2 T-cell clones and not 
by Th1, Th17 or Th22. This expression was dependent on autocrine IL-4 expression and even Th1 
clones were able to express IL-31 if IL-4 was added to culture. IL-31 alone had a marginal effect on 
the gene expression of NHBE but was found to act in synergy with Th2 cytokines to amplify the 
expression of pro-inflammatory chemokines and growth factors. Taken together, IL-31 appears to be 
a cytokine induced by allergen stimulation that can enhance and maintain allergic inflammation.  
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1 Introduction 
1.1 Allergy 
The term Allergy describes an inappropriate immune response to an innocuous environmental 
antigen (allergen). The archetypal allergic response is an IgE-mediated, type 1 hypersensitivity, 
potentially resulting  in tissue damage (Kay 2001). Allergic disease is highly prevalent in developed 
countries and is increasing (Bauchau and Durham 2004; Janson et al. 2001). There is a wide range of 
severity from mild seasonal allergic rhinitis to life threatening asthma and anaphylaxis. The reasons 
behind this increased prevalence are unclear. Genetic predisposition clearly plays a significant role in 
the risk of an individual developing allergic disease (Vercelli 2008), but evidence also suggests  a 
strong environmental component (Reidler J et al. 2001; von Mutius et al. 1998). It has been 
suggested that early life exposure to microbes and helminths may protect against the development 
of allergic disease (Strachan and Carey 1995); Yazdanbakhsh et al. 2002). Whether early life 
exposure - including in utero exposure - or avoidance of allergen is protective remains the subject of 
debate (Du Toit, Katz et al. 2008; Fox, Sasieni et al. 2009; Lodrup Carlsen, Roll et al. 2012) .  
 Allergens are usually commonly encountered water soluble proteins of about 10- 40 kDa such as 
grass and tree pollens, animal dander, insect venom, house dust mite faecal particles and various 
foods,  but may also include smaller, synthetic compounds, such as medicinal drugs, usually in the 
form of haptens (Kay 2001). The body becomes sensitised to allergens through the generation of 
immunoglobulin E (IgE) antibodies following exposure. Upon re-exposure to the specific allergen, IgE 
antibodies bound to the surface of immune cells are able to bind allergen and induce an immune 
response. The immediate allergic response is produced when allergen cross-links adjacent IgE 
molecules on the surface of mast cells and basophils, inducing degranulation and the release of 
inflammatory mediators.  The term atopy describes the tendency to develop allergen-specific IgE. 
This process of allergic sensitisation is required for the development of an allergic response; 
however it is possible to be sensitised to an allergen without mounting a response on natural 
exposure.  
Allergic disease can occur at any interface between the body and the environment such as skin, 
lungs, gut and nose; although symptoms may not be limited to the exposed organ, as is seen in 
systemic anaphylaxis. Depending on how often the allergen is encountered, the effects of an allergic 
reaction can resolve completely, e.g. after a wasp sting, or can cause more persistent changes, such 
as seen in allergen-induced non-specific bronchial hyperreactivity (Arshad, Hamilton et al. 1998). 
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Whether allergen exposure alone is sufficient to produce the irreversible airways remodelling seen 
in chronic asthma is unclear (Lloyd and Robinson 2007). 
1.1.1 Allergic Rhinitis 
Allergic rhinitis is a very common IgE mediated disorder in developed countries (ISAAC report(1998; 
Janson, Anto et al. 2001; Bauchau and Durham 2004). It occurs when an allergic individual is exposed 
to an aeroallergen such as grass pollen or cat dander via the nasal mucosa. The most recognisable 
presentation is that of  seasonal allergic rhinitis (hay fever), due to grass or tree pollen allergen 
exposure, with symptoms  including rhinorrhoea, sneezing, itching eyes and nose, nasal congestion 
and eye watering (Durham 1998). Symptoms generally occur within minutes of allergen exposure 
(the early phase response), but can persist or even recur (the late phase) for up to 24 hours 
afterwards. Symptoms can be seasonal, in line with pollen release, or perennial in the case of 
allergens such as house dust mite. Cross reactivities (e.g. apple with birch) may also cause allergic 
responses outside the pollen season. Although not life-threatening, severe allergic rhinitis 
significantly impairs quality of life, results in lost work or school days, and even impairs examination 
performance (Walker, Khan-Wasti et al. 2007). In addition, allergic rhinitis is often suffered in 
conjunction with asthma, conjunctivitis and rhinosinusitis (Bousquet, Khaltaev et al. 2008). 
1.1.2 Allergic Asthma 
Asthma is a chronic inflammatory disease of the airways. When severe and uncontrolled, the lungs 
may be progressively damaged resulting in airway remodelling such as increased smooth muscle, 
increased mucus producing cells, fibrosis and angiogenesis. Such changes are associated with 
significantly impaired lung function (Holgate 2007). Asthma is also characterised by airway 
hypersensitivity whereby low levels of airborne irritants, chemicals (e.g. histamine, methacholine) or 
even temperature changes can provoke acute bronchospasm. Such airways hypersensitivity may be 
the trigger for acute attacks of asthma. Viral infections have for some time been known to be 
important triggers for asthma exacerbations (Beasley, Coleman et al. 1988). Additional factors may 
include exercise, and allergen exposure. In fact, allergen exposure may have a synergistic effect with 
viral infection in causing exacerbations (Murray, Poletti et al. 2006), and acute allergen exposure 
may be a significant factor in severe asthma and asthma deaths (Roberts, Patel et al. 
2003);(Anagnostou, Harrison et al. 2012). Allergic asthma is strongly associated with allergic rhinitis. 
64% of asthma patients have allergic rhinitis and allergic rhinitis sufferers are at increased risk of 
developing asthma at a younger age (Eriksson, Bjerg et al. 2011). There are similarities between the 
diseases such as eosinophilia and mucus hypersecretion. The acute symptoms of both diseases are 
frequently treated with symptomatic, ‘reliever’ medication – anti-histamines in the case of allergic 
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rhinitis, β2-agonists in asthma; but the underlying pathology in both cases is generally responsive to 
corticosteroids, reflecting the similar inflammatory processes.  
1.1.3 Allergen sensitisation 
In order to generate an acute allergic response, allergen exposure and sensitisation must have 
previously taken place. In the case of allergic rhinitis and allergic asthma, the allergen is inhaled and 
sticks to the moist surface of the nasal and lung epithelium. Dendritic cells sample the airway lumen 
with dendrites that pass between the cells of the epithelial monolayer (Jahnsen, Strickland et al. 
2006). They process antigens into peptides which are then presented on major histocompatibility 
complex (MHC) molecules at the cell surface. In certain contexts, allergen uptake may be 
accompanied by dendritic cell activation – including the expression of adhesion and co-stimulatory 
molecules – and migration to local lymph nodes, followed by presentation of allergen-MHC 
complexes to  naïve T-cells (Godthelp, Fokkens et al. 1996). T-cell recognition of allergen-MHC in an 
IL-4 rich microenvironment may then lead to the development of a Th2-type allergen-specific T-cell 
response. 
Defined by the expression of IL-4, IL-5 and IL-13, Th2 cells are the primary effector T-cell subtype in 
allergic disease (Del Prete, De Carli et al. 1991; Durham, Ying et al. 1992).Th2 cells may activate B-
cells by CD40 binding CD40L on B-cells and, via the expression of IL-4 and IL-13, can promote B cell 
germline immunoglobulin class switching to IgE (Coffman, Ohara et al. 1986). Following their release 
into the circulation by IgE-expressing plasma cells, allergen-specific IgE molecules may bind to innate 
immune cells including mast cells and basophils via the high affinity Fc receptor.  
 
1.1.4 The allergic response 
An allergic response has distinct phases that are driven by different cells. The immediate response, 
or early phase, occurs within minutes of allergen exposure; the late phase peaks a few hours after 
exposure and may lead to chronic inflammation in conditions of continuous or repeat allergen 
exposure (Galli, Tsai et al. 2008).  
1.1.4.1 Early phase response 
Following sensitisation, re-exposure to allergen may result in allergen-induced cross-linking, via IgE, 
of adjacent Fc-receptors on the surface of mast cells and basophils. This reaction is also known as 
Type I hypersensitivity according to the classification by Coombs and Gell (Coombs 1968). Within 
minutes, the activated Fc receptor signalling induces degranulation, a rapid release of inflammatory 
substances that had been stored pre-formed in granules in the cells. The most well known of these is 
histamine, a vasodilator and sensory nerve stimulant which helps produce the classic symptoms of 
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hayfever, including itch, sneezing, nasal congestion and rhinorrhoea, as well as the wheal and flare 
reaction observed in the skin following skin prick testing. Other mediators released by degranulation 
include leukotrienes and prostaglandins that also have an acute effect on the surrounding tissue 
such as smooth muscle contraction and mucus secretion (Drazen, Israel et al. 1999; Boyce 2007). 
Activated mast cells and basophils also secrete tryptase, a protease that can cleave the surface 
receptor PAR-2 on epithelial and endothelial cells leading to the expression of chemokines and 
adhesion molecules that attract a new wave of cells to the area (Holgate 1999).  
1.1.4.2 Late phase response 
Following the initial burst of activity induced by mast cell degranulation, approximately 6-12 hours 
later, the allergic reaction enters a second phase. Chemokines, cytokines and growth factors recruit 
and activate immune cells such as eosinphils, neutrophils and monocytes. Effector T-cells are also 
recruited which, in turn, recruit and activate further immune cells. The majority of inflammatory 
cells found in allergen challenged tissue are T-cells and eosinophils (Masuyama, Till et al. 1998).  The 
influx of cells and release of inflammatory mediators damages the epithelium as the infiltrating cells 
pass through. If the inflammation occurs regularly then the tissue becomes permanently damaged, 
each attempt to repair the epithelium producing fibrous scar tissue that remodels and impairs the 
structure and function of the tissue (Davies, Polosa et al. 1999).  
 
1.2 T-cells 
T-cells help provide the immune system with an antigen specific response. During T-cell 
development, the T-cell receptor (TCR) genes have the ability to recombine in an almost infinitesimal 
number of configurations producing a receptor that preferentially recognises one single peptide 
when presented by an MHC molecule.  T-cells originate in the bone marrow but develop in the 
thymus where they undergo a number of processes to ensure that only those cells with sufficient 
ability to recognise MHC complexes, but not those with high self-peptide-MHC recognition, survive. 
Upon entering the thymus sub-capsular region, the pre-thymic T-cells proliferate and enter the 
thymic cortex where the TCR genes rearrange. T-cells with newly expressed TCRs may adhere to 
MHC molecules on cortical epithelial cells. If the gene rearrangement has produced a molecule of 
sufficient affinity, binding will occur and the cell will be salvaged; failing this, the cell will undergo 
apoptosis. After this positive selection, the cells will upregulate the expression of the surface 
markers CD3, CD8 and CD4. The next stage of selection is to ensure that the TCR cannot bind self-
antigens. As the cells pass through the thymic cortex they pass interdigitating cells and macrophages 
that present self-antigens. T cells binding these antigens are also deleted, in a process known as 
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negative selection. Successful T-cells then migrate out of the cortex into the medulla where they lose 
the expression of either CD4 or CD8 (von Boehmer 1992; Love and Bhandoola 2011). These naïve T-
cells then migrate out to the periphery and await activation with their cognate antigen. It is possible 
for a self reactive T-cell to escape detection and pass through the thymus, however there are 
mechanisms to help remove or inactivate these cells in the periphery (Mueller 2010). These include 
induction of anergy - an inert state that results from TCR binding to antigen in the absence of co-
stimulatory molecules, activation induced cell death where repeated TCR signalling induces 
apoptosis, and active suppression by regulatory T-cells. The majority (~95%) of T-cells express a TCR 
consisting of an α and β subunit. The remaining T-cells express γδ TCRs, these rare cells play a role in 
microbe surveillance and are mainly found in the gut mucosa.  
αβ T-cells can be further differentiated into CD4 and CD8 T-cells based on the expression of these 
surface markers. CD8+ T-cells, also known as cytotoxic T-cells, are restricted to recognising only 
antigen peptides presented on class I MHC which are derived from the degradation of internal 
proteins such as those produced by viruses (Jensen 2007). CD4+ T-cells recognise only antigens 
bound to class II MHC which present peptides derived from external proteins endocytosed by the 
antigen presenting cell (Jensen 2007). CD4+ T-cells are also known as helper or effector T-cells 
because they can orchestrate a specific immune response by secreting cytokines to activate a 
number of different immune cells and by inducing B-cells to produce antibodies.  
1.2.1 Activation 
T-cells are activated only if a combination of receptors are simultaneously engaged to form an 
immune synapse between T-cell and antigen presenting cell (APC). The first binding event is 
between the TCR and MHC presenting the correct peptide on an APC such as a dendritic cell, B-cell 
or macrophage. A second binding event between co-stimulatory molecules then has to occur to 
prevent  T-cell anergy. The co-stimulation is usually mediated between CD28 on T-cells and B7 
proteins on APCs. Once activated, a T-cell will have more receptors that can act as co-stimulators, 
such as OX40 and ICOS, but CD28 is the only such molecule that is constitutively expressed on naïve 
T-cells. These regulatory steps help ensure T-cells are only activated by appropriate antigens and, in 
particular, not by self antigens (Germain and Stefanova 1999). 
In addition to the α and β subunits, the TCR also includes CD3 and CD28 proteins which aggregate 
when the immune synapse forms (Grakoui, Bromley et al. 1999). CD3 and CD28 then set off a chain 
of phosphorylation events that activate NFκB (nuclear factor kappa light chain activator of B-cells) 
and release calcium, activating calcineurin and then NFAT (nuclear factor of activated T-cells) (Oh-
hora 2009). NFAT and NFκB are transcription factor that translocate to the nucleus and promote the 
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expression of IL-2, a T-cell growth factor, and cell division (Naito, Tanaka et al. 2011). T-cells can be 
activated by molecules that mimic the clustering of the TCR subunits. In this thesis antibodies 
directed against CD3 and CD28 were used to induce efficient T-cell activation in the absence of an 
APC or the cognate antigen, in order to minimize multiple influences that can arise by the complex 
nature of dendritic cells and their multiple differentiation and activation levels. 
1.2.2 Differentiation 
Once activated, the naïve CD4+ T-cell proliferates and expands but secretes only IL-2, as an 
autologous growth factor. In order to act as an effector T-cell, the population of T-cells can polarise 
towards various phentotypes that secrete cytokines appropriate to the threat of the presented 
antigen. As a general rule, a fully differentiated T-cell constitutively expresses a particular set of 
cytokines and cannot switch between phenotypes or revert back to a naïve T-cell. The direction of T-
cell differentiation is driven initially by cytokines that are expressed by the antigen presenting cells in 
addition to other factors such as the site of antigen presentation, co-stimulatory molecules, peptide 
density and the genetic background (Tao, Constant et al. 1997; Sanders 2006; Sharpe 2009). 
Epigenetic changes occur during T-cell differentiation increasing the stability of each phenotype so 
that the gene expression of characteristic cytokines, transcription factors and other markers of each 
phenotype can be maintained. Chromatin remodelling occurs when an amino acid in a histone 
protein tail is post-translationally modified, often with a methyl or acetyl group. The altered shape of 
the histone can then either promote or inhibit gene expression depending on the change of 
interaction between the histone and DNA. Other mechanisms of epigenetic regulation include 
changes in DNA methylation and formation of DNase1 hypersensitive sites and differences in both of 
these have been observed in different T-cell phenotype (Gilmour and Lavender 2008).  
 CD8+ T-cells also develop into subtypes that secrete different cytokines, known as Tc1 and Tc2, but 
they both have a similar cytotoxic function (Sad, Marcotte et al. 1995). Once a T-cell has been 
activated it is no longer naïve and becomes a memory cell. Upon restimulation, the memory cell 
does not need to differentiate so can rapidly provide the appropriate effector response. 
There are around 5 different effector T-cell types that have been described so far, plus regulatory T-
cells. Th1 and Th2 cells were first described more than 20 years ago by Mossman et al and are the 
best described subsets of effector T-cells (Mosmann, Cherwinski et al. 1986). They can be thought of 
as being extremes on a scale whereas the more recent additions to the effector T-cell family Th17, 
Th22 and Th9, defined by the expression of IL-17, IL-22 and IL-9 respectively, have niche functions 
but can co-exist within an immune response. Chronic diseases can show bias to different T-cell 
phenotypes, for example psoriasis is generally dominated by Th1 cells (Lew, Bowcock et al. 2004) 
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whereas infiltrates of Th2 cells can be found in atopic dermatitis (Novak, Bieber et al. 2003) and 
allergic rhinitis (Durham, Ying et al. 1992).   
1.2.2.1 Th1 cells 
Th1 cells are characterised by the expression of IFNγ, in addition to TNFα, IL-12, TGFβ and IL-2. These 
cells provide the response required to clear intracellular bacterial and viral infection by activating 
macrophages, cytotoxic T-cells and promoting the expression of IgG2a opsonising and complement-
fixing antibodies (Finkelman, Holmes et al. 1990; Romagnani 2000). Th1 differentiation is driven by 
IL-12 derived from dendritic cells and macrophages during T-cell activation. IL-12 induces 
differentiation of T-cells that secrete IFNγ which in turn induces further IL-12 production by APCs 
and inhibits the production of non-Th1 cytokines such as IL-4 thereby promoting Th1 polarisation. 
Signal transducer and trans-activator 4 (Stat-4) is an important transcription factor for Th1 
development because it mediates IL-12 signalling, therefore an absence of stat-4 inhibits Th1 
differentiation (Thierfelder, van Deursen et al. 1996). Th1 cell differentiation is dependent on the 
transcription factor T-Bet which is strongly expressed by Th1 cells (Szabo, Kim et al. 2000). T-bet 
promotes Th1 polarisation by inducing IFNγ, inducing IL-12 receptorβ2 and inhibiting IL-4 
transcription (Mullen, High et al. 2001). T-bet-/- mice cannot develop Th1 cells and retroviral T-bet 
gene transduction can induce Th1 cytokines in fully differentiated Th2 cells, highlighting the potency 
of this gene (Szabo, Sullivan et al. 2002). T-bet also induces a transcription factor HLX which when 
co-expressed with T-bet acts synergistically with T-bet to amplify IFNγ expression (Mullen, Hutchins 
et al. 2002). T-bet can induce the transcription factor Runx3 which also acts synergistically with T-bet 
to promote maximal IFNγ expression but the combination of T-bet and Runx3 also silences the IL-4 
gene via histone modifications carried out by the enzyme lysine methyl transferase (KMT)6 (Djuretic, 
Levanon et al. 2007). 
1.2.2.2 Th2 cells 
Th2 cells promote a humoral (antibody mediated) response and evolved to neutralise extracellular 
immune challenges such as helminths, ticks and extracellular bacteria, but are also the cells that 
mediate allergic responses. They are characterised by the secretion of IL-4, IL-5, IL-9, IL-10 and IL-13 
which have multiple targets and result in the promotion of the IgE secretion, mucus cell 
differentiation, mast cell maturation, eosinophilia and inflammation observed in the allergic 
response (Figure 1.2.2.1). T-cell clones specific to the nematode Toxocara canis and purified protein 
derivative (PPD) of tuberculin were isolated from healthy donors (Del Prete, De Carli et al. 1991). The 
nematode specific T-cell clones were found to be nearly all Th2 phenotype with high expression of 
IL-4 in contrast to the PPD specific T-cells which were nearly all Th1, highlighting the influence that 
the antigen type has on T-cell effector phenotype. Allergen-specific Th2 cells produce much more IL-
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13 and IL-5 from allergic than non-allergic donors (Till, Durham et al. 1997).There is an up-regulation 
of Th2 cells in the broncho-alveolar lavage (BAL) fluid from atopic asthma patients compared with 
healthy controls (Robinson, Hamid et al. 1992). 
 
Figure 1.2.2.1The effects of Th2 cytokines 
Similar to Th1 cells, Th2 cells also have positive regulatory mechanisms to promote their own 
differentiation. IL-4 acts upon the cells to induce the Th2 roster of cytokines and also inhibits Th1 
cytokines such as IFNγ to prevent Th1, t-reg and Th17 differentiation. The source of IL-4 to initiate 
Th2 differentiation is attributed to dendritic cells (Hammad, Plantinga et al. 2010) and basophils 
(Sokol, Barton et al. 2008).  Stat-6 mediates IL-4 signalling and is essential for Th2 development 
(Kaplan, Schindler et al. 1996). The Th2 specific transcription factor Gata-3 is induced by IL-4 and 
promotes the differentiation of Th2 cells (Yamashita, Ukai-Tadenuma et al. 2004). Other 
transcription factors are important for Th2 differentiation, such as GFI-1 (Zhu, Jankovic et al. 2006) 
which is essential for Th2 expansion and Ikaros which also appears to promote Th2 lineage 
commitment, as Ikaros-/- T-cells cannot develop into Th2 cells (Quirion, Gregory et al. 2009).  
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1.2.2.3 Th17 cells 
In addition to Th1 and Th2 effector T-cells, 3 other subtypes have been identified and it is likely that 
there will be further T-cell subtypes described as more cytokines are discovered and multi-colour 
flow cytometry and other techniques are optimised.  
Th17 cells were characterised in 2005. They develop from naïve T-cells into a distinct phenotype that 
is characterised primarily by the strong expression of IL-17A and F (Harrington, Hatton et al. 2005; 
Stockinger and Veldhoen 2007) in addition to IL-21 and IL-22. Th17 cells are induced from naïve T-
cells by TGFβ and IL-6 and require IL-23 to maintain the population (Veldhoen, Hocking et al. 2006). 
The primary transcription factor for regulating Th17 differentiation is RORγt (Ivanov, McKenzie et al. 
2006), RORC2 in man, which can promote the expression of IL-17 in response to IL-6 and TGFβ. Th17 
cells induce neutrophilic inflammation and are thought to be important for clearance of extracellular 
bacteria (Ouyang, Kolls et al. 2008) as well as in the pathogenesis of autoimmune disorders such as 
rheumatoid arthritis (Nakae, Nambu et al. 2003). Th17 cells may also have a role in allergic airway 
inflammation as they have been found to be more frequent in the blood of patients with allergic 
rhinitis and allergic asthma than healthy controls (Ciprandi, Filaci et al. 2010) (Aujla and Alcorn 
2011). 
1.2.2.4 Th9 cells 
Th9 cells have been recently described and are characterised by a strong expression of IL-9 and IL-
10. Th9 cells develop from naïve T-cells or mature Th2 cells in response to IL-4 and TGF-β (Veldhoen, 
Uyttenhove et al. 2008). IL-9 acts on the epithelium to promote mucus secretion and also activates 
mast cells. Th9 cells may therefore be important in the pathogenesis of allergic airway disease 
(Durrant and Metzger 2010), as evidenced by the finding that IL-9 mRNA is up-regulated in allergic 
asthma compared to non-allergic controls (Erpenbeck, Hohlfeld et al. 2003). Whether Th9 cells are a 
fully distinct T-cell phenotype or a deviation from Th2 cells under artificial conditions requires 
clarification. 
1.2.2.5 Th22 cells 
Th22 cells are characterised by the sole expression of IL-22, a cytokine that acts only on non-
immune, structural cells. As mentioned previously, Th17 cells can also express IL-22, but Th22 cells 
are a separate IL-17- subset that express CCR10, a skin homing chemokine not found on Th17 cells 
(Duhen, Geiger et al. 2009). When infiltrating T-cells were cloned from various skin diseases, it was 
found that the proportion of the IL-17-  IL-22+ clones were enriched in inflammatory skin diseases 
such as psoriasis, atopic eczema and atopic dermatitis but were much more infrequent in peripheral 
blood (Eyerich, Eyerich et al. 2009). The role of these cells is unclear; Th22 supernatants can 
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promote epidermal wound healing but also induce chemokine expression from keratinocytes. Th22 
cells can be induced from naïve T-cells with IL-6 and TNFα (Duhen, Geiger et al. 2009; Trifari, Kaplan 
et al. 2009). The aryl hydrocarbon receptor (AHR) has been shown to be an important regulator of 
Th22 differentiation - treatment of naïve T-cells with AHR agonists induces IL-22 and inhibits IL-17 
production via a down-regulation of RORγt (Ramirez, Brembilla et al. 2010). AHR and IL-22 mRNA 
was found to be increased in allergic asthma compared to non-allergic asthma and healthy controls 
(Zhu, Cao et al. 2011). Th22 cells may be important for allergic airway inflammation as well as skin 
disorders. 
1.2.3 Regulatory T-cells 
Regulatory T-cells (T-reg) are CD4+ T-cells that suppress the actions of other immune cells such as T-
cells, B-cells, dendritic cells, macrophages and mast cells. During thymic selection of T-cells, effector 
T-cells are selected based on their weak or absent binding to self MHC and T-cells that bind strongly 
are deleted; T-regs develop following intermediate binding to self MHC (Hsieh, Lee et al. 2012). Due 
to natural variations in the thymic selection process cells with the same TCR may end up as effector 
T-cells or T-regs which allows for suppression of an antigen specific response. In order to suppress, T-
regs must be activated by a TCR signal in the same way that as effector T-cells. T-regs are 
characterised by expression of the transcription factor FoxP3 and surface expression ofCD25, the IL-2 
receptor, whilst not producing IL-2 themselves. The mechanisms by which T-reg suppress the 
immune response are not fully understood. They include the expression of the immunosuppressive 
cytokines TGFβ and IL-10 and competition with effector T-cells for IL-2. Direct contact between T-
regs and target cells can result in cytolysis similar to that performed by CD8+ cytotoxic T-cells. T-regs 
may express surface markers that down-regulate effector T-cell activation such as galectin-1 or 
molecules which modify APC function, causing them to inhibit T cell activation, such as CTLA-4 
(Shevach 2009). The balance of T-regs to effector T-cells is very important; an excess of T-regs can 
permit cancers or viral infections by suppressing the immune response, but a diminished T-reg 
compartment may potentiate harmful inflammatory, autoimmune and allergic processes. When 
allergic and non-allergic donors were compared, there was a marked decrease in allergen-specific T-
regs amongst the allergics (Akdis, Verhagen et al. 2004). 
1.2.4 Follicular T-helper cells 
Follicular T-cells (Tfh) are a newly recognised T-cell subset and are induced by, and produce, IL-6 and 
IL-21. They have the specific function of promoting antibody production from B-cells and are 
characterised by the expression of CXCR5, a chemokine that homes these cells to B-cell follicles 
(Schaerli, Willimann et al. 2000). The transcription factor BCL-6 is essential for Tfh development. 
However, the fact that they can express IL-4, IL-17 and IFNγ raises the question of whether Tfh cells 
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develop from naïve T-cells or are converted from existing Th2, Th17 or Th1 cells (Yu, Batten et al. 
2009). The role Tfh cells play in allergy is unclear as the effect they have on IgE production is not 
consistent between mice and humans. However, IL-21 has been shown to induce IgE from human B-
cells (Kobayashi, Haruo et al. 2009) so Tfh cells may promote allergic responses via increased IgE 
production. 
1.2.5 T-cell plasticity 
As more T-cell phenotypes have been discovered there has been an assumption common to all of 
them - that once differentiated, these phenotypes are fixed and cannot de-differentiate to a naïve T-
cell or convert into another T-cell phenotype. For Th1 and Th2 cells this is likely to be the case, 
because the cytokines that induce one inhibit the development of the other. However, Th17, Th22 
and Th9 cells have shared cytokine expression and can be induced by some of the same factors so 
the possibility of interconversion seems more plausible. Epigenetic studies revealed less epigenetic 
silencing of the Th1 and Th2 specific transcription factors T-bet and Gata3 in the opposite T-cell type 
than predicted (Wei, Wei et al. 2009) suggesting that these phenotypes may not be as fixed as 
previously assumed. A number of studies have demonstrated that certain T-cells can change 
phenotype, but this is not a universal property. Th17 cells can convert into Th1 cells in the presence 
of IL-12 and IL-23 but not vice versa (Lee, Turner et al. 2009) and Th2 cells can convert to Th9 in the 
presence of TGFβ (Veldhoen, Uyttenhove et al. 2008). As mentioned previously, Tfh cells are possibly 
derived from any T-cell, including T-regs. They then retain the cytokine expression of their original 
cell type whilst gaining B-cell follicle localisation via CXCR5 expression, allowing the promotion of a 
particular antibody sub-type (Zaretsky, Taylor et al. 2009). T-reg cells have been shown to lose FoxP3 
expression and convert into pro-inflammatory Th1 cells (Zhou, Bailey-Bucktrout et al. 2009). These 
examples all demonstrate that T-cell phenotypes are more flexible than previously thought and 
shows that the immune system can develop effector T-cells for any situation. However, this also 
means that pharmaceutical neutralisation of single cytokines may not simply inhibit certain T-cells, 
but rather promote their conversion to alternative subtypes.  
1.3 Lung epithelium 
The lung epithelium is a contact point between our body and the environment. In order to optimise 
gas exchange, the bronchial and alveolar epithelium also has an enormous surface area which may 
also increase the chance of an allergen sticking to the mucosa and binding to surface IgE. The 
epithelium is one cell thick and consists mainly of ciliated columnar cells, mucus producing goblet 
cells, and basal cells that can differentiate into other cell types and are important for repair after 
injury. In the throat, the airway epithelium is subject to abrasion from swallowing food and the 
epithelial surface consists of continually renewing flat squamous cells that can slough off without 
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damaging the integrity of the epithelial barrier. Each cell in the epithelium is attached to its 
neighbour, and to the basement membrane immediately below, by cell junctions such as tight 
junctions, desmosomes, adherens junctions and gap junctions, and also via cytoskeletal components 
such as actin and keratin filaments (Green and Jones 1996; Matter and Balda 2007) providing 
strength to the sheet of cells.  
1.3.1 Airway epithelium in allergic disease 
1.3.1.1 The airway epithelium provides a barrier against allergens 
The continuous sheet of epithelial cells provides an effective barrier with most allergens becoming 
trapped in mucus and swept up out of the lungs by the beating ciliated cells. Therefore most 
allergens do not make it below the epithelium surface where the tissue resident immune cells can be 
found and potentially sensitised. Dendritic cells can sample the airway by protruding dendrites 
between the epithelial cells, expressing tight junction proteins in order to maintain the epithelial 
barrier integrity (Sung, Fu et al. 2006), before migrating to the lymph nodes to present antigen to T-
cells (Vermaelen, Carro-Muino et al. 2001). This process is naturally restricted by the epithelium. If 
the barrier is compromised in some way then the amount of allergen being detected by dendritic 
cells is markedly increased, allowing increased allergen sensitisation, activation of allergen-specific T-
cells and activation of mast cells via IgE Fc crosslinking. Indeed, null mutations in the filaggrin gene 
have been  linked with an increased risk and severity of atopic asthma  (Palmer, Ismail et al. 2007) 
(Henderson, Northstone et al. 2008; Weidinger, O'Sullivan et al. 2008) in addition to atopic 
dermatitis (Palmer, Irvine et al. 2006). Filaggrin is a key protein component of epithelial tight 
junctions. Null mutations in other genes involved with tight junctions or maintaining the epithelial 
barrier such as SPINK5 have also been linked with an increased risk of developing asthma and allergic 
skin disorders (Cookson 2004). It is rare for the epithelium deep in the lungs to be physically injured 
but it is vulnerable to enzymatic damage. Many allergens are thought to be allergenic because they 
have an intrinsic protease activity, such as house dust mite, many pollens and fungi (Matsumura 
2012), which degrades the contacts between epithelial cells allowing passage of allergens through to 
the immune cells. Proteases also cleave receptors on epithelial cells such as PAR-2 (protease 
activated receptor 2) which trigger a number of responses including promoting the secretion of TSLP 
(thymic stromal lymphopoietin, a Th2 promoting cytokine that acts on DCs), MMP9 (matrix 
metallopeptidase 9, a metalloprotease that can degrade tight junctions) and the pro-inflammatory 
cytokines IL-6 and IL-8 (Page, Strunk et al. 2003; Page, Hughes et al. 2005; Page, Hughes et al. 2006; 
Yu, Angkasekwinai et al. 2010). Such mechanisms may help provide the danger signal that leads to 
sensitisation to an antigen without intrinsic protease activity.  Mice exposed to intranasal ovalbumin 
(OVA) alone did not develop allergy, but when combined with a PAR-2 agonist developed allergic 
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sensitisation and responded to subsequent challenges with OVA by developing airway inflammation 
and hyperresponsiveness (Ebeling, Lam et al. 2007).   
1.3.1.2 Airway epithelium and innate immunity 
The epithelial surface is far from just being a physical barrier to the environment. There is evidence 
that the epithelium can influence every aspect of the immune response via the secretion of 
chemokines, growth factors, cytokines and anti-microbial products. Pathogen recognition receptors 
such as toll like receptors (TLR), nucleotide-binding oligomerisation domain (NOD)-like (NLR) family 
receptors, helicases and double stranded RNA binding kinase are expressed on the lumenal surface 
of the airways and can detect bacterial and viral products and induce a host defence response (Bals 
and Hiemstra 2004). Once activated, the epithelium can secrete anti-microbial substances such as β-
defensin, lysozyme and lactoferrin in addition to pro-inflammatory chemotactic mediators that 
attract phagocytes such as LL-37/CAP-18 and leukotrienes (Schleimer, Kato et al. 2007). 
Inflammatory cytokines such as IL-1 and TNFα and various TLR ligands induce airway epithelium to 
produce TSLP (Thymic Stromal lymphopoeitin) which can then activate mast cells to produce Th2 
cytokines such as IL-4 and IL-13, thus amplifying allergic inflammation (Allakhverdi, Comeau et al. 
2007).   
1.3.1.3 Airway epithelium and dendritic cells 
The epithelium can also direct the adaptive immune response via interactions with dendritic cells 
(DC), T-cells and other leukocytes. The direction of T-cell differentiation is driven, in part, by the co-
stimulation and cytokine expression patterns from DCs that occur alongside antigen presentation. 
TSLP is an epithelial derived cytokine that is induced by TLR-3 activation, double stranded viral RNA, 
and Th2 cytokines (Kato, Favoreto et al. 2007). It acts upon DCs to promote Th2 differentiation. 
Epithelial cell expression of type I interferons (IFNα and IFNβ) may act upon DCs to skew T-cell 
polarisation towards Th1 (Takaoka, Hayakawa et al. 2003; Santini, Lapenta et al. 2011). 
1.3.1.4 Airway epithelium and T-cells 
The epithelium can interact directly with T-cells by secreting chemokines to attract particular 
phenotypes of helper T-cells, generally in response to cytokines expressed by these T-cells, and 
acting to amplify the response. For example IFNγ from Th1 cells can induce the release of CXCL10 
and CXCL9 from epithelial cells which in turn attract more Th1 cells; whereas IL-4 and IL-13 from Th2 
cells can induce the chemokines CCL22 and CCL17 which attract further Th2 cells (Nickel, Beck et al. 
1999). Th17 cells require the epithelium to elicit their effects, with IL-17 acting on the epithelial cells 
inducing the chemokines IL-8 and CXCL1 which attract neutrophils (Laan, Cui et al. 1999). The 
epithelium is also able to express TGFβ, IL-33 and IL-6 which can help promote the differentiation of 
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T-regs, Th2 cells and Th9 or Th17 cells. Bronchial epithelial cells express MHC-II (Romaniuk, Prop et 
al. 1987) the co-stimulatory molecules B7-H2 (Kurosawa, Myers et al. 2003) and CD40 which can 
promote T-cell activation (Propst, Denson et al. 2000) in the absence of professional antigen 
presenting cells.  
1.3.1.4.1 Chemokines 
Chemokines and chemokine receptors, in addition to adhesion molecules, are the means by which 
immune cells are attracted to and migrate to different areas of the body. Chemokines are generally 
expressed by tissue cells and induce circulating cells with the cognate chemokine receptor to leave 
the bloodstream and enter tissue. The late phase allergic response is mediated by chemokines 
released by mast cells and epithelial cells that attract T-cells and eosinophils to the site of allergen 
exposure. Some chemokines promote homeostasis, controlling normal cell migration as part of 
tissue maintenance and immune surveillance, but others play an important role in the inflammatory 
response. 
 Chemokines are small proteins and are classified by the position of the first two cysteine residues 
into C, CC, CXC and CX3C type chemokines. The receptor for each chemokine has the same 
nomenclature but with the postfix R in place of L, e.g. CCR2 is the receptor for chemokine CCL 
(ligand) 2. Chemokine receptors can often bind more than one chemokine allowing for redundancy 
in the system.  
The various T-cell phenotypes are associated with the expression of different chemokine receptors, 
allowing the recruitment of specific cell types during immune responses. Th1 cells are associated 
with the expression of CXCR3 and CCR5; whereas CCR3, CCR4, CCR8 and CrTh2 are preferentially 
found on Th2 cells (Bonecchi, Bianchi et al. 1998; Sallusto, Lenig et al. 1998; Nagata, Hirai et al. 
1999). Th17 cells have up-regulated CCR6 expression (Acosta-Rodriguez, Rivino et al. 2007), Th22 
cells express CCR10 (Eyerich, Eyerich et al. 2009) and Tfh cells express CXCR5 (Fazilleau, Mark et al. 
2009). The differential expression of these receptors also reflects the different locations that the 
cells home to, e.g. CCR10 is found on skin homing cells and CXCR5 will draw cells to B-cell follicles. 
Lung homing markers include CCR4 and CCR8 (Panina-Bordignon, Papi et al. 2001) and gut homing 
cells often express CCR9 (Wurbel, Philippe et al. 2000). 
In addition to  chemokine and chemokine receptor interactions, migration of circulating cells to 
tissues relies on the up-regulation of adhesion molecules on vascular endothelium. Circulating 
immune cells bind, roll, and undergo extravasation through the endothelium, via interaction with 
these adhesion molecules.. Inflammatory cytokines such as IFNγ and TNFα up-regulate intercellular 
adhesion molecule-1 (ICAM-1) on endothelial and epithelial cells, allowing binding to LFA-1 on 
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leucocytes and MAC-1 on macrophages (Subauste, Choi et al. 2001). Studies have found up-
regulated ICAM-1 levels in the lungs of allergic asthma compared to non-allergic asthma and healthy 
controls and that these level correlate with the numbers of infiltrating eosinophils and T-cells 
(Gosset, Tillie-Leblond et al. 1995). 
1.3.1.5 Airway epithelium and B-cells 
B-cell activity is also facilitated by the epithelium. Expression of BAFF (B-cell activating factor) and 
APRIL (a proliferation-inducing ligand) - members of the TNF family - is induced by TLR3 signalling 
(dsRNA) in airway epithelium and promotes the proliferation and antibody production of B-cells 
(Kato, Truong-Tran et al. 2006). These factors also promote class switch recombination from IgM to 
IgE and IgA. The epithelium has the ability to transport both IgE (Li, Nowak-Wegrzyn et al. 2006) and 
IgA (Goodman, Link et al. 1981) from the airway lumen across to the sub-epithelial tissue where it 
can bind Fc receptors, as well as in the opposite direction, secreting antibody into the airway lumen.  
 
1.4 IL-31 
IL-31 is a recently described cytokine and was identified as a result of a genomic screen for 
sequences with similarity to type I cytokine receptors (Dillon, Sprecher et al. 2004). These receptors 
are grouped together because they share a common WSXWS motif near the C-terminal end and 4 
conserved cysteines in the N-terminal segment (Boulay, O'Shea et al. 2003). The cytokines they bind 
are nearly all pro-inflammatory or growth factors for other immune cells, such as the interferons, 
interleukins 2-15,G-CSF and GM-CSF. The aim of the study was to identify further members of this 
receptor family and identify new pro-inflammatory factors that could be potential drug targets. The 
screen identified 4 splice variants of a previously unknown type I receptor - part of a sub family of 
gp130-like chains which includes leukemia inhibitory factor receptor (LIFR), oncostatin M receptor 
(OSMR), IL-12 receptor β and IL-23 receptor - which was subsequently named IL-31 receptor alpha. 
IL-31 was then identified using a cell line transduced with IL-31RA and OSMR which would 
proliferate in response to receptor signalling. Type I cytokine receptors are only active as 
heterodimers and OSMR is the only subunit that would function with IL-31RA.  This cell line was 
found to proliferate in response to supernatants from activated T-cells and IL-31 was eventually 
identified from high throughput screening with supernatants from a T-cell cDNA library. IL-31 is part 
of a cytokine family known as short chain four α-helical bundle cytokines that includes IL-2, -4, -5, -
13, G-CSF and GM-CSF, all of which, except G-CSF, are  expressed by Th2 cells. IL-31 receptor 
signalling utilised the transcription factors STAT3 and, to a lesser extent, STAT5, which are both 
34 
 
important for promoting cytokine expression and proliferation of T-cells, particularly Th17 cells 
(Grimley, Dong et al. 1999; Yang, Panopoulos et al. 2007). 
 A screen of human tissue mRNA libraries found IL-31 to be specifically up-regulated in activated 
CD4+ T-cells and enhanced in mouse T-cells that had been polarised towards Th2 for 4 days (Dillon, 
Sprecher et al. 2004). A similar screen for IL-31RA demonstrated an up-regulation in human skin, 
thymus and testis; in mice IL-31RA was up-regulated in skin and testis derived tissue. IL-31RA 
expression was minimal amongst most immune cells but found to be up-regulated in monocytes that 
had been treated with IFNγ and LPS. The initial study by Dillon et al also generated transgenic mice 
that overexpressed IL-31, both in a systemic and a lymphocyte specific manner, utilising the 
promoters for EF1-a and Eµ-Lck respectively. Both types of mice developed dermal disorders such as 
alopecia, pruritus and skin lesions that looked identical to atopic dermatitis (AD), as did mice 
receiving subcutaneous IL-31 via an osmotic pump or daily subcutaneous injections (Dillon, Sprecher 
et al. 2004). In particular, IL-31 induced severe pruritus causing the mice to scratch until they broke 
the skin. Pruritus is attributed partly to histamine, tryptase and other mast cell derived factors 
(Stander and Steinhoff 2002) and indeed, the transgenic mice exhibited increased levels of mast cells 
upon histological examination,  suggesting a link between IL-31 and mast cells. Of note, pruritus 
remains an uncontrolled phenotype of allergic disease and its therapy an unmet clinical need. In 
addition to the skin symptoms, mice treated with IL-31 had peripheral lymphadenopathy of2-5 times 
the size of non-transgenic littermate controls and showed an increased proportion of activated and 
memory T-cells relative to B-cells. The mice did not show inflammation or damage in any other 
organ. In contrast to usual atopic dermatitis animal models, IL-31 transgenic mice had low or normal 
levels of IgE, suggesting that IL-31 can act independently of IgE to induce alopecia and pruritus.  
Together, these data suggested that IL-31 is a T-cell cytokine that acts on the skin. 
 
1.4.1 Expression of IL-31 
The original Dillon paper suggested that IL-31 was expressed by activated T-cells, particularly those 
of the CD45RO+ memory subset, but there have been few papers which further characterise IL-31 
producing cells. Current literature has focussed on T-cells but one study has identified IL-31 
expression from mast cells treated with β-defensins and cathelicidin LL-37, both anti microbial 
agents expressed by epithelium that can induce mast cell degranulation (Niyonsaba, Ushio et al. 
2010). Although not confirmed by any other group, this result expanded the potential role for IL-31 
into innate immunity and further highlights IL-31 as a pruritic agent. 
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The lack of literature on IL-31 producing cells may have been due, in part, to a lack of commercially 
available antibodies optimised for flow cytometry or immunohistochemistry. There have been plenty 
of studies comparing IL-31 mRNA levels in tissue by RT-PCR between different diseases but these 
cannot reveal the source of IL-31. However, a study circumvented this problem by isolating subsets 
of T-cells from donors and then measuring IL-31 by RT-PCR, ELISA and western blot (Bilsborough, 
Leung et al. 2006). This study compared the expression of IL-31 protein from memory and naïve T-
cells isolated from the peripheral blood of healthy donors and confirmed that memory T-cells 
express higher levels of IL-31. They then compared IL-31 protein expression by western blot of 
lysates derived from  epidermis or epidermal infiltrate of patients with AD or healthy controls and 
found IL-31 to be absent in healthy patients. T-cells with the skin homing marker CLA (cutaneous 
lymphocyte antigen) were then isolated from the peripheral blood of patients with AD, psoriasis or 
healthy controls. Again, IL-31 was up-regulated in the atopic condition. CLA is only expressed by 
memory T-cells so these data confirmed the link between IL-31 and memory T-cells. They also 
highlight the importance of IL-31 in skin disorders, particularly as CLA negative memory T-cells had 
much reduced levels of IL-31 expression. The differential expression of IL-31 from atopic dermatitis 
and psoriasis is significant and suggests that IL-31 could be important for Th2 mediated allergic 
inflammation and pruritus – both features absent from psoriasis.  
A genetic haplotype of IL-31 that results in a 3.8 fold enhancement in IL-31 expression has been 
identified as over-represented in patients with eczema (Schulz, Marenholz et al. 2007). Although the 
presence of IL-31 appears to be associated with Th2 cell-dominant disease, there is no information 
on the effect of an absence of IL-31 as, currently, no IL-31 knockout mice are available.  
Of note, IL-31 has also been found in the tissue from the inflamed lesions of ulcerative colitis and 
Crohns disease at higher levels than non-inflamed tissue and healthy donors (Dambacher, Beigel et 
al. 2007), suggesting a role in other, non-allergic, inflammatory diseases  
Investigations into the factors that induce IL-31 expression from T-cells have been similarly sparse, 
especially for human cells. Dillon and colleagues were able to demonstrate enhanced IL-31 from 
mouse T-cells stimulated under Th2 skewing conditions (IL-4 and anti-IL12), but did not show parallel 
results from human T-cells. A study has shown IL-31 to be strongly up-regulated by the superantigen 
staphylococcus enterotoxin B (SEB) in the PBMC from healthy and, to a greater extent, from AD 
patients (Sonkoly, Muller et al. 2006).  Although the total expression was less, there was a similar 
difference in IL-31 mRNA expression from atopic and healthy donors stimulated by anti-CD3 implying 
that there are increased numbers of IL-31 positive T-cells in AD. Interestingly, this study was unable 
to detect IL-31 in PBMC cultures stimulated with IL-4, in contrast with murine data. Another study 
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linking IL-31 expression with allergy was able to demonstrate IL-31 mRNA upregulation in human 
Th2 cells in response to histamine via the newly described histamine H4 receptor (Gutzmer, 
Mommert et al. 2009). IL-31 could even be induced by sunburn: a study has demonstrated UVB 
treatment of PBMC from healthy donors can upregulate IL-31 mRNA expression from T-cells, B-cells, 
macrophages and mature dendritic cells (Cornelissen, Brans et al. 2011). Hydrogen peroxide reactive 
oxygen species were also found to be potent inducers of IL-31. 
1.4.2 IL-31 and allergy 
The AD-like phenotype exhibited by IL-31 transgenic mice led to the hypothesis that IL-31 was 
involved in allergic inflammation- at least in the skin. Analysis of human skin biopsy specimens 
showed increased levels of IL-31 mRNA in Th2 driven allergic dermatitis and allergic contact 
dermatitis but not Th1 dominant psoriasis (Neis, Peters et al. 2006). The level of IL-31 in these 
biopsies correlated with IL-4 mRNA expression, underlining the association with Th2 cells, but did 
not correlate with IgE serum levels or severity of disease. Subsequently, IL-31 has also been found to 
be up-regulated in other allergic diseases. For example, serum IL-31 was detected in significantly 
higher levels in allergic asthma patients when compared to non-allergic asthma, COPD or healthy 
controls (Lei, Liu et al. 2008). The role IL-31 may play in airway allergy is being investigated. A study 
of patients with Japanese cedar/cypress pollinosis (JCCP) found that JCC extract could strongly 
stimulate IL-31 expression from the PBMC from JCCP donors compared to healthy non-allergic 
donors (Okano, Fujiwara et al. 2011). Not all the JCCP donors expressed IL-31 but there was a clear 
increase in severity of AR symptoms observed from the patients that were positive for IL-31 
compared to the IL-31 low/negative JCCP donors. In addition, the levels of IL-31 decreased 
significantly in patients who had undergone allergen-specific immunotherapy (SIT). This study 
highlighted not only that IL-31 is up-regulated in AR, but that it is contributing to disease severity 
and may be expressed by allergen-specific effector T-cells. SIT has multiple effects but a shift in the 
ratio of Th2 towards Th1 cells (Durham, Ying et al. 1996) could explain the reduction in IL-31 
expression. SIT also increases the number of regulatory T-cells (Verhoef, Alexander et al. 2005) – the 
JCCP study suggests that IL-31 may be a target of T-reg inhibition. 
A recent study has been able to detect IL-31 in the nasal secretions derived from AR patients that 
have undergone an inhaled allergen challenge (Baumann, Rabaszowski et al. 2012). Although the 
study did not include healthy controls, they were able to demonstrate a positive correlation with 
disease severity indicating a pro-inflammatory role for IL-31. Increased IL-31 also correlated with IL-
13 expression. A time course measuring IL-31 at 2, 5 and 24 hours showed IL-31 secretion peaked at 
5 hours post provocation. This indicates that IL-31 is principally expressed as part of the late-phase 
response, rather than during early phase mast cell degranulation. This study also found that IL-31 
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expression was localised to the site of allergen challenge with IL-31 undetectable in the serum or the 
contralateral, unchallenged nostril. Although not extensive, the literature strongly suggests that IL-
31 has a role to play in allergic airway disease. 
1.4.3 IL-31 receptor 
The IL-31 receptor is a heterodimeric membrane bound complex comprising IL-31 receptor alpha (IL-
31RA) subunit and Oncostatin M receptor beta chain (OSMRβ) subunit (Dillon, Sprecher et al. 2004). 
As mentioned earlier, the receptor was discovered as a result of screening genomic databases for 
putuative receptors in the type I cytokine receptor family. Although the Dillon group went on to 
identify IL-31 itself, the receptor was actually discovered independently by three groups (Ghilardi, Li 
et al. 2002; Dillon, Sprecher et al. 2004; Diveu, Lak-Hal et al. 2004), and was additionally known as 
GLM-R (gp130 like monocyte receptor) and GPL (gp130 like receptor). GP130, also known as 
glycoprotein 130, is a common receptor component in the IL-6 cytokine family. IL-31RA shares 28% 
amino acids homology with gp130, but lacks the Ig-like domain present at the N terminal (Zhang, 
Putheti et al. 2008). 
1.4.3.1 Expression of the IL-31 receptor 
OSMR is a common subunit of many receptor complexes and so is found in high levels in many 
tissues, whereas IL-31RA expression is more selective. Constitutive expression of IL-31RA mRNA is 
found in human skin, testis and thymus, in smaller amounts in brain, bone marrow and trachea and 
abundantly in dorsal root ganglia (Sonkoly, Muller et al. 2006). Immune cells can express IL-31RA but 
generally require particular conditions to upregulate IL-31RA expression.  Expression in peripheral 
blood monocytes was undetectable in fresh cells but those cultured with IFNγ showed a substantial 
increase in IL-31RA (Dillon, Sprecher et al. 2004). Similarly, IFNγ can upregulate IL-31RA expression in 
human dermal microvascular endothelial cells (Feld, Shpacovitch et al. 2010) and  CD1c+ dendritic 
cells (Horejs-Hoeck, Schwarz et al. 2012).  
The abundance of IL-31RA varies in disease settings, with increased levels being detected in AD 
lesion biopsies (Neis, Peters et al. 2006) in comparison to healthy and psoriatic plaques. IL-31RA 
mRNA was increased in murine lung cell isolates enriched for epithelial cells 24 hours post intranasal 
OVA challenge compared with PBS challenge (Dillon, Sprecher et al. 2004). This suggests that IL-31RA 
is up-regulated in tissues at the sites of allergic inflammation. These observations suggest an 
enhanced responsiveness to IL-31 via an augmented expression of IL-31RA. 
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1.4.3.2 IL-31 signalling 
Within the cytoplasmic domain of the IL-31 receptor is a box motif that can associate with tyrosine 
kinases of the JAK (Janus Kinase) family and tyrosines that can associate with signalling molecules 
that have a corresponding SH2 domain. These suggest that IL-31 receptor signalling utilises the 
JAK/STAT signalling pathways and indeed, activation of this complex by IL-31 in normal human 
epidermal keratinocytes (NHEK) leads to activation of a number of transcriptional activators such as 
STAT1, STAT3 and STAT5. These are linked to the expression of chemokines such as CXCL1, CCL17, 
CCL19, CCL22, CCL23, CCL4 and I-309, suggesting a role for IL-31 in recruiting neutrophils, monocytes 
and T-cells to sites of inflammation (Dillon, Sprecher et al. 2004). 
Further studies have shown that IL-31 can also activate the MAPK and PI3K/AKT signalling pathways 
which are important for stimulating proliferation and inhibiting apoptosis (Fukada, Hibi et al. 1996). 
IL-31RA and OSMR cannot promote MAPK phosphorylation in isolation but can when in a 
heterodimer (Diveu, Lak-Hal et al. 2004). However, this signal is transduced by the OSMR, with IL-
31RA required only for binding IL-31 and recruiting OSMR (Dreuw, Radtke et al. 2004). 
An IL-31RA knockout mouse has been generated to investigate the relative roles of IL-31RA and 
OSMR (Bilsborough, Mudri et al. 2010). These mice are healthy but exhibit an enhanced response to 
allergen challenge with much greater lung cell infiltrate and cytokine production than wild-type 
littermate controls. This surprising result suggests that IL-31 signalling is involved in the suppression 
of lung inflammation. There was a contrast between the cellular compositions of the lung infiltrates, 
with IL-31RA KO infiltrates being neutrophil and lymphocyte predominant, and WT infiltrates 
consisting mainly of eosinophils, as expected for an allergic inflammation model. When lung 
infiltrates were collected from mice prior to allergen sensitisation high levels of neutrophils and 
lymphocytes were already present in the naïve KO mice. This observation was explained by the lack 
of IL-31RA freeing up OSMR subunits to form heterodimers with gp130, the receptor complex for 
oncostatin M thus rendering the mice more sensitive to OSM. The exact function of OSM is not clear 
but it promotes the expression of vascular endothelial growth factor (VEGF) and IL-6 which are both 
pro-inflammatory. Therefore this study showed that IL-31RA is important for promoting an 
eosinophilic allergic response, and its absence promotes a marked OSM-mediated neutrophilic 
response. 
1.4.4 Function of IL-31 
The precise role of IL-31 remains unclear. The presence of IL-31 at sites of allergic inflammation 
certainly suggests that it plays a pro-inflammatory role. Conversely, its presence may reflect a role in 
suppression and regulation of inflammation. Recombinant IL-31 can promote the expression of 
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epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) in a bronchial epithelial 
cell line, BEAS-2B. These growth factors stimulate the proliferation of epithelial and endothelial cells 
respectively, mechanisms that are vital for airway remodelling (Ip, Wong et al. 2007).  
IL-31 has been shown to interfere with keratinocyte differentiation resulting in reduced epidermal 
thickness and disturbed epidermal patterning in 3D in vitro skin cultures (Cornelissen, Marquardt et 
al. 2012). This was due in part to IL-31 inducing IL-20 and IL-24 from the keratinocytes which in turn 
inhibited the expression of filaggrin. As mentioned earlier, filaggrin null mutations are associated 
with impairment of the skin barrier and an increased risk of allergy. IL-31 also had an effect on the 
proliferation and differentiation of keratinocytes which resulted in their failure to reach terminal 
differentiation. This study would support IL-31 being a factor that promotes chronic skin disease by 
inhibiting the correct development of the renewing epidermis. IL-31 might be induced by allergic 
inflammation and then prevent skin healing, leaving the dermal tissues exposed to further microbes 
and allergens. 
An alternative mechanism for IL-31 promoting allergic skin disease was proposed by Wong and 
colleagues who found that IL-31 can influence the interaction between eosinophils and dermal 
fibroblasts (Wong, Leung et al. 2012). When eosinophils and fibroblasts were co-cultured the 
fibroblasts released pro-inflammatory chemokines, CCL2, CXCL10 and CCL5. When IL-31 and the Th2 
driving cytokine IL-33 were added to the co-culture, the expression of chemokines, cytokines and 
adhesion molecule ICAM-1 were significantly up-regulated in addition to the secretion of CXCL1 and 
CXCL8. These chemokines attract a variety of immune cells including neutrophils, basophils, 
monocytes, activated T-cells and eosinophils which would therefore prolong and amplify the 
inflammation of the late phase allergic response. Dendritic cells can also respond to IL-31 to produce 
TNFα, IL-6, CXCL8, CCL2, CCL5 and CCL22 which would also drive chronic inflammation (Horejs-
Hoeck, Schwarz et al. 2012). 
A characteristic of IL-31 expression is its association with pruritus. This symptom of many skin 
diseases is often the means by which patients measure the severity of their disease and impairment 
of quality of life. The mechanism by which IL-31 promotes pruritus is unclear. The fact that sensory 
nerve endings  express the IL-31 receptor may prove to be significant and a means by which IL-31 
can exert this effect. The physical act of scratching the skin can cause mast cells to degranulate, 
which release mediators such as histamine to further stimulate the nerves and induce pruritus. 
However, histamine is not thought to be the primary pruritic agent in AD (Wahlgren 1991), instead 
IL-31 may prove to be the key pruritic factor. IL-31 could even have a role in airway hyperreactivity in 
asthma by stimulating nerve endings directly. 
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Despite stimulating epithelial cells to secrete cytokines, chemokines and growth factors, IL-31 
appears to inhibit their proliferation by prompting G0 arrest (Chattopadhyay, Tracy et al. 2007). In 
addition, an IL-31RA-/- mouse was found to have exacerbated lung inflammation in response to 
infection with Schistosoma mansoni eggs, suggesting that IL-31 is involved in anti-parasitic responses 
(Perrigoue, Li et al. 2007). Similar to IL-17, IL-31 may not have such a clear-cut pro- or anti-
inflammatory role. 
In summary, the literature on IL-31 is thinly spread amongst research groups, with a focus on various 
different diseases and cell types. Whilst in some cases results are contradictory, taken together they 
suggest that IL-31 is a cytokine that plays an active role in allergic inflammation and links the 
epithelium with innate and adaptive immunity. 
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2 Hypotheses and Aims 
 
2.1 IL-31 is a pro-allergic Th2 cytokine 
In murine studies, IL-31 expression has been linked to Th2 cells which promote and maintain allergic 
responses. I tested whether IL-31 is expressed by human Th2 cells and upregulated by allergen 
stimulation. 
2.2 IL-31 affects function of airway epithelium 
Immune interaction with the airway epithelium is the source of many of the symptoms of allergic 
asthma and rhinitis such as excessive mucus production, rhinorrhoea, and airway remodelling and 
narrowing due to repair mechanisms following inflammation. IL-31 may interact with airway 
epithelium and I want to test the hypothesis that IL-31 can affect the function of the airway 
epithelium.  
2.3 IL-31 acts in concert with other Th2 cytokines to induce airway inflammation 
Activated Th2 cells secrete a number of cytokines simultaneously in order to perform a number of 
functions. Therefore the airway would never experience IL-31 in isolation. It may be possible that the 
combination of cytokines synergise and have an effect greater than the sum of their single actions. I 
tested the hypothesis that IL-31 can synergise with Th2 cytokines to induce pro-inflammatory genes 
from lung epithelium. 
2.4 Aims 
2.4.1 Investigate IL-31 expression in vitro in allergen- stimulated cultures of peripheral blood 
mononuclear cells from atopic grass pollen allergic individuals and healthy non-atopic controls. 
By use of immunofluorescence microscopy examine the expression and co-localisation of IL-31 in 
vivo after allergen provocation in human skin and nasal mucosa.   
2.4.2 Investigate IL-31 expression in CD4+ T cells derived from peripheral blood of non-atopic 
subjects cultured under Th1/Th2 polarising conditions.  
2.4.3 Examine regulation of IL-31 expression in CD4+ T cells, lines and clones derived from 
peripheral blood. Under what conditions is IL-31 expressed? 
2.4.4  Examine effects of IL-31 on human airway epithelium – gene expression, proliferation 
and epithelial wound healing.  
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3 Methods and materials 
 
3.1 Human Blood 
 
3.1.1 Consent/ethical statement 
Blood was donated following written informed consent. The study was approved by the Royal 
Brompton and Harefield NHS trust and National Heart and Lung Institute ethics committee 
(reference: REC 07-119). 
 
3.1.2 Allergy characterisation 
Potential donors were characterised by Ms Andrea Goldstone, Dr. Shireen Quli-Khan and Ms 
Benedikte Pedersen who assessed symptoms and performed skin prick testing and phlebotomy.   
All allergic donors were required to be allergic to grass pollen and reported seasonal allergic rhinitis 
during the UK grass pollen season (around June and July). Allergy was confirmed by a positive skin 
prick test for Timothy grass (Phleum pratense) pollen and increased total and allergen-specific IgE. 
Polysensitised individuals were included in the study. 
Non-allergic subjects had not experienced any allergic symptoms. Clinical descriptions were 
confirmed by negative skin prick tests and negative allergen-specific IgE.   
 
3.1.2.1 Skin prick testing 
Skin prick tests were performed on the forearm with aeroallergen extracts (Table 3.1.2.1) along with 
a negative diluent control and positive control of Histamine (10mg/ml). A drop of allergen extract 
was applied to the skin and introduced subcutaneously via a pierce with a sterile lancet through the 
drop. After 15 minutes, the size of any wheals produced by allergen challenge was measured. A 
positive result was defined as a wheal 3mm or greater in diameter than the negative control and had 
to coincide with a positive control wheal.
43 
 
 
Table 3.1.2.1. List of allergen extracts used for skin prick testing 
Binomial name Alternative name 
Alternaria alternate  Alternaria 
Artemisia vulgaris  Mugwort 
Betula verrucosa  Silver Birch 
Aspergillus fumigatus  Aspergillus 
Canis familiaris  Dog hair 
Cladosporium herbarum Cladisporium 
Dermatophagoides 
pteronyssinus  
House dust mite 
Equus caballus  Horse dander 
Felis domesticus  Cat hair 
Phleum pratense  Timothy grass 
3 Tree mix: Alnus 
glutinosa/Alnus incana, 
Betula verrucosa, Corylus 
avellana  
Black/grey Alder, Silver birch, Hazel 
6 grass mix: Avena sativa, 
Dactylis glomerata, Poa 
pratensis,Festuca 
pratensis, Lolium perenne, 
Phleum pratense  
Common oat, Orchard grass, smooth 
meadow grass, Meadow fescue, Rye 
grass, Timothy grass 
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3.1.2.2 Total and allergen-specific IgE measurements. 
Total and allergen-specific serum IgE was measured in the Biochemistry department at the Royal 
Brompton Hospital. The normal range of total serum IgE concentration was defined as 3-150 IU/ml 
and a positive result of an allergen-specific IgE had to be in excess of 0.35 IU/ml. 
3.1.3 Peripheral blood mononuclear cell (PBMC) isolation 
Venous blood was collected in Sodium Heparin coated Vacutainers (Becton Dickinson, NJ, USA) and 
processed within 1 hour. Blood was diluted in an equal volume of PBS and 35ml immediately layered 
over 15mls room temperature (RT) Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) and 
centrifuged for 25 minutes x 1136g at RT with no brakes. The PBMC formed a layer between FIcoll-
Paque and plasma which was then removed by Pasteur pipette and washed three times with excess 
PBS by centrifugation (10 minutes x 528g). PBMC were then resuspended in a small volume of 
culture medium and viable cell concentration ascertained by trypan blue exclusion. Cells were then 
diluted to a working concentration in culture medium (usually 1 million/ml). 
3.1.4 Culture medium 
T-cells were cultured in RMPI 1640 plus 50U/ml Penicillin, 50µg/ml streptomycin sulphate, 2mM L-
glutamine (all Gibco) and 10% foetal calf serum (Sigma-Aldrich). 
3.1.5 Trypan blue viable cell stain 
A 20µl sample of cell solution was diluted 1:1 with Trypan blue (Sigma-Aldrich) before being added 
to a haemcytometer to be counted under 40x magnification. Non-viable cells stained blue and so 
were excluded from the final cell count. 
 
3.2 PBMC culture 
3.2.1 Allergen stimulation 
Freshly isolated PBMC were resuspended at 2 million cells/ml in culture medium. 200μl of cell 
solution was plated per well of a flat bottom 96 well tissue culture plate. Whole Phlp protein (ALK-
Abello) was used to stimulate PBMC at a concentration of 0.1, 1 and 10µg/ml in triplicate. A positive 
control of soluble monoclonal antibodies against CD3 and CD28 (both 1μg/ml, both from R&D 
Systems) was employed. Two negative controls were employed, one of no stimulation and a non-
allergy related stimulation by Purified protein derivative (PPD) of Tuburculin 1μg/ml (Statens Serum 
Institute, Copenhagen, Denmark). Cells were cultured for 6 days before 100μl supernatant was 
harvested for protein analysis and cells were either pulsed with 20μl tritiated thymidine or lysed and 
total RNA isolated for RT-PCR analysis. 
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3.2.2 Proliferation measurement by Tritium incorporation. 
Allergen stimulated PBMC in 96 well plates were pulsed with 5µCi if [3H]-thymidine (MP Biomedicals, 
Cambridge, UK) for the final 16hrs of a 7 day culture. Plates were frozen at -20°C for at least 24 hours 
before harvesting. Cells were lysed and genetic material transferred onto glass fibre mats (Wallac, 
Turku, Finland) with a Mach III M Harvester, beta- scintillant (Perkin-Elmer, Wal-Tham, USA)  was 
added and scintillation was counted using 1450 Microbeta TRILUX (Wallac). 
 
3.3 Magnetic activated cell sorting (MACS) 
Cells in a mixed population can be isolated using Magnetic activated cell sorting (MACS) which 
separates cells based on the expression of surface markers.  Antibodies conjugated to paramagnetic 
microbeads bind specific cell surface antigens. Once labelled, the cells are passed though a column 
in the presence of a strong magnetic field. Any labelled cells are retained in the column while 
unlabelled cells pass through. Once taken out of the magnetic field, the retained cells can be eluted 
from the column. 
Two approaches to isolation can be used, positive and negative selection, dependant on how rare 
the target cells are and whether it is desirable leave the target cells unlabelled. Positive selection 
uses antibodies specific for the target cell, so that target cells are directly labelled and therefore 
retained in the magnetic field. This approach is often used for very rare cell types. Negative selection 
uses antibodies to label all the cells apart from the target cell, thus retaining all unwanted cells in the 
column and leaving the unlabelled target cells to flow through. 
3.3.1 CD4+ T-cell isolation 
CD4+ T-cells were isolated from freshly isolated PBMC using a MACS CD4 negative selection kit 
(Miltenyi Biotec, Gladbach, Germany). PBMC were washed and resuspended in MACS buffer (1x PBS 
pH 7.2-7.4, 0.5% Foetal calf serum (FCS, Sigma-aldrich), 2mM EDTA (Sigma-Aldrich)) 40µl buffer per 
107 cells.  
Biotinylated antibody cocktail was added, 10µl per 107 cells and incubated on ice for 10 minutes. The 
antibody cocktail contains biotinylated monoclonal antibodies specific for markers on all non-CD4+ T-
cells in PBMC (CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRγ/δ and Glycophorin A). 
30µl MACS buffer was added per 107 cells along with 20µl anti-biotin Microbeads per 107 cells and 
incubated for a further 15 minutes on ice. Cells were washed with excess cool MACS buffer (300g x 
10 minutes at 4⁰C). Supernatant was carefully removed and the cell pellet resuspended in 500µl 
MACS buffer per 108 cells. The cells were then passed through a MACS column (Miltenyi-Biotec) of 
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the appropriate size held in a MidiMACS separation magnet (Miltenyi-Biotec) and washed three 
times with MACS buffer. The column flow-through plus the washes were collected together and 
contained the unlabelled fraction of PBMC, the CD4+ fraction. If required as feeder cells for T-cell 
clone culture, the non-CD4+ fraction was eluted from the MACS column by removing the column 
from the magnetic field and flushing through 1ml MACS buffer with the supplied plunger. Both 
fractions were then washed in excess MACS buffer (300g x 10 minutes at 4⁰C), resuspended in 
culture medium and counted using trypan blue staining. 
3.3.2 CD45RO and CD45RA T-cell isolation 
CD4+ T-cells can be separated into memory and naive T-cells by MACS via the differential expression 
of the CD45RO surface antigen. CD45RO is specifically expressed by memory T-cells so MACS 
separation can be employed to isolate memory T-cells leaving behind a naive T-cell population.  
This isolation was performed on previously isolated CD4+ T-cells using CD45RO microbeads (Miltenyi-
Biotec). CD4+ T-cells were washed by centrifugation in excess MACS buffer (300g x 10 minutes at 4⁰C) 
and the cell pellet resuspended in 80µl buffer and 20µl CD45RO microbeads per 107 cells and 
incubated on ice for 15 minutes. Cells were washed in excess MACS buffer as before. Supernatant 
was carefully removed from the resulting cell pellet and cells resuspended in 500µl MACS buffer per 
108 cells and this solution applied to a MACS column held in a MidiMACS magnet. The Column was 
washed three times with MACS buffer and all column flow-through was collected as the naive 
CD45RA+ T-cell fraction. The CD45RO+ fraction was eluted from the MACS column outside of the 
magnetic field with 1ml MACS buffer with the propriety plunger. Both fractions were then washed in 
excess MACS buffer (300g x 10 minutes at 4⁰C), resuspended in culture medium and counted using 
trypan blue staining. 
 
3.4 T-cell culture 
3.4.1 Stimulation by plate-bound anti-CD3 and anti-CD28 
Wherever possible, T-cells were stimulated with plate bound anti-CD3 (R&D Systems MAB100) and 
anti-CD28 (R&D Systems MAB342). A solution of these antibodies at (both at 1μg/ml in PBS) was 
added to tissue culture plates for 1 hour at 37°C to allow antibody to bind and remaining solution 
was pipetted off just prior to adding T-cells. The volume of antibody solution added per well is 
summarised in Table 3.4.1.1. 
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Table 3.4.1.1.Volume of anti-CD3 and anti-CD28 solution required to coat different sized wells of 
tissue culture plates for plate-bound T-cell stimulation 
Number of wells per plate Antibody solution added per well 
(μl) 
96 50 
48 100 
24 250 
12 500 
6 1000 
 
3.4.2 Generation of Th1 and Th2 lines. 
This protocol was optimised by D. Cousins et al (2002).  
Naive T-cells were isolated from PBMC as described and diluted to 1x106/ml in culture medium. They 
were stimulated by plate bound anti-CD3, anti-CD28 and rIL-2 (20ng/ml) in 24 well plates under the 
following polarisation conditions: 
Th1: rIL-12 (2.5ng/ml, Peprotech, Rocky Hill, NJ, USA), anti IL-4 (5µg/ml, R&D Systems, MAB304) 
Th2: rIL-4 (12.5ng/ml, Peprotech), anti-IFNγ (5µg/ml R&D Systems, MAB2851), anti-IL-10 (5µg/ml, 
R&D Systems MAB2171) 
Neutral: no additional cytokines 
The cells were cultured for 4 weeks and restimulated with fresh anti-CD3 and anti-CD28 every 7 
days. Cells were fed with polarising cytokines and IL-2 at each restimulation and midweek. As 
cultures expanded, they were split into more wells with fresh culture media as required. 
 
3.5 T-cell cloning 
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Cloning T-cells by limiting dilution allows the development of cultures derived from single T-cells, 
thus allowing observations of the frequency of certain phenotypes and to draw correlations 
between the expression of various proteins or genes. T-cell clones can be screened by ELISA and flow 
cytometry once they have reached high enough numbers. 
CD4+ T-cells were isolated from PBMC as described but were cultured in cloning media – Culture 
media plus 5% Human AB serum (Sigma-Aldrich), 1mM Sodium Pyruvate (Gibco), 50µM 2-
Mercaptoethanol (Sigma-Aldrich), 5% Non-Essential Amino acid mix (PAA).  T-cells were serially 
diluted, 1:10, and the concentration of each solution measured by trypan blue exclusion. Cells were 
eventually diluted to 7 cells/ml, in 50mls cloning media, and plated out at 100μl per well of a round 
bottom 96 well plate. This final concentration of 0.7 cells per well is a level that should prevent 
polyclonal cultures.  
In addition to the T-cell solution, irradiated feeder cells were added to each well. Autologous CD4- 
cells remaining from the CD4 isolation were irradiated for 4000 rads of γ-radiation (Gammacell 3000 
Elan irradiator, Nordian International Inc.) before being washed (300g x 10 minutes at 4°C) in cloning 
medium and adjusted to 2.5 million cells/ml. PHA (Sigma-Aldrich 2μg/ml) and recombinant IL-2 
(Peprotech, 40ng/ml) were added to the feeder cell solution which was then plated out with the T-
cells, 100μl per well. A minimum of 5 plates was set up per donor. In addition, control wells were set 
up with feeder cells only, and higher concentrations of T-cells to aid the correct identification of 
growing clones. After 7 days culture, half the clone culture medium was replaced with fresh media 
plus IL-2 at 40ng/ml (to give a final concentration of 20ng/ml). Any growing clones could be 
identified by day 10 and transferred to 2 wells of a flat bottom plate. Clones were fed with fresh 
media plus IL-2 every 2 days from day 10. Once the proliferation of clones slowed down and cells 
had returned to the rounded instead of a pear shape, they were restimulated with plate bound anti-
CD3 and anti-CD28 and every fortnight from then on. As cultures expanded they were transferred 
from 96 well plates to 24 well and eventually to 6 well plates. At each restimulation, a sample of 
each clone was frozen for storage; 500μl clone plus 500μl freezing mix (50% FCS Sigma-Aldrich, 35% 
culture media and 15% Dimethyl Sulphoxide (Sigma-Aldrich)). 
Clone phenotypes were determined by flow cytometry and ELISA of supernatants. 
 
3.6 Enzyme linked Immunosorbant assay (ELISA) 
ELISA can measure specific proteins in a solution by means of a pair of antibodies. The first layer of 
plate-bound antibody can capture target protein and then a colorimetric reaction coupled to a 
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detection antibody can quantify the bound protein via comparison to a dose response curve 
constructed from protein standards. 
 
3.6.1 Supernatant generation  
 
3.6.1.1 T-cells 
T-cells or T-cell clones were adjusted to a concentration of 1x106/ml in fresh media and stimulated 
with plate bound anti-CD3 and anti-CD28 antibodies as described earlier, for 48 hours.  Where 
possible, cells were split into 3 wells of a 96 well plate, 200µl/well. Supernatants were carefully 
removed from the top of the well, in order to not take any cells, and frozen until use at a minimum -
20⁰C. 
 
3.6.1.2  PBMC 
PBMC were stimulated with allergen for 7 days and a portion of cell-free supernatant was removed 
to be assayed by ELISA just before cells were pulsed with tritiated thymidine. Supernatants were 
frozen until use at a minimum -20⁰C. 
 
3.6.1.3  NHBE 
50% confluent NHBE in 24 well plates were washed and 500µl fresh growth media added for 48hrs 
along with any treatments such as recombinant cytokines. Supernatants were then removed and 
stored at a minimum -20⁰C. 
 
3.6.1.4 Human IL-31 ELISA 
IL-31 concentration in T-cell supernatants was determined using the Human IL-31 ELISA 
development kit from Peprotech (Rocky Hill, NJ, USA). 
 
Buffers required: 
PBS: Phosphate buffered saline pH 7.20 
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Wash buffer: 0.05% Tween-20 (Sigma-Aldrich) in PBS 
Block buffer:  5% Bovine serum Albumin (BSA, Millipore, Watford, UK) in PBS 
Diluent: 0.05% Tween-20, 0.1% BSA in PBS  
Substrate solution :  20mls 0.05M Phosphate-citrate buffer (2.84g Na2HPO4 (Sigma-Aldrich), 1.92g 
anhydrous citric acid (Sigma-Aldrich) in 200mls deionised water, Ph5), 200µl 
TMB solution (100mg Tetramethylbenzidine (TMB, Sigma-Aldrich) in 10mls Dimethyl Sulfoxide 
(DMSO, Sigma-Aldrich)), 6µl H2O2 (Sigma-Aldrich). 
Stop solution: 2N H2SO4   
Capture antibody was diluted in PBS to 2µg/ml and 100µl of this solution was added to each well of 
the ELISA plate (Nunc Maxisorb, Roskilde, Denmark), sealed and incubated overnight at room 
temperature.  Wells were washed 3 times with wash buffer; wells were completely filled and then 
aspirated before being blotted on a paper towel. Any spaces on the plate that could potentially bind 
sample indirectly without binding the capture antibody were then blocked with 300µl block buffer 
for 90 minutes at room temperature. Plates were then washed as before. 50µl of neat sample 
supernatant was then added per well, ideally in triplicate. A 7 point standard curve was prepared by 
2-fold serial dilution of recombinant IL-31 in reagent diluent with the highest concentration of 
1000pg/ml and lowest of 15.125pg/ml and added in triplicate to the plate. A blank of diluent only 
was also included. The plate was sealed and incubated for 2hr at room temperature before being 
washed three times as before. Detection antibody was diluted in diluent to 0.5µg/ml and 100µl 
added to each well for 2 hours at room temperature. After washing three times, the avidin-
Horseradish peroxidase conjugate supplied in the ELISA kit was diluted 1:2000 in diluent and 100µl 
added to each well for 30 minutes at room temperature.  During this time Phosphate-citrate buffer 
was brought up to room temperature and TMB aliquot defrosted. Plates were washed a final three 
times with wash buffer and 100µl complete substrate solution (add the H2O2 as late as possible) 
added to each well. Colour was developed for about 5 minutes, or when a bluish tinge could be seen 
in the blank wells, before 50µl stop solution was added to each well. Plates were then read at 450nm 
using an automated ELISA plate reader (Emax, Molecular Probes, Oregon, USA). Cytokine 
concentrations were extrapolated  from the Log-Log curve-fit standard curve using Softmax Pro 
software (Version 4.3.1. Molecular Devices, Wokingham, UK). If samples were diluted prior to assay, 
results were multiplied by the dilution factor to account for this. 
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3.6.2 IL-4, IL-13, IL-22, IFNγ and CCL2 ELISA (R&D Systems) 
The buffers used for the R&D systems ELISA development kits vary slightly from the Peprotech ELISA, 
although the protocol is the same. Another difference is that the peroxidase supplied by R&D 
Systems is light sensitive so the final two incubations have to be carried out in the dark and has a 
batch dependant concentration so has to be diluted as per instruction on each vial. Different 
cytokines are produced in different quantities by cells so samples may have to be diluted prior to 
assay. These variations in techniques are summarised in Table 3.6.2.1. 
 
Buffers required: 
PBS: Phosphate buffered saline pH 7.20 
Wash buffer: 0.05% Tween-20 (Sigma-Aldrich) in PBS 
Substrate solution:  20mls 0.05M Phosphate-citrate buffer (2.84g Na2HPO4 (Sigma-Aldrich), 1.92g 
anhydrous citric acid (Sigma-Aldrich) in 200mls deionised water, Ph5), 200µl 
TMB solution (100mg Tetramethylbenzidine (TMB, Sigma-Aldrich) in 10mls Dimethyl Sulfoxide 
(DMSO, Sigma-Aldrich)), 6µl H2O2 (Sigma-Aldrich). 
Stop solution: 2N H2SO4   
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Table 3.6.2.1 Summary of reagents required for different ELISA kits. 
Cytokine 
detected 
Diluent Block 
Buffer 
Top 
Standard 
Antibody 
concentrations 
Sample 
dilution 
factor 
IL-4 0.1% BSA 
0.05% 
Tween-20 
PBS 
1% BSA 
PBS 
2000pg/ml Capture: 
4μg/ml 
Detection: 
12.5ng/ml 
1:10 for T-
cell clones, 
neat for T-
cell lines 
IL-13 1%BSA PBS 1% BSA 
PBS 
6000pg/ml Capture: 
2μg/ml 
Detection: 
150ng/ml 
1:50 and 
1:10 for T-
cell clones, 
1:10 for T-
cell lines 
IL-17 1%BSA PBS 1% BSA 
PBS 
2000pg/ml Capture: 
4μg/ml 
Detection: 
150ng/ml 
1:10 for T-
cell clones, 
neat for T-
cell lines 
IL-22 1%BSA PBS 1% BSA 
PBS 
2000pg/ml Capture: 
2μg/ml 
Detection: 
250ng/ml 
1:10 for T-
cell clones, 
neat for T-
cell lines 
CCL2 1%BSA PBS 1% BSA 
PBS 
1000pg/ml Capture: 
1μg/ml 
Detection: 
100ng/ml 
Neat for 
NHBE 
supernatants 
IFNγ 0.1% BSA 
0.05% 
Tween-20 
PBS  
(When 
diluting 
detection 
antibody, 
add 2% heat 
inactivated 
goat serum 
to diluent.) 
1% BSA 
PBS 
2000pg/ml Capture: 
4μg/ml 
Detection: 
50ng/ml 
1:50 and 
1:10 for T-
cell clones, 
1:10 and 
neat for T-
cell lines 
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3.7 Fluorescence activated cell sorting (FACS) 
Flow cytometry (FACS) is a technique that enables analysis on a single cell level. Cells can be 
characterised for physical features such as size and granularity and can be phenotyped by the 
expression of proteins, both intracellular and extracellular, via labelling with fluorochrome 
conjugated antibodies. Intracellular cytokine staining was utilised to characterise T-cell clones for T-
cell phenotype as well as confirm the monoclonality of the clones.  
3.7.1 Stimulation of cells for FACS 
In order to stain cytokines with a single layer of antibody, it is necessary to boost production and 
retention of cytokine prior to staining. This was performed with 10ng/ml Phorbol Myristate Acetate 
(PMA, Sigma-Aldrich), a lectin that cross-links all surface receptors causing a widespread stimulation. 
1μg/ml Ionomycin (Sigma-Aldrich) is a calcium ionophore that promotes an influx of calcium, and 
further broad stimulation of cells. Protein secretion and transport was halted via the use of 0.7μl/ml 
Brefeldin-A and 1μg/ml Monensin (Both Becton-Dickinson ready-made solutions).  
120μl of cell solution was aliquoted into a number of wells of a 96 well round bottom plate. 10μl of a 
10x solution of PMA, Ionomycin  and Brefeldin A was added to each well and incubated at 37°C for 5 
hours. After 2 hours of this incubation, 10μl of a 10x monensin solution was added to each well. 
3.7.2  Fixation and permeabilisation of cells for FACS 
Cells were washed in situ by using a plate holder in the centrifuge; 150μl FACS buffer (PBS, 1% Foetal 
calf serum) was added to the wells and plates spun at 300g x 5 minutes, before buffer was flicked 
out into a sink and cells remaining as a pellet in the wells. Any surface staining for compensation 
controls was carried out now, 1μl CD4 FITC or 1μl CD3 PE added to cells for 20 minutes on ice, in the 
dark before being washed again with FACS buffer. Surface stained cells were still fixed and 
permeabilised as to have a forward/side scatter profile consistent with the remaining intracellularly 
stained cells.  
Cells were then fixed and permeabilised using 100μl fix/perm buffer (BD Biosciences) per well, 
incubated for 20 minutes on ice before being washed in 200μl Fix/Perm wash buffer (BD 
Biosciences). Cells were then resuspended by holding the plate to a vortexer set to low and 50μl 
wash buffer added.  
The following stains were used to phenotype T-cell clones; 
1) mouse IgG1 FITC/Mouse IgG1 PE (isotype controls) 
2) IFNγ FITC/IL-4 PE 
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3) IL-22 APC/ IL-17 FITC 
All antibodies were from BD and were all added 1μl per well (recommended sample size and 
antibody usage scaled down ten-fold) and incubated 20 minutes in the dark, on ice. 
Cells were washed once more with 200μl FACS buffer before being resuspended in a final 50μl of 
FACS fix buffer (BD) and kept in the dark and on ice until read on the FACS machine, within 48 hours 
of staining. 
3.7.3 Flow cytometry  
Cell stain data were acquired using a FACScanto flow cytometer (BD Biosciences) and analysed with 
FACSdiva software (BD Biosciences). Compensation settings were determined for each cell type 
using single stains for common antigens (CD3, CD4) in each colour fluorochrome used. Cells were 
gated on live lymphocytes as determined from forward/side scatter profile. 
3.7.4 IL-31 staining optimisation 
IL-31 expression by T-cells was confirmed by ELISA. In comparison to flow cytometry, the ELISA 
process has a number of signal amplification steps such as an avidin-biotin binding step which 
quadruples the number of molecules at that level. This means that ELISA can be perfectly sensitive 
and yet rely on sub-optimal antibodies. FACS staining is single layer, and much more dependent on 
antibodies with high affinity and avidity for the antigen to get the strongest signal. During this 
project, no commercially available FACS antibodies were available for IL-31.  
The monoclonal Mouse anti human IL-31 antibody from R&D Systems (MAB28241) had been 
successfully employed for immunohistochemical staining of frozen tissue samples. 
3.7.5  IL-31 MAb plus anti-mouse IgG1 FITC 
T-cell clones were stimulated for intracellular cytokine staining as described earlier with protein 
transport inhibited with Monensin and Brefeldin A. IL-31 was detected by staining cells with an 
unconjugated IL-31 antibody. IL-31 staining was detected with a FITC conjugated anti-Mouse 
Immunoglobulin G1 antibody which was added at 5µg/ml in 50µl FACS buffer for 20 minutes on ice 
in the dark following a wash after the first layer. A negative isotype control was employed to show 
background staining, and an IL-4 unconjugated antibody and IL-4 PE antibody were used as positive 
controls for cell stimulation and the two-step staining technique. 
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Cells were stained with the following conditions –  
1) Mouse IgG1 isotype control 10µg/ml (R&D Systems, MAB002) followed by anti-
mouse IgG1 FITC (Abcam , Ab11588, 5µg/ml) and  5µl Mouse IgG1 PE isotype 
control (BD Biosciences, clone MOPC21) 
2) IFNγ FITC 5µl (eBioscience,clone 4s.B3) and IL-4 PE 5µl (BD Biosciences, clone 8D4-
8)  
3) Mouse IL-4 IgG1 10µg/ml (R&D systems, MAB304) followed by anti-mouse IgG1 
FITC (Abcam , Ab11588, 5µg/ml)  
4) Mouse IL-31 10µg/ml (R&D systems,MAB18241) followed by anti-mouse IgG1 FITC 
(Abcam , Ab11588, 5µg/ml)  
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Figure 3.7.5.1 IL-31 cannot be detected by flow cytometry. (a) T-cell clones from an atopic donor 
were stimulated for 6 hrs with PMA (20ng/ml) and Ionomycin (1µg/ml) and brefeldin A/monensin 
before being stained with monoclonal Abs towards IL-31, Il-4 or an isotype matched control, 
followed by and anti-mouse FITC Ab or directly conjugated IFNγ FITC and IL-4 PE. Cells were gated on 
viable cells . (b) Cell supernatants from these clones were assayed for IL-31 by ELISA following a 48hr 
stimulation with plate bound anti-CD3 and anti-CD28 (1µg/ml).  
This technique was not considered successful as a method to detect IL-31 by flow cytometry. 
Although the negative isotype control was a clear negative signal, the technique failed to pick up IL-4 
when it could be detected by a conventional PE conjugated FACS Il-4 antibody (Figure 3.7.5.1). Clone 
2.6 was a strong producer of IL-31 as shown by ELISA but the difference between the IL-31 FACS 
plots of clones 2.1 and 2.6 was not discernible. 
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IL-31 cannot be detected by flow cytometry. (a) T-cell clones from an atopic donor were 
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matched control, foll wed by and a ti-mouse FITC Ab or directly conjugated IFNγ FITC and 
IL-4 PE. Cells were gated on viable cells . (b) Cell supernatants from these clones were 
assayed for IL-31 by ELISA following a 48hr stimulation with plate bound anti-CD3 and anti-
CD28 (1µg/ml). 
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3.7.6 IL-31MAb conjugated in-house with Alexa fluor 647 
The use of a secondary antibody to detect IL-31 antibody staining proved unsuccessful so another 
approach was tried. This time the IL-31 antibody was to be labelled directly with Alexa Fluor 647, a 
fluorophore that absorbs and fluoresces light at 650 and 668nm respectively and is considered 
brighter than FITC.  
A commercially available antibody labelling kit (Molecular Probes, Grand Island, NY, USA) was used 
to conjugate IL-31 monoclonal Ab from R&D Systems with Alexa Fluor 647 dye.  
100µg of IL-31 MAb and mouse IgG1 isotype control were labelled. 
Briefly the technique comprised: 
The antibodies were reconstituted at 1mg/ml in PBS. 100µl antibody and 11µl 1M sodium 
bicarbonate buffer (pH 8.3, supplied with kit) were added to the vial of reactive dye, inverted gently 
to mix and incubated for 1 hour. The Alexa fluor 674 dye has a succinimidyl ester moiety that reacts 
with primary amines of proteins to form stable dye-antibody ester bonds. 
The labelled antibodies were then purified by means of a purification resin that can bind unbound 
dye. A spin column was packed with purification resin, about 1.5ml, before being spun at 1100g x 
3mins to remove the storage buffer from the resin. The antibody-dye conjugation reaction mixture 
was added to the spin column and centrifuged for 5 minutes at 1100g in a fresh collection tube. The 
labelled antibody was then stored in the fridge at 4⁰C and protected from light. 
The cells used to test the antibody were T-cell lines that had been  cultured for 3 weeks and the Th2 
line had been shown by ELISA to be strongly expressing IL-31 with Th1 and neutral conditions 
negative for IL-31. 
These lines were stimulated for 6 hours with PMA/Ionomycin/Monensin and Brefeldin A as 
described previously. 
 Staining conditions were –  
1) Mouse IgG1 isotype control labelled with Alexa Fluor 647 (10µg/ml) and mouse 
IgG1 PE control 5µl. 
2) IL-31 MAb labelled with Alexa fluor 647 (10µg/ml) and IL-4 PE 5µl. 
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Figure 3.7.6.1  IL-31 detection by flow cytometry. CD4 T-cells from a non-atopic donor were 
polarised towards Th2 for 3 weeks and then stimulated for intracellular staining and stained with 
Alexa Fluor 674 labelled IL-31 antibody and IL-4 PE and isotype matched controls. A)Cells were gated 
on viable cells, quadrants set against isotype control. B) Histogram of mean fluorescence intensity of 
IL-31 staining 
This primary data looked encouraging with a visible difference between neutral and Th2 conditions 
but unfortunately was never repeated. T-cell clones proved a more robust method to examine IL-31 
on a single cell level. 
 
3.8 Immunohistochemistry. 
Immunohistochemistry was used in order to visualise IL-31 and IL-31 receptor positive cells in the 
skin and nose and attempt to identify the cell type that co-localises with IL-31 or IL-31 receptor.  
3.8.1 Slides used. 
All immunohistochemistry was performed on 5µm frozen sections of either skin or nasal biopsies, 
with the vast majority staining utilising fluorescent secondary antibodies to visualise staining. Prior 
to microtome cutting and slide preparation, biopsies were bisected and fixed in either 
paraformaldehyde or acetone and stored at -80⁰C. 
 
Isotype
control Neutral Th2
A
B
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3.8.1.1 Details of allergen challenge 
All of the sections used in this study were generated for a study completed previously by Graham 
Banfield (Banfield, Watanabe et al. 2010). Briefly, this study comprised two groups of patients, those 
who were allergic to either timothy grass pollen (Phlp) or house dust mite (HDM) extract and 
age/sex matched healthy non-atopic controls. Allergy was confirmed by skin prick testing and 
presence of allergen-specific IgE in blood.  
Each volunteer then underwent two sessions of intradermal challenge to the forearm at least three 
weeks apart. One session consisted of two injections of allergen (either Phlp or HDM depending on 
the patient status, 10 biological units in 0.02ml, ALK Abello) in one arm, no less than 10 cm apart, 
and a diluent challenge on the opposite arm. The second challenge consisted of two intradermal 
injections of PPD (10 tuburculin units in 0.02ml , Evans Vaccines, Richmond) on one forearm and a 
diluent challenge on the opposite arm. At 8 and 48hours post challenge, any wheal produced was 
measured and a 4mm skin biopsy taken under local anaesthetic. The diluent challenge site was 
biopsied at 8 hours for the allergen challenge and at 48 hours for the PPD challenge. 
Nasal biopsies from the same study group were also generated. Volunteers provided nasal biopsies 8 
hours following a challenge with allergen spray (ALK Abello, Denmark) or diluent. The two challenges 
were performed on different nostrils and at least three weeks apart. These were performed out of 
the pollen season for those patients allergic to grass pollen.   
 
3.8.2 IL-31 single stain 
The first stain developed was a single IL-31 fluorescent stain. To increase the chance of finding IL-31, 
only allergic, allergen challenged skin sections were used and a three step avidin/biotin system was 
used to amplify any signal from the staining. Prior to this study, no images of IL-31 staining had been 
published. Therefore there were no validated antibodies to choose. Luckily, the first antibody we 
tried, Mouse monoclonal IgG1 anti-IL-31 from R&D Systems (MAB28241), worked so there was no 
need for costly studies comparing a panel of antibodies from different companies. 
Saponin was used as a permeabilising agent for all staining protocols as standard practice.  
3.8.2.1 Basic single staining with Avidin-Biotin-chromogen (ABC) visualisation protocol 
 
 Retrieve slides from freezer, unwrap and bring up to room temperature. Label with pencil 
and encircle each section with ImmEdge pen (Vector labs). 
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 Make plenty of fresh PBS with de-ionised water, at least 3 litres, for washing. 
 Place slides in staining rack and soak in 0.1% w/v Saponin/PBS for 30 minutes. From this 
point on, do not let sections dry out, work in batches if staining large number of slides, use 
the lid on a humid chamber during incubations 
 Transfer to PBS and then wash with agitation 3 x 5 minutes in PBS. Place slides on humid 
chamber rack. 
 Serum blocking; Block with serum from the species of the secondary antibody at a 
concentration of 3 drops in 10 mls PBS (Serums from Vecta stain ABC kit). For a mouse 
primary antibody, use horse serum, because the secondary antibody is a horse anti-mouse 
antibody. Use a dropper bottle to cover each section with diluted serum for 30 minutes. Tip 
off before adding antibody (no need to wash). 
 Primary antibody: Dilute Ab in 5% v/v normal human serum (NHS) /PBS. Make enough stock 
to allow 60µl per section. Add 58µl antibody per section and incubate for 1 hour at room 
temperature (RT). 
o  When trying a new antibody try a wide range of concentrations on either side of the 
manufacturer recommended concentration (if no recommended concentration, try 
10µg/ml). Always use an isotype matched control per donor, used at the same 
concentration of the highest concentration of primary antibody. If the staining is 
likely to be very rare or weak, include a positive control slide of a common marker 
such as CD3. 
 Wash slides 3 x 5 minutes PBS with agitation 
 Secondary antibody: biotinylated secondary from Vecta ABC kit. Dilute 1:170 in 10%  
NHS/PBS, specific for the species of primary antibody used. Add 58µl per section. Incubate 
45 minutes at RT.  
 Wash 3 x 5 minutes in PBS 
 Avidin fluorophore layer: dilute streptavidin Alexafluor 488 (Sigma Aldrich) 1:400 in PBS and 
spin 3 minutes at high speed in a microcentrifuge to sediment any precipitated free 
fluorophore that can cause non-specific fluorescence. Add 58µl per section and incubate for 
30 minutes. Keep slides in the dark from now on. 
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 Wash 3 x 5 minutes in PBS 
 Tap slides dry; wipe excess PBS off (without touching the section) with a lens tissue. Add a 
small drop of Vectashield (Vector Labs) with DAPI to each section and mount.  
 Store slides level (Vectashield does not set so cover slips can slide off), in the dark, at 4⁰C.  
o Variations to this protocol can be made: If saponin is not to be used, then briefly 
soak the slides in PBS before proceeding straight to the blocking step. If performing 
a simultaneous co-stain, combine the different blocking serums required into one 
blocking step. If performing a sequential staining with two mice primary antibodies, 
include a 20% mouse serum blocking step between the two protocols. If possible 
always add fluorescent layers on last, if carrying out a two-step and three-step co-
stain, add the second stage of the two-step stain until the same time as the avidin-
Alexafluor incubation. 
 
3.8.2.2 Acetone vs paraformaldehyde 
The first stage in optimising the IL-31 stain was to choose between Acetone and Paraformaldehyde 
fixed tissue. Acetone is a very light fixative that is very gentle on antigens but can leave tissue fragile. 
Paraformaldehyde is a much stronger fixative and preserves the morphology of the tissue well; 
however, it can modify or mask antigens so that they are unavailable to antibody binding sites. 
Generally, if an antibody works on paraformaldehyde fixed tissue, it will work on acetone but not the 
other way round. 
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Figure 3.8.2.1 Immunofluorescent staining for IL-31 (green) on acetone and paraformaldehyde fixed 
frozen skin sections, nuclei counterstain DAPI (blue). Three layer staining with mouse anti-human IL-
31 (R&D Systems) (10µg/ml) or mouse IgG1 isotype control (R&D Systems), then horse anti-mouse 
biotinylated secondary antibody (Vector) followed by streptavidin Alexafluor 488. 
As shown above Figure 3.8.2.1, The IL-31 antibody did not stain any IL-31 on paraformaldehyde fixed 
tissue but stained well the acetone fixed tissue. Acetone fixed tissue only was used from here on. 
This was true for nasal and skin tissue sections. 
3.8.2.3 Concentration curve 
 A range of concentrations of primary antibody were used. The manufacturer recommended 
concentration of 10µg/ml (as shown above) was considered optimal and so used from here on. 
3.8.2.4 Validation of staining (absorption) 
In order to validate the staining we observed from the IL-31 antibody, the antibody was pre-
absorbed with recombinant IL-31 from another supplier before being used. If the antibody is specific 
to IL-31 then mixing it with IL-31 protein prior to staining should block up the binding sites so that 
the antibody then cannot bind IL-31 on the section producing a negative stain. The absorption was 
carried out by mixing anti IL-31 antibody with a 15x molar excess of recombinant IL-31 (Peprotech) 
and allowing it to bind overnight at 4⁰C. The antibody was used as per usual for a single stain on 
allergen challenged nasal tissue sections, with non-adsorbed antibody as a control (Figure 3.8.2.2). 
Due to availability of antibody, the IL-31 had to be used at 6µg/ml which still produced staining.   
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Figure 3.8.2.2. A three step staining of IL-31 on allergen challenged nasal tissue section. IL-31 
antibody, free and pre-absorbed stained with biotinylated secondary Ab and avidin Alexa fluor 488 
(Green). Nuclei counter-stained with DAPI (blue). (B) Number of positive cells per field of vision for 
the whole section taken at 40x magnification. (also includes data for antibody absorbed with 30x 
molar excess IL-31)   
3.8.3 CD3 single stain  
In order to support in vitro studies of the expression of IL-31 by T-cells, we intended to develop a 
dual-fluorescence IL-31 / CD3 stain that would hopefully demonstrate IL-31 and CD3 co-localised in 
the tissue. A very reliable CD3 staining protocol developed in house was available, utilising the 
mouse antibody UCHT1. However, the IL-31 antibody was also mouse, so a different species of CD3 
antibody was required. A polyclonal rabbit anti-CD3 (Ab828) from Abcam was tested for 
compatibility with the IL-31 staining conditions.    
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3.8.3.1 Saponin vs no saponin 
The CD3 antibody was tested first on tonsil tissue as this has a high concentration of CD3+ T-cells and 
was compared against a mouse monoclonal CD3 antibody.  
 
Figure 3.8.3.1 Immunofluorescent staining of CD3 on paraformaldehyde fixed tonsil tissue.  Abcam 
antibody detected with Tritc conjugated Swine anti-rabbit and Dako antibody was visualised with 
FITC conjugated rabbit anti-mouse. Where used, permeabilisation was performed by a 30 minute 
treatment with 0.1% Saponin PBS.  
 
Figure 3.8.3.1 demonstrates the benefits of permeabilisation by saponin with considerably brighter 
staining achieved. At a dilution of 1:5 (400µg/ml) the polyclonal staining was as bright as the 
standard monoclonal antibody so was used at this concentration from here on. 
3.8.4  IL-31 /CD3 co-stain 
A panel (n=8) of allergen and diluent challenged skin sections from allergic donors were stained for 
IL-31 and CD3. Briefly the protocol comprised – 30 minutes 0.1% saponin permeabilisation, horse 
serum blocking, 1 hour primary antibodies (Mouse anti-IL-31 MAB28241 1:20 dilution, Rabbit anti-
CD3 ab828, 1:5 dilution or mouse IgG1 and normal rabbit Ig isotype controls), 45 minutes 
biotinylated horse anti-mouse secondary Ab, 1:170 dilution and swine anti-rabbit TRITC (dako) 
1:400, 30 minutes streptavidin alexa fluor 488 1:800, mounted in vectashield with DAPI. 
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3.8.5 Microscopy 
3.8.5.1 Microscope 
The microscope used for fluorescence microscopy was a Nikon Eclipse E400.  
3.8.6  Quantification of cells 
IL-31 or CD3 positive cells were bright and usually a complete ring around the nucleus. For example 
in Figure 3.8.6.1 there were 6 CD3+ cells (red) and 4 IL-31+ cells (green) 
         
Figure 3.8.6.1 Representative slide of IL-31 CD3 co-staining of allergen challenged skin 
All counting of cells was carried out at 40x magnification. Each section had an epithelium, with tissue 
tending to become more fragmented the further it is from the epithelial layer so for each section a 
two field depth of tissue adjacent to the epithelium was counted (Figure 3.8.6.2). 
 
Figure 3.8.6.2. Description of area of section to be captured and counted. 
IL-31+
cell
CD3+
cells                                
Epithelium
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Biopsy
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Each section and slide was captured at the same exposure to prevent bias. Lucia 4.8 software was 
used to aid counting cells. Layers of images taken with different lights can be combined so that any 
co-localisation of green and red fluorescence appears yellow. Cell counts were expressed as mean 
cells/mm2.  
3.8.7  Validation of counting 
Every image of a section was counted twice on separate occasions and the two counts plotted 
against each other on a Bland-Altman plot (Figure 3.8.7.1). 
 
  
All pairs of counts have to lie within 95% limits of agreement. If there are more than one outlier than 
the whole sample has to be re-counted. The CD3 counts had no outliers but the IL-31 staining had to 
be recounted, hence the Bland-Altman plot representing the difference between the second and 
third counts. 
 
3.9  Histological stains 
 
An alternative to antibody-directed immunofluorescence, histological stains can also be employed to 
stain specific cell types or structures such as nuclei. IL-31 was still stained with IL-31 antibody but 
instead of a fluorescent tag, Fastblue or Fastred were used which are blue or red precipitates that 
develop at the site of an alkaline phosphatise reaction. 
Figure 3.8.7.1 Bland-Altman plot of IL-31 and CD3 counts. Each symbol represents the difference between the 
two counts.   
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3.9.1 Congo red 
The basic granules contained within Eosinophils attract the acidic red colour of congo red. We 
stained skin sections with mouse monoclonal IL-31 antibody as before but instead of streptavidin 
Alexafluor 488, IL-31 was visualised with Fast blue. Briefly, after the biotinylated secondary antibody, 
sections were incubated for 30 mins with Vecta Stain ABC-AP (alkaline phosphatase) reagent (Vecta 
labs). Then 20 minutes with Fast Blue reagent (Sigma Aldrich)  – (10mls 1x Tris buffer plus 
dimethylformamide and napthol as-mx phosphate, 1mg Fast Blue BB salt. Once dissolved, filter 
0.2µm and add 2 drops of levamisole solution. Use immediately. Stop reaction with excess distilled 
water). Then counterstain with congo red (generous gift from Tim Oates) by adding to section with 
pastette, incubating 20 minutes and rinsing with 10% ethanol. Nuclei were counterstained with 
haematoxylin (BDH laboratory supplies) 3 seconds before rinsing in tap water. Slides were mounted 
in Faramount (Dako) 
 
 
Figure 3.9.1.1. Histological staining of IL-31 and eosinophils with congo red and Fast Blue. Allergen 
challenged skin section. Arrows show potential IL-31+eosinophils. 40x magnification. 
As shown in Figure 3.9.1.1 above, IL-31 could be visualised with Fast Blue but was slightly less 
sensitive and showed non-specific staining. Congo Red is useful at identifying eosinophils but a 
nuclear counterstain with haematoxylin has to be very faint or it will obscure the eosinophils.  These 
results were encouraging as IL-31+ eosinophils were identified (white arrows), However, they were 
never seen in any other slides or when a dual-fluorescent protocol was used later. 
3.9.2  Toluidine Blue 
Toluidine blue is a histological stain that is basic, therefore will stain acidic mast cells blue. We 
attempted to stain IL-31 with Fast red  (same as fast blue but red end-product) and then stain mast 
cells with toluidine blue (generous gift from Lorraine Lawrence), with a counterstain of eosin. 
Eosinophils IL-31
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However, these three were a bad combination and the toluidine blue and eosin disappeared within 4 
hours (Figure 3.9.2.1.1). 
 
Figure 3.9.2.1. Toluidine blue and Fast red IL-31 staining of a nasal frozen section. Shown with (right) 
and without (left) eosin counterstain. 
 
3.9.3 Rabbit polyclonal IL-31 antibody 
In order to utilise the wide panel of monoclonal mouse antibodies already available in house, an IL-
31 antibody of a different species was sought. A rabbit polyclonal antibody (PAb) from Abcam 
(Ab102750) was marked as suitable for staining paraffin sections so we tried it on frozen sections.  
A co-stain was devised with IL-31 rabbit PAb (1:10) detected with biotinylated goat anti-rabbit, 
Vector Labs, (1:170) and streptavidin alexafluor 594 (1:1250, red) and CD3 mouse MAb, Dako, (1:10) 
detected with rabbit anti-mouse FITC (Dako) (1:30). 
 
 
Figure 3.9.3.1. IL-31 rabbit polyclonal antibody staining. Polyclonal antibody and control Ig visualised 
with ABC system and streptavidin alexafluor 594 (red). Monoclonal antibodies visualised with FITC 
conjugated anti-mouse antibody (green). Sections were acetone fixed allergen challenged atopic 
skin. 
The polyclonal staining was very fuzzy and hard to determine specific staining (Figure 3.9.3.1), 
especially because the isotype control bound to everything. When co-stained with IL-31 monoclonal 
stain, the positive cells did co-localise, although staining IL-31 with just anti-mouse FITC is not quite 
IL-31
Mast cell
IL-31
Mast cell
Eosin
IL-31 Pab
IL-31 MAB
Rabbit normal Ig
IL-31 MAB
IL-31 Pab
Eosinophil (MBP)
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sensitive enough. This was a problem for some of the other monoclonal antibodies which were 
normally detected with three-step staining. 
3.9.4 FITC on FITC 
To enhance the staining of the mouse monoclonal antibodies a novel technique was applied using a 
mouse anti-FITC antibody (Sigma, FL-D6). Slides were stained as usual with rabbit anti-mouse FITC 
antibody. This was then followed by an hour’s incubation with mouse anti-FITC antibody (1/670) and 
30 minute incubation with the rabbit anti-mouse FITC. This technique provided a means to bind two 
layers of FITC onto the section, amplifying any weak staining and allowing a bright co-stain with IL-31 
PAb plus the ABC system. 
 
Table 3.9.4.1  Monoclonal antibodies used for IL-31 co-stain. 
Antigen Company Clone/order 
number 
Dilution 
Neutrophil 
elastase 
Dako NP57 1/90 
Major basic 
protein (MBP) 
AbD Serotec BMK13 1/100 
Mast cell 
tryptase 
Dako AA1 1/100 
CD68 
(Macrophage) 
Dako PG-M1 1/50 
Myeloid 
dendritic cell 
(BDCA-1) 
Miltenyi 
Biotec 
 1/50 
T-cell (CD3) Ebioscience UCHT1 1/50 
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3.10 IL-31 receptor staining 
The IL-31 receptor comprises the subunits IL-31RA and OSMR. OSMR is ubiquitously expressed and 
part of many receptor complexes but IL-31RA is unique to the IL-31 receptor. IL-31RA was stained for 
in frozen skin sections using a goat polyclonal antibody from R&D Systems (AF2769) and detected 
using the vector labs goat ABC system and streptavidin alexafluor 488. 
3.10.1 Optimisation 
 
Figure 3.10.1.1. Optimisation of IL-31RA staining. Acetone and Paraformaldehyde fixed skin sections 
from the same donor compared in addition to two concentrations of primary antibody and a normal 
goat Ig control. Biotinylated rabbit anti-goat and streptavidin alexafluor 488 amplify the signal, DAPI 
counterstain the nuclei.   
 
As shown in Figure 3.10.1.1 the antibody worked at both concentrations and with both fixatives. 
Acetone fixed tissue and 20µg/ml antibody were used from here on. Although the epithelium 
showed diffuse non-specific staining, the dermal layer showed distinct IL-31RA positive cells, 
especially when compared to the Ig control, so this staining was considered to be specific. The 
specificity of the stain was improved by later switching to a horse secondary antibody from the 
rabbit secondary that was initially in use. 
3.10.2 Co-stain with IL-31RA 
In order to determine which cells were expressing IL-31RA, a co-stain was developed. IL-31RA was 
stained with the goat PAb and Avidin/biotin/alexafluor 594 (red), monoclonal antibodies towards 
various cell types were used (Table 3.10.2.1) and detected with rabbit anti-mouse FITC. 
  
Acetone
Paraformaldehyde
IL-31RA 40μg/ml IL-31RA 20μg/ml
Normal Goat Ig
Control
(no section)
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Table 3.10.2.1 Monoclonal antibodies used to co-stain with IL-31RA 
Antigen Company Clone/order 
number 
Dilution 
CD31 (Endothelium) Dako JC70A 5.15 
T-cell (CD3) Ebioscience UCHT1 1/50 
CD68 (Macrophage) Dako PG-M1 1/50 
IL-31 R&D Systems MAB28241 1/20 
 
 
3.10.3 IL-31RA staining of normal human bronchial epithelial cells 
In order to confirm that normal human bronchial epithelial (NHBE) cells expressed IL-31RA on a 
protein level we stained them with the same antibody used for frozen sections. NHBE are quite 
adherent so we developed a technique to grow them directly on slides before fixing and staining. 
Cell preparation: 
Trypsinise sub-confluent NHBE, wash in PBS and resuspend at 2x 105 /ml in growth media. (see NHBE 
culture section of methods and materials) 
Sterilise normal glass microscopy slides by spraying with 70% ethanol and leave to dry in sterile 
hood. Draw three 1cm diameter circles with wide borders on slide with ImmEdge pen. 
Place a layer of blue roll in a petri dish, dampen with sterile PBS and place slide on top, being sure to 
keep level. 
Drop 200µl cell solution on each circle of the slide, or as much as you can fit without the drop going 
beyond the ImmEdge layer.  
Replace lid of petri dish, return cells to incubator (37⁰C, 5% CO2) until they have bound to the slide, 
at least 5 hours.  
Fixation of cells: 
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Tap off media and rinse slides in PBS.  
Incubate slides at room temperature 15 minutes in 4% paraformaldehyde PBS.  
Wash 3 x 5 minutes PBS 
Leave to airdry, wrap in foil and store at -20⁰C  
Staining: slides were treated as frozen so used the basic protocol; Slides were permeabilised with 
0.1% saponin, blocked with horse serum, primary IL-31RA antibody diluted 1/20 (10µg/ml) 1 hour, 
biotinylated horse anti-goat secondary (1/170 dilution) 45 minutes, streptavidin alexafluor 488 
(1/800 dilution) 30 minutes. Mounted in vectashield plus DAPI and stored in the fridge. 
3.11 Normal Human Epithelial cells (NHBE) 
Primary NHBE were purchased from LONZA and all experiments in this study use the same cells. The 
anonymous donor was 43 years old, male, Caucasian and free of disease. (lot number 7F4167)  
3.11.1 Growth media 
NHBE were maintained in proprietary bronchial epithelial growth media (BEGM) from Lonza. This 
consisted of a basal media to which aliquots of the following supplements were added: 
Bovine pituitary extract, hydrocortisone, human epidermal growth factor, epinephrine, insulin, 
triidothryronine, transferring, gentamicin/amphotericin-B, retinoic acid.  
3.11.2 Cell culture 
NHBE were expanded in T-75 flasks (Corning, with vented caps) and then 12 well plates were seeded 
for use in assays. 250, 000 cells could seed a T-75 flask with 14mls BEGM and be ready to passage in 
~6-7 days.  Cells were fed every other day by replacing half the media with fresh. 24 well plates 
could be maintained in 0.5ml media and seeded with 250000 cells in 24 mls (10,000 cells/well) 
3.11.3 Passaging and freezing  
When flasks reached near confluence they were passaged. This means they were enzymatically 
removed from the flask and re-seeded in a fresh flask. Cryovials were taken off at this point for 
freezing to build up stocks of cells. Cells were not used beyond passage 7. 
Flasks were rinsed twice with 10ml PBS to remove trypsin inhibitors that are present in the media. 
5mls TrypLE (Sigma) was added and the flask returned to the incubator for 5 minutes.  
The flask was given a few raps on the side to loosen cells and check under the microscope that most 
cells are in suspension (you’ll never get all of the cells free but 95% is a good aim). 
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Wash cells with growth media 10 minutes x 1500 rpm. Resuspend in fresh media and re-seed as 
many flasks or plates as required.  
To freeze cells resuspend in fresh media at 2 million/ml and aliquot 500,000 cells per cryovial 
(250µl). Add 750µl freezing mix (50% FCS 30% RPMI media 20% DMSO) and immediately move the 
cryovials to an isopropanol bath (Mr frosty) in a -80⁰C freezer for at least 24 hours before storing 
long term in liquid nitrogen.  
3.11.4 Stimulation with cytokines 
Assays with NHBE were carried out in 24 well plates with cells at 70% confluence. Wells were 
aspirated and fresh media added plus any recombinant cytokines. A media control was always 
included to account for any stimulation brought on by the fresh growth media. 
 At the required time-point media was aspirated as much as possible (and stored at -20⁰C for ELISA) 
and the cells were lysed directly in the well with 350µl RLT buffer (Qiagen) and stored at -20⁰C for 
RNA isolation at a later date.   
3.11.5 Proliferation 
NHBE were plated in 96 well plate and when at 60% confluence, stimulated with cytokines for 24 
hours. For the final 16hrs, 5µCi if [3H]-thymidine (MP Biomedicals) for the final 16hrs of a 7 day 
culture. Plates were frozen at -20°C for at least 24 hours before harvesting. Cells were lysed and 
genetic material transferred onto glass fibre mats (Wallac) with a Mach III M Harvester, beta- 
scintillant (Perkin-Elmer) was added and scintillation was counted using 1450 Microbeta TRILUX 
(Wallac). 
3.11.6 Scratch assay 
NHBE were cultured in 24 well plates until just confluent. The media was exchanged for 4ml fresh 
and any stimulating recombinant cytokines added. Using a 200µl pipette (yellow) tip, three straight 
scratches were made per well across the width of the well. On the lid of the plate three lines were 
drawn at right angles to the scratches; where the scratch and pen line intersect is where the scratch 
was monitored (9 positions / well). 
These positions were photographed at 0, 5, 16 and 25 hours with a microscope mounted camera 
(Moticam 2000, Motic). The clear area, where cells had been scratched away, was calculated by 
highlighting the area using Motic software and a mean % wound closure was calculated over time 
for each cytokine concentration. 
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3.12 Real-time Polymerase chain reaction 
 
3.12.1 RNA preparation 
RNA was prepared using the Qiagen quick spin mini column kit. A minimum of 500, 000 T-cell per 
sample or a 24 well plate’s well worth of NHBE was used per sample. RNA isolation was carried out 
in batches of 24 (the maximum the centrifuge can hold), at room temperature and in semi-sterile 
conditions in a protective hood.  
3.12.1.1 Lysate preparation 
Cells were lysed in RLT buffer (350µl/sample) which was supplemented with 1% β-mercaptoethanol 
to help inhibit RNAses. RLT buffer contains guanidine thiocyanate and is very powerful, completely 
disintegrating most cell membranes. To ensure a completely homogenous cell lysate, the samples 
were spun through a “QIAshredder” (Qiagen). Samples were added to the top of the column, spun at 
top speed (8000g) in a microcentrifuge for 2 minutes and the lysates collect in the bottom of the 
column.   
3.12.1.2 RNA precipitation 
Absolute ethanol was added to each sample in equal quantities (usually around 335µl) to precipitate 
total RNA. The samples were mixed well by pipetting up and down before being transferred to a 
quickspin column and spun for 15s at high speed in a micro centrifuge. The supernatant collected in 
the bottom of the tube was discarded, as the RNA is now bound to the column. Due to the high salt 
content of the lysis buffer, absolute ethanol and specific binding properties of the column, genomic 
DNA cannot bind.  
3.12.1.3 Column washing 
The RNA was further purified with 3 washes of the column, firstly with 700µl buffer RW1, containing 
guanidine salts. 15s x full speed microcentrifuge. Discard the flow through. Then two washes with 
ethanol containing buffer RPE, both 500µl at full speed. The first for 15s and the second for 2 
minutes to ensure there is no buffer remaining on the membrane. A further spin with no wash 
buffer and a fresh collection column is performed for 1min at full speed to fully ensure the column 
membrane is dry and that there will be no flow through of ethanol when the RNA is eluted. 
3.12.1.4 RNA elution 
The quickspin columns were then placed in a new collection tube (1.5ml Eppendorf), 40µl RNAase 
free water pipette onto the centre of the membrane and the columns spun 15s at full speed. The 
pure RNA is now in the Eppendorf tube and stored at -20⁰C. 
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3.12.1.5 RNA purity check 
The RNA was checked for purity and concentration with a ND-1000 spectrophotometer (Nanodrop 
technologies). A ratio of absorption at 260/230nm was ideally at 2.0/2.2. 
3.12.2 Reverse transcription 
RNA was reversed transcribed using Revertaid First strand cDNA synthesis kit (Fermentas).   
1µg RNA was adjusted to 11.5µl in RNAase free water per sample in a 0.2ml PCR tube. To each tube 
was added ; 4µl 5X reaction buffer, 1µl random hexamer primer, 2µl 10mM dNTP mix, 0.5µl RNase 
inhibitor (20 U/µl) and 1µl Revertaid M-MuLV reverse transcriptase (200 U/µl). A reverse 
transcription master mix was usually made to speed up the preparing the tubes and ensure that the 
reverse transcriptase enzyme and RNA was not at room temperature for too long.  The mixture was 
incubated at 25⁰C for 5 minutes then 42⁰C for 60 minutes and finally 70⁰C for 5minutes to terminate 
the reaction. The resulting cDNA was stored at -20⁰C until used. 
3.12.3 Primer design 
All PCR performed was real-time PCR performed in arrays so that all primers had to be compatible 
with each other and with the standard PCR protocol. Primers were designed to be exon spanning to 
ensure that any contaminating genomic DNA was not amplified within the time of the PCR cycle in 
comparison to the cDNA derived from mRNA which is exon free. Primers were chosen with the 
software Primer 3.0 (Applied Biosystems) which checked any potential primers pairs for secondary 
structures, primer dimers and ensured that primers were in a suitable range of annealing/melting 
temperature for the cycles used in the PCR machine. All amplicons were 50-150bp long. Primer 
sequences are listed in the appendix.   
3.12.3.1 Primer validation 
Primer efficiency was checked by running a standard RT-PCR protocol for each primer with a ten-fold 
dilution standard curve of cDNA derived from activated T-cells or NHBE. A slope could be generated 
for each cDNA concentration to calculate percentage primer efficiency using the formula (10^(-
1/slope)-1)*100 All primers used were at least 50% efficient although the majority were within 90-
110%..  
3.12.4 Real time PCR 
RT-PCR was carried out on an Applied Biosystems machine 7900 HT FAST with a standard 40 cycle 
protocol: 
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10 min 95⁰C (AmpliTaq Gold polymerase activation) 
40 cycles of  15 s 95⁰C (denature), 1 min 60⁰C (anneal/extend) 
Hold 4⁰C 
Reactions were carried out in a 384 well plate, a 10µl reaction volume, in triplicate.  
cDNA was diluted 1:10 with water and 3.4µl used per reaction.  
The PCR master mix used was SYBR green (Applied Biosystems) 5µl per reaction 
PMM (Primer master mix, 4nM each forward and reverse primers in water) 1.6µl per reaction.  
The plates were pipetted with an Epimotion (Eppendorf) robot which allowed for a great accuracy 
and speed of pipetting.(40 minutes for 1 plate) 
SYBR green is a compound that fluoresces upon incorporation in a double stranded DNA, therefore 
fluorescence increases proportionately with amount of PCR product and can be measured with the 
RT-PCR machine. SYBR green PCR master mix contains SYBR green dye, AmpliTaq Gold DNA 
polymerase, dNTPS with dUTP, ROX Passive reference (An internal reference that allows the RT-PCR 
analysis software to account for any well to well fluorescence variation) in an optimised buffer.  
3.12.5 RT-PCR analysis 
Results were analysed using the delta delta ct method which normalises results against firstly, a 
house keeping gene (EF2a for T-cells and 18s for NHBE) and secondly, an experimental control such 
as no treatment or 0hr timepoint. This technique gives a relative rather than absolute gene 
expression result but we are interested in changes in gene expression rather than absolute copy-
number. 
 
3.13 Microarray 
The initial studies into the effect of IL-31 on NHBE gene expression were biased towards genes 
commonly regulated in allergy or inflammation. As the effect of IL-31 is unknown, an unbiased 
approach to measure all genes regulated by IL-31 was sought. A single colour whole human genome 
microarray (Agilent Technologies) was performed using RNA from NHBE treated with IL-31. The 
microarray chip has 44,000 probes that cover the entire human genome. RNA is amplified and 
labelled with Cy3 fluorescent dye and then hybridised onto the chip. The fluorescent intensity of 
each spot can be detected with a scanner and relative expression of each gene calculated. 
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Total RNA was isolated and sent to Miltenyi Biotec who performed the microarray hybridisation. The 
raw data was then analysed in house using Genespring (Agilent Technologies).  
In addition to treatment with recombinant IL-31, NHBE were also treated with supernatant from T-
cell clone cultures, which contained natural IL-31, in a biologically relevant setting.Overview of 
experiment design 
  
Figure 3.13.1.1. Overview of microarray experiment. 
The microarray experiment is described in Figure 3.13.1.1. Overview of microarray experiment.The 
experiment had a dual approach to identifying genes regulated by IL-31; firstly genes could be up-
regulated by recombinant IL-31. Secondly, genes regulated by IL-31 could be identified by a 
differential expression between IL-31 supernatant and IL-31 containing supernatant plus a 
blocking/neutralising IL-31 antibody. Conditions of media only and supernatant only were used as 
controls. An alternative control of anti-IL-13 blocking antibody plus supernatant was also used as an 
experimental control; genes regulated by IL-13 are known and therefore should be identified by 
analysing the effect of the anti-IL-13 compared with the supernatant only control. 
3.13.2 Supernatants  
T-cell clones from one atopic donor were screened by ELISA for the highest IL-31 expression and 
then expanded over a number of weeks. The clones were washed, adjusted to 1 million/ml and 
restimulated with plate bound anti-CD3 and anti-CD28 for 48 hours. The supernatant was 
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centrifuged (10minutes x 528g) to remove the cells and stored at -20⁰C. The concentration of IL-31 
and IL-13 was determined by ELISA (Figure 3.13.2.1) 
 
 
Figure 3.13.2.1 Concentration of IL-31 and IL-13 in clone supernatants used for microarray 
3.13.3 Optimisation steps 
A number of variable factors needed to be optimised before performing the microarray. They are 
summarised in Table 3.13.3.1. Optimisation steps prior to microarray 
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Table 3.13.3.1. Optimisation steps prior to microarray 
Potential variable Conditions tested Result 
Confluent vs. non-confluent 
NHBE. When primary 
epithelial cells grow to 
confluence they differentiate 
to a non-proliferating, stable 
monolayer with tight 
junctions. However, our Lab 
has found that proliferating 
NHBE show more robust and 
reliable gene expression 
changes. 
2.5x105 NHBE were plated in 
a 6 well plate (non-
confluent) or 24 well plate 
(confluent) overnight. Total 
RNA was harvested, reverse 
transcribed and RT-PCR 
performed for the genes 
CCL2, CCL5 and VEGF  
No significant differences 
between confluent or non-
confluent cells. Confluent 
cells used for the assay as 
they should be more stable 
during the 24 hours 
Effect of Immunoglobulin on 
NHBE. Previous experiments 
showed that blocking 
antibodies slightly stimulated 
gene expression from NHBE. 
This may be due to a low 
expression of Fc receptor, so 
it was necessary to 
determine that an fc 
receptor block would not 
affect gene expression 
either. 
2.5x105 NHBE in a 24 well 
plate were treated with 
combinations of Isotype 
control (Mu IgG1) at 
10μg/ml, recombinant  IL-31 
at 25ng/ml and Fc blocking 
reagent (Miltenyi Biotec) (20 
μl/107  cells) for 8 hours. 
Total RNA was then 
harvested, reverse 
transcribed  and RT-PCR  
performed for CCL2, CCL5 
and VEGF. 
The presence of antibody in 
the media does very slightly 
induce gene expression; 
however the commercially 
available Fc block 
ameliorates this effect whilst 
having no effect of its own 
and therefore was used for 
the microarray. 
Cell number. In order to use 
the minimum TCC 
supernatant, without 
compromising the 
experiment, the RNA yield 
from various starting cell 
numbers was compared. 
7.5x104, 1x105, 2.5 x105 , 5 
x105 NHBE were seeded into 
appropriate sized plates in 
various volumes of media. 
Cells were stimulated for 8 
hours with PMA (20ng/ml) 
and ionomycin (1µg/ml) 
before Total RNA was then 
harvested, reverse 
transcribed and RT-PCR 
performed.  
The minimum cell number 
and media volume required 
that produces sufficient RNA 
for the microarray was 2 x105 
cells in a 24 well plate with 
1ml media. 
Time point to show 
maximum change in gene 
expression. 
Time course experiments 
were performed for a small 
panel of pro-inflammatory 
genes. NHBE were 
stimulated with 50ng/ml IL-
31 for 2, 4, 8, 16 and 24 
hours and RT-PCR performed 
Different genes have 
different expression kinetics 
but 8hrs was a timepoint 
that showed elevated gene 
expression (if not maximal) 
for the majority of genes 
tested. 
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3.13.4 Final conditions for Microarray experiment 
 
2x105 NHBE, passage 3, per well of 24 well plate were plated in 1ml BEGM overnight. Wells were 
washed with fresh, warmed cloning media and then 1ml supernatant from TCC added to 3 wells. 
Fresh cloning media was added to remaining wells. 5 conditions were set up in triplicate – 
1. Media alone 
2. TCC supernatant 
3. TCC supernatant plus IL-31 blocking antibody 10µg/ml (Goat polyclonal R&D Systems, cat. 
no. AF2824) 
4. TCC supernatant plus IL-13 blocking antibody 15µg/ml (mouse monoclonal R&D Systems, 
cat. no. MAB2131) 
5.  Media plus recombinant IL-31 50ng/ml (R&D Systems) 
Normal goat Ig and mouse IgG1 (both R&D systems) was added to condition 2 at the same 
concentration as used in conditions 3 and 4. Fc block (Miltenyi Biotec) was added to conditions 2, 3 
and 4 at the manufacturers recommended dose (diluted 1:3 then 1.2µl per well). Additional test 
wells of condition 1 and 2 were set up to verify the experiment had been successful prior to sending 
the remaining 15 samples to Miltenyi Biotec. 
After 8 hours culture, each well was washed with PBS before cells were lysed with 350µl RLT lysis 
buffer for RNA isolation using the Qiagen Quickspin columns as described previously. 
 
3.13.5 Pre-Validation of Microarray 
The supernatants used in the experiments had been assayed for IL-31 and IL-13 but to ensure they 
induced gene expression in NHBE extra test wells of NHBE were set up of media control and TCC 
supernatants.  
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Figure 3.13.5.1. T-cell clone conditioned media can induce the expression of genes from NHBE. Data 
shown represent mRNA expression relative to media control and each replicate represents 
supernatant from different clones. 
As shown in Figure 3.13.5.1. T-cell clone conditioned media can induce the expression of genes from 
NHBE. Data shown represent mRNA expression relative to media control and each replicate 
represents supernatant from different clones. The supernatants were able to induce genes from 
NHBE and so the remainder samples were sent to Miltenyi Biotec to be analysed by Microarray. 
3.13.6 Quality control from Miltenyi Biotec 
All RNA samples were analysed prior to Microarray for RNA quality by Miltenyi Biotec. A RNA 
Integrity number (RIN) was generated following analysis by gel electrophoresis and an 
electropherogram in an Agilent 2010 Bioanalyzer platform (Figure 3.13.6.1). A RIN is between 1 and 
10 with 10 indicating the highest quality RNA and >6 being sufficient (Fleige and Pfaffl 2006) for 
Microarray experiments. 
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Figure 3.13.6.1. Gel image (A) and electropherogram (B) of total RNA samples. As a reference, the 
RNA molecular weight ladder (in nucleotides, nt) is shown in the first lane. The lowest migrating 
green band represents an internal standard. The two prominent peaks within the electropherograms 
represent ribosomal RNA: left 18S RNA, right 28S RNA. Scaling of the y-axis is done automatically, 
relative to the strongest signal within a single run. 
Figure 3.13.6.1 shows the purity analysis of RNA samples sent to Miltenyi Biotec. Representative of 
15 samples, all samples showed a RIN value between 9.9 and 10.  
3.13.7 Cy3 Labelling 
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Table 3.13.7.1. CY3 labelling of RNA.  
For linear T7-based amplification step, 1 μg of each total RNA sample was used. To produce Cy3-
labeled cRNA, the RNA samples were amplified and labelled using the Agilent Quick Amp Labeling Kit 
(Agilent Technologies) following the manufacturer’s protocol. Yields of cRNA and the dye-
incorporation rate were measured with the ND-1000 Spectrophotometer (NanoDrop Technologies) 
(Table 3.13.7.1Table 3.13.7.1).  
3.13.8 Microarray hybridisation and scanning 
The Cy3 labelled cRNA was hybridised to the microarray and fluorescence was detected with an 
Agilent Microarray scanner.  The resulting image files were processed with the Agilent Feature 
extraction software (FES) which subtracts the background, reject outliers and calculates statistical 
confidences of the fluorescence detected. The data was then normalised by dividing the intensity 
value by the median of all samples. This flags probe sets that have signal intensity below background 
to minimise non-biological differences. The normalised data was then imported into Genespring 
(Agilent) to identify genes with significant upregulation compared to controls. 
3.13.9 Genespring analysis 
Genespring is software designed to process large datasets generated by microarrays, filtering out 
any genes that are false positives or negatives to garner a list of genes with significant differential 
expression between the groups. 
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Upon importation genes were filtered on expression so that the lowest 20th percentile of signal 
intensity in addition to genes that don’t change in any sample are discarded. The remaining genes 
could then be analysed for significant expression changes as described in the results. Another 
feature of Genespring is Gene Ontology (GO) analysis which screens published scientific literature 
for gene functions and relations and then annotates the genome database so that any connections 
between genes, e.g. those up-regulated by IL-31, can be highlighted. 
3.13.10 Validation steps  
The Genespring analysis put forward candidate genes regulated by IL-31. To validate this analysis, 
the original RNA samples sent to Miltenyi were analysed by RT-PCR using primers for these 
candidate genes. 
To validate the experiment as a whole, new Th2 supernatants were generated and used to repeat 
the microarray experiment. RT-PCR was then used to analyse the expression of candidate genes 
identified during the microarray.   
 
3.14 Statistics 
Statstical analyses were performed by Prism software (Graphpad). The majority of experiments had 
low n-numbers so were considered non-parametric and therefore non-parametric tests were 
employed. These were either Mann-whitney or Wilcoxen tests depending on whether the 
comparisons were for unpaired or paired data respectively. Multiple comparisons were analysed by 
a Kruskal-Wallis anova with Bonferroni post-hoc test. Results were considered significant with a p 
value less than 0.05. 
Many of the comparisions made in this thesis were to determine significant gene expression change. 
This was limited due to the expression values generated by RT-PCR being relative rather than 
absolute quantity.  All delta delta ct comparisons were performed against 1 replicate of the 
experimental control which allows an error bar on the experimental control group on each figure. 
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4 An investigation into the expression of IL-31  
4.1 IL-31 expression from allergen stimulated cultures of peripheral blood mononuclear cells 
from atopic grass-pollen allergic individuals and non-atopic controls. 
 
IL-31 has been detected at sites of allergic inflammation. This may suggest that IL-31 is induced by 
allergen stimulation, but does not exclude the possibility that IL-31 is induced by a secondary factor, 
such as a bacterial infection, or a physical stimulus such as scratching. The following set of 
experiments aimed to investigate the relationship between allergy and IL-31 expression. The 
objectives of this chapter were to detect IL-31 in PBMC and tissue from allergen challenged donors 
at both an mRNA and protein level. I also aimed to investigate the conditions under which T-cells 
could be induced to express IL-31. 
 
4.1.1  Memory and naive T-cells from grass pollen allergic individuals express IL-31 under 
polyclonal stimulation 
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Figure 4.1.1.1 Memory and naive T-cells from grass pollen allergic individuals express IL-31 upon polyclonal 
stimulation.  CD45RA
+
 and CD45RO
+ 
CD4
+
 T-cells were isolated from atopic donors (n=3 for 0 and 4 hours, n=1 
for 8 and 24hr) and stimulated with PMA (20ng/ml) and ionomycin (1µg/ml) for 4, 8 and 24 hours before RNA 
was isolated and RT-PCR performed for IL-31. Data shown are relative to zero hour time point and normalised to 
EF1a expression. (B) Shows IL-31, IFNγ and IL-4 expression from (a) at 4 hours. A Mann-Whitney test was 
employed to show significant differences between groups. 
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Previous studies have linked IL-31 expression to allergy.  In order to start to test the hypothesis that 
IL-31 is a pro-allergic Th2 cytokine (page 41) The IL-31 mRNA expression from naive and memory T-
cells was measured in response to a general polyclonal stimulation (Figure 4.1.1.1.a). There is a peak 
of IL-31 gene expression between 4 and 8 hours for both naive and memory cells. There is a very 
nearly significant difference (p=0.06) between the groups at 4 hours with CD45RO+ cells exhibiting a 
1377.9 ± 320 SEM fold increase of IL-31 expression compared with an increase of 484.6 ± 225.3 SEM 
fold increase of CD45RA upon stimulation. There was a trend towards a greater difference between 
memory and naive T-cell expression of IL-31 (Figure 4.1.1.1.b) in comparison to IL-4 and IFNγ, 
although there were no significant differences between either groups. 
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4.1.2 IL-31 expression is elevated in peripheral blood mononuclear cells from atopic grass 
pollen allergic donors upon stimulation with Phlp, timothy grass protein, but not with PPD 
 
 
 
Figure 4.1.2.1 IL-31 expression is elevated in peripheral blood mononuclear cells from atopic grass pollen allergic donors 
upon stimulation with Phlp, timothy grass protein, but not with PPD. PBMC from healthy and grass pollen allergic donors 
(n=6 for each group) were stimulated for 7 days with Phlp extract (10μg/ml), PPD (1μg/ml) or polyclonal anti-CD3 and anti-
CD28 (1μg/ml for both). Real-time PCR performed for the genes IL-31 (a), IL-4 (b) and IFNγ (c). Data are represented as 
mean ct value ± SEM normalised to the housekeeping gene EF1a and are relative to the non-atopic polyclonal stimulation 
group. * P≤0.05 as determined by unpaired t-test. D) PBMC from atopic donor (n=3) were stimulated for 5 hours with 
increasing dose of grass pollen Phlp protein before RNA extracted and RT-PCR performed. Data shown are relative to 
untreated cells and normalised to Ef1a housekeeping gene expression.  
  
IL-31
Polyclonal PPD 1g/ml Phlp 10g/ml
0
5
10
15
20
40 *
Non-Atopic
Atopic
A
m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
IL-4
Polyclonal PPD 1g/ml Phlp 10g/ml
0
5
10
15
B
m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
IL-31 5 hour stimulation
0 0.1 1 10
0.0
0.5
1.0
1.5
2.0
2.5
PHLP [g/ml]
D
m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
ns
IFN
Polyclonal PPD 1g/ml Phlp 10g/ml
0
5
10
15
C
m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
89 
 
IL-31has been detected in atopic skin diseases  (Neis, Peters et al. 2006) such as Dermatitis and 
Eczema but it has not been determined what factor is inducing IL-31 expression or whether the 
association is coincidental. We therefore asked whether IL-31 is produced during an in vitro 
stimulation of peripheral blood mononuclear cells (PBMC) with a common aeroallergen.  PBMC were 
incubated with recombinant Phlp 5 protein, out of the dominant Timothy grass pollen, a very 
common allergen for UK Allergic Rhinitis patients (D’Amato, 1998). IL-31 expression was then 
measured by RT-PCR, and found to be 10 times higher (atopic mean fold change 20.6 ± 11.89 SEM 
vs. non-atopic mean fold change 1.8 ± 1.06 SEM) in the cultures from atopic donors compared to 
non-atopic (a.). Phlp protein induced expression of IL-4 (b.) with a trend towards increased 
expression by atopic donors (atopic mean fold change 9.23 ± 2.32SEM increase vs. non-atopic 4.01 ± 
2.22 SEM mean fold increase). 
 A control of PPD stimulation (purified protein derivative of Tuburculin) was employed as PPD 
specific T-cells are mostly Th1 phenotype (Del Prete, De Carli et al. 1991) in contrast to current 
literature suggesting that IL-31 is produced by Th2 cells. PPD stimulation did not induce appreciable 
amounts of IL-31 or IL-4 from PBMC from either atopic or non-atopic donors but did induce IFNγ (c, 
3.35 ± 0.58 SEM mean fold increase from non-atopic vs. atopic 5.77 ± 1.33 SEM mean fold increase) 
from both types of donors. Although all T-cells were stimulated, as opposed to just the antigen 
specific portion, the polyclonal stimulation had very low gene expression for all genes measured. 
In contrast to a 7 day culture, a short term 5 hour allergen stimulation of PBMC was performed to 
examine the direct effects of allergen stimulation. As shown in d, there was no significant 
upregulation of IL-31 from PBMC at 5 hours, even when stimulated with 10µg/ml Phlp, which shown 
a good stimulation of PBMC at day 7. 
4.2 Expression and co-localisation of IL-31 in vivo after allergen provocation in human skin and 
nasal mucosa. 
 
IL-31 has been detected by RT-PCR in skin biopsies from various skin diseases (Sonkoly, Muller 
et al. 2006) but this study wanted to confirm the existence of IL-31 protein producing cells in 
tissue, particularly from allergen challenged atopic individuals.  
As fully described in the methods section, all immunohistochemistry was performed on nasal 
and skin biopsies that had undergone allergen, PPD or diluent challenge. 
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4.2.1  IL-31 can be detected in human skin and nasal mucosa from atopic donors. 
 
 
 
Figure 4.2.1 0.1.IL-31 can be detected in human skin and nasal mucosa from allergic donors. Dermal (a) and nasal (b) punch 
biopsies were taken 8 hours post intradermal/nasal allergen challenge from allergic donors. Sections were fixed in acetone 
and frozen. IL-31 was stained using a mouse monoclonal antibody, visualised with a biotin-avidin-alexa488. Nuclei were 
counterstained with DAPI. All pictures taken at 400x magnification. Arrows denote representative IL-31
+ 
cells.  
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In order to maximise the chance of detecting IL-31, the first sections stained for IL-31 were 
allergen challenged sections from atopic donors. Skin sections from donors G9, G3 and G7 and 
nasal sections from donors P003b and P006b were all biopsies from atopic donors who had 
undergone an 8 hours allergen challenge with either Timothy grass or house dust mite extract 
as appropriate. These sections were stained with a mouse monoclonal IL-31 antibody which 
was then visualised with the ABC three layer staining and Alexa Fluor 488. As shown in Figure 
4.2.1 0.1, IL-31 positive cells (in green) can be easily found in all of the sections by 
immunofluorescent microscopy. Although the epithelium is not always visible, IL-31 positive 
cells were found scattered throughout the dermis but not the epidermis. These initial stains did 
not hint towards a phenotype of an IL-31 producing cell, staining could be found in a wide area 
of the biopsy, not clustered around a blood vessel, lymph vessel or localised to basement 
membrane for example.
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4.2.2 Cutaneous IL-31+ cells are detectable by specific fluorescence microscopy after both 
intradermal allergen and diluent challenge but do not co-localise to CD3+ cells. 
 
 
 
Figure 4.2.2.1. IL-31 and CD3 can be stained in human skin from atopic donors after an allergen or diluent challenge 
but do not co-localise. Frozen dermal sections from 3 atopic donors following an 8 hour allergen or diluent 
intradermal challenge were stained with a mouse monoclonal IL-31 Ab, plus FITC rabbit anti-mouse antibody. T-cells  
stained with a rabbit polyclonal CD3 Ab (Abcam) plus ABC -Alexa fluor 594. Nuclei were counterstained with DAPI. 
Images taken at 400x maginification.  
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Current literature on IL-31 suggests that IL-31 is a T-cell cytokine. Skin sections from atopic donors 
that had undergone an 8 hour allergen or diluent challenge were stained for CD3 and IL-31 or 
isotype matched control for the IL-31 antibody (Mouse IgG1). CD3 staining fluoresced red with 
Alexa-Fluor 594, IL-31 appeared green with FITC staining, DAPI staining rendered any nucleic acid 
blue, thereby highlighting nuclei of individual cells.  Figure 4.2.2.1. shows clear green staining of IL-
31 in the allergen challenged tissue which is absent in the isotype control and also, in these sections, 
apparently completely absent in the diluent challenge. There were CD3 cells in both allergen and 
diluent challenged skin sections, although possibly more CD3 cells in the allergen challenged tissue. 
In this sample of sections, no IL-31/CD3 double positive cells were observed. 
 
4.2.3 Cutaneous IL-31 and CD3 positive cells are increased at 8 hours after intradermal 
allergen challenge. 
 
Due to the encouraging result of IL-31 being potentially induced by allergen challenge and not 
diluent challenge in the skin, this study was expanded to include 8 individuals and quantification of 
the degree of IL-31 staining in the skin. 
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Figure 4.2.3.1 Frequency of IL-31 positive cells changes upon an 8hr allergen challenge. Dermal sections from 8 atopic 
donors following an 8 hour allergen or diluent intradermal challenge were stained with a IL-31 Mab and FITC  
secondary (green).  T-cells stained with CD3 PAb (Abcam), biotin, avidin-Alexa fluor 594. Nuclei were counterstained 
with DAPI. A two field-depth of tissue immediately below the epithelium was captured at 400x magnification and IL-31 
and CD3 positive cells counted (a-b). Representative slides of allergen challenged tissue are shown in (c-d) and (e) 
shows average frequency of IL-31/CD3 positive cells across all donors. A Mann-Whitney test shows differences 
between groups where significant. *p<0.05 
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IL-31 and CD3 were stained in skin sections from 8 atopic individuals that had undergone an 8 hour 
intradermal challenge with allergen or diluent. As shown in Figure 4.2.3.1.a. there was a significant 
increase in the numbers of CD3+ cells found in the skin following an allergen challenge compared to 
the baseline diluent challenge from a mean value of 44.41 to 148.8 cells/mm2. 7 out of 8 samples 
showed an increase with one showing no change. In contrast, as shown in Figure 4.2.3.1.b, IL-31 
positive cells were detectable at baseline (after allergen diluent) but did not change at 8 hr after 
allergen challenge. Although the mean IL-31+ cell density rose from 4.57 to 16.51 cells/mm2, this was 
due to a few donors exhibiting a large increase in IL-31 expression following allergen challenge and 
equal numbers showed no change or a decrease in IL-31 positive cells.  IL-31 CD3 double positive 
cells were observed in over 200 captured images, as summarised in Figure 4.2.3.1.e. 
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4.2.4  Cutaneous CD3 and IL-31 expression   48hr after intradermal challenge with tuberculin 
protein (purified protein derivative, PPD) allergen or diluent. 
 
Figure 4.2.4.1 The frequency of IL-31 and CD3 positive cells in human skin changes upon a 48hr allergen or PPD 
challenge. Skin sections from atopic donors (n=3) taken 48hrs post allergen (a), diluent or PPD (b) intradermal 
challenge were stained for IL-31 with IL-31 MAb, plus FITC secondary PAb. T-cells were stained with CD3 PAb plus 
avidin-Alexa fluor 594. Nuclei were counterstained with DAPI. A two field-depth of tissue immediately below the 
epithelium was captured at 400x magnification and CD3 and IL-31 positive cells counted.  
 
 
D
ilu
en
t
A
lle
rg
en
0
100
200
300
400
500
G6
G7
G16
CD3
48 hour challenge
C
D
3
+
 c
e
ll
s
/m
m
2
D
ilu
en
t
P
P
D
0
200
400
600
G6
G7
G16
CD3
48 hour challenge
C
D
3
+
 c
e
ll
s
/m
m
2
IL-31
D
ilu
en
t
A
lle
rg
en
0
5
10
15
G6
G7
G16
48 hour challenge
IL
-3
1
+
c
e
ll
s
/m
m
2
IL-31
D
ilu
en
t
P
P
D
0.0
0.5
1.0
1.5
2.0
2.5
G6
G7
G16
48 hour challenge
IL
-3
1
+
c
e
lls
/m
m
2
A)
B)
97 
 
Skin biopsies were taken from the same individuals at 48 hour afterchallenge with PPD, allergen and 
diluent.Representative cutaneous sections (n=3) were stained for IL-31 and CD3. Thes cells were quantified in a two-field 
depth below the epithelium as before (Figure 4.2.4.1). The allergen mediated T-cell infiltration had lessened compared to 
the 8 hour time point but there was a strong increase in CD3
+
 T-cells in response to PPD challenge (diluent mean CD3
+
 
cells/mm
3
 150.85 ± 129.9SEM  vs. PPD 395.2 ± 104.3 SEM mean CD3
+
 cells/mm
3+ 
, a 2.6 fold increase). In agreement with 
previous in vitro studies, ( 
) PPD does not induce IL-31 expression, with very low densities of IL-31+ cells found in both diluent 
and PPD challenge conditions, (0.5 and 0.9 cells/mm2 respectively). In concordance with the 8hr time 
point result, IL-31 was not consistently induced by allergen challenge with only 1 of the 3 samples 
showing an increase in IL-31 staining compared with diluent and PPD. No IL-31 + CD3+ double 
positive cells were observed at this time point.  
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4.2.5  IL-31 does not co-localise with granulocytes.
 
Figure 4.2.5.1. IL-31 is not co-localised to other immune cells. Skin sections from allergen challenged atopic donors 
were stained for IL-31 with a PAb and avidin-biotin Alexa fluor 594. Co-stains were carried out for other cell types with 
mouse monoclonal Abs against  towards Neutrophil elastase (a), Major basic protein (b), Mast cell Tryptase (c). 
Staining visualized with FITC labelled rabbit anti- mouse Ab, amplified with a mouse anti-FITC plus another layer of 
FITC-rabbit anti-mouse. Nuclei were counterstained with DAPI. All images were captured at 400x magnification. 
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Following the lack of co-localisation of IL-31 and T-cells, a panel of different immune cells were co-
stained with IL-31 to try and identify the IL-31 producing cells. We were able to identify robust 
staining for the entire panel however IL-31 did not co-localise with neutrophil, eosinophil or mast 
cell staining on the sections tested (Figure 4.2.5.1). As shown in Figure 4.2.5.2. IL-31 staining also did 
not co-localise with CD68+ macrophages or BDCA-1 myeloid dendritic cells. Due to the distribution of 
IL-31 positive cells being close to other immune cell infiltrates, only co-stains with other immune 
cells were carried out.  The lack of colocalisation of IL-31 on structural tissue such as blood vessels, 
lymph glands or epithelium was confirmed by an experienced independent histology technician.  
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Figure 4.2.5.2. IL-31 is not co-localised to other immune cells. Skin sections from allergen challenged atopic donors 
were stained for IL-31 with a PAb (Abcam) and visualised with biotin -avidin-Alexa fluor 594. Co-stains were carried 
out for other cell types with mAbs against  CD68 (d) and  BDCA-1 (e). Staining visulualised with a FITC labelled rabbit 
anti- mouse Ab, amplified with a mouse anti-FITC plus another layer of FITC-rabbit anti-mouse. Nuclei were 
counterstained with DAPI. All images were captured at 400x magnification. 
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4.2.6  IL-31RA is expressed by structural tissue cells  
 
Figure 4.2.6.1. IL-31 receptor expression on different  cell types. IL-31 receptor was stained for in a variety of atopic, 
normal, diluent and allergen challenged tissue using a PAb (Abcam), biotin-avidin-Alexa fluor 594. Co-stains for CD31 
(a), CD3 (b) and CD68 (c) were carried out with mAbs and visualised with a rabbit anti-mouse FITC Ab. Nuclei were co-
stained with DAPI. All images were captured at 400x magnification. 
 
102 
 
 IL-31 receptor A subunit (IL-31RA) was stained in allergen challenged skin tissue from normal (N 
donors) and atopic (G donors) with a polyclonal rabbit antibody. As shown in Figure 4.2.6.1, IL-31RA 
staining was widespread with positive cells within the epithelium, endothelium and dermis. The 
control sections stained with normal rabbit immunoglobulin showed a complete absence of staining. 
.IL-31RA has been reported in literature as being expressed by epithelium (Dillon, Sprecher et al. 
2004) and this was confirmed in Figure 4.2.6.1. When co-stained with antibodies for CD31, IL-31RA 
always colocalised to this endothelial cell marker. 
In this study IL-31RA did not colocalise to immune cells such as T-cells and CD68+ macrophages, 
despite the latter having been demonstrated in the literature. Any change in IL-31RA expression in 
response to allergen challenge was not observed so the study was not expanded to increase the n 
number.
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4.3 IL-31 expression in CD4+ T-cells derived from peripheral blood cultured under Th1/Th2 
deforming conditions. 
 
Once activated, CD4+ T-cell cultures differentiate to a number of effecter T-cell phenotypes 
appropriate to the nature of the provocation. The differentiation is directed by various polarising 
cytokines from dendritic cells but is then maintained by the T-cells themselves. The opposing Th1 
and Th2 differentiation paths actually inhibit the differentiation of each other, strengthening the 
degree of polarisation. Allergen stimulation has been shown to polarise activated T-cells towards a 
Th2 phenotype (Del Prete, De Carli et al. 1991) so we wanted to examine the effects of Th2 
polarisation on IL-31 expression and test the hypothesis that IL-31 is a Th2 cytokine in the same 
manner as IL-4 and IL-13. 
 
4.3.1  IL-31 is expressed by non-atopic T-cells after 7 days in Th2 deforming conditions. 
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Figure 4.3.1.1.  IL-31 is expressed by T-cells after 7 days culture in Th1/Th2 deforming conditions. CD4
+ 
T-cells from 
non-atopic donors (n=3) were polarised towards Th1 or Th2 phenotypes in the presence of IL-12 (25ng/ml) and anti IL-
4 (5µg/ml) or IL-4 (25ng/ml) and anti-IFNγ (5µg/ml) respectively. After 7 days, RT-PCR performed for IL-31 (a), T-bet (c) 
and Gata3 (d), data shown are relative to neutral conditions then normalised to Ef1a housekeeping gene expression. A 
Wilcoxen test was used to test significance. B) IL-31 protein measured in day 7 Th1 and Th2 cultures, stimulated 48hrs 
with plate bound anti-CD3 and anti-CD28 (both at 1µg/ml) 
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CD4+ T-cells from three healthy donors were cultured for 7 days in Th1 and Th2 deforming conditions 
before being analysed by ELISA and RT-PCR. As can be seen in Figure 4.3.1.1.b Th2 conditions 
induced a strong upregulation of IL-31 secretion into the supernatants, with an almost ten-fold 
difference between Th1 (15 pg/ml) and Th2 (148.3 pg/ml) groups. These data were parallel with the 
RT-PCR data which showed an upregulation of IL-31 mRNA expression in the Th2 group compared 
with Th1 and neutral. Th1 and Th2 polarisation was confirmed by the induction of T-bet and Gata3 
transcription factors respectively. Although these fold changes were small, 7 days is a fairly short 
timepoint and cultures may still be slightly heterogeneous with respect to T-cell phenotype. 
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4.3.2  IL-31 is expressed by atopic T-cells during a 4 week Th2 deforming culture. 
 
 
Figure 4.3.2.1. Th2 deforming conditions can induce IL-31. CD4 T-cells from grass pollen allergic donors were cultured 
for 4 weeks, restimulated every week with anti-CD3 and anti-CD28 (both 1µg/ml), IL-2 (20ng/ml) and polarising 
cytokines. IL-4 , anti IFNγ and anti IL-10 (5µg/ml) directed Th2 differentiation and IL-12 and anti-IL-4 to induce Th1. 
48hr post restimulation, supernatants were assayed for IL-31 by ELISA. Data represent mean ± SEM of experimental 
repeat (n=3).   
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CD4+ T-cells from three grass pollen allergic donors were expanded and differentiated towards 
neutral, Th1 and Th2 phenotypes for 4 weeks according to the protocol devised by David Cousins 
(Cousins, Lee et al. 2002)  
 As can be observed in Figure 4.3.2.1, there was a wide variance in the IL-31 expression from the 
different donors. In general, Th2 cultures produced more IL-31 than the neutral cultures and the 
neutral cultures produced more IL-31 than the Th1 cultures. Although all donors showed this trend 
by week 4, T-cell 154 produced a lot less IL-31 (17.4 pg/ml) than T-cell 155 and T-cell 153 donors 
(135.96pg/ml and 490pg/ml respectively). There was not a clear upregulation of IL-31 over the 
weeks either, with levels of IL-31 only increasing slightly over the 4 timepoints. When comparing the 
IL-31 production between atopic and non-atopic donors at day 7, there seems to be a much greater 
variance between the atopic donors and perhaps, a lower IL-31 expression from the atopic donors 
than non-atopic. A result that was consistent between non-atopic and atopic donors was that Th1 
conditions, IL-12 and anti-IL-4, did not induce and possibly suppressed IL-31 expression from T-cells. 
 
4.4 Regulation of IL-31 expression in CD4+ T-cells, lines and clones derived from peripheral 
blood.  
 
Having demonstrated that IL-31 is induced by allergic stimulation of the skin and peripheral blood 
and that T-cells can produce IL-31 when stimulated with allergy biased Th2 deforming conditions, 
this section focuses on T-cell expression of IL-31; to investigate the conditions under which IL-31 is 
expressed and hopefully elucidate the role IL-31 plays in the allergic reaction. 
 
4.4.1  In vitro induction of IL-31 from CD4+ T-cells 
 
These set of experiments were carried out on CD4+ T-cells isolated from the PBMC of atopic and non-
atopic donors. A range of stimulatory cytokines and antibodies were applied to the cells and IL-31 
mRNA expression was measured by RT-PCR. Although not as robust as a protein read-out from 
ELISA, RT-PCR was used for its high sensitivity which the ELISA lacks. Previous experiments have 
shown that IL-31 mRNA and protein expression are generally equivalent. 
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1.1.1.1 IL-31 is induced by IL-4 in memory and naive T-cells from non-atopic donors 
 
 
Figure 4.4.1.1. IL-31 is induced by IL-4 in  memory and naive T-cells. CD45RA
+
 and CD45RO
+ 
CD4
+
 T-cells were isolated 
from non- atopic donors (n=3) and stimulated with anti-CD3 and anti-CD28 (both plate-bound at 1µg/ml) for 48 hours 
in the presence of an increasing dose of IL-4. RT-PCR detected genes IL-31 (a,b), IL-4 (c,d) and IFNγ (e,f). Data shown 
are relative to the 0ng/ml IL-4 condition and normalised to EF1a expression. 
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Memory and naive T-cells were isolated from CD4+ T-cells derived from non-atopic donors based on 
CD45RO expression. CD45RO+ cells being memory and CD45RO- cells considered naive. Memory and 
naive T-cells were stimulated with plate-bound anti-CD3 and anti-CD28 in the presence of 0, 10, 50 
or 100ng/ml recombinant IL-4. At 48hrs RT-PCR was performed to measure IL-31, IL-4 and IFNγ gene 
expression fold change in comparison to the negative control of 0ng/ml IL-4 for that cell type. As 
seen in Figure 4.4.1.1 IL-4 induced IL-31 from both memory and naive T-cells of about a 5 fold 
increase over no treatment. There was a trend to towards a dose response curve, with the greatest 
IL-31 expression observed for the 50ng/ml IL-4 (memory cells 6.03 ± 1.9 SEM and naive cells 4.62 ± 1 
SEM fold change over 0ng/ml IL-4 condition). This tailed down again at 100ng/ml IL-4 There was 
fairly high variance between the donors for the different IL-4 concentrations, at 50ng/ml IL-4 p=0.12 
and p=0.07 for memory and naive cells respectively when compared to media control. There was no 
significant difference in IL-31 expression between naive and memory T-cells. 
IL-4 did not have any effect on IL-4 mRNA expression from memory or naive T-cells at every 
concentration despite being included as a marker of IL-4 stimulation. However, IL-4 did appear to 
suppress IFNγ expression. IFNγ measurement was included as negative control because it is a Th1 
cytokine and therefore not induced by IL-4. 
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4.4.1.1 IL-4 is only Th2 cytokine to induce IL-31 from CD4+ T-cells. 
 
Figure 4.4.1.2 Th2 cytokines other than IL-4 do not induce IL-31. CD4
+
 T-cells from non-atopic donors (n=3) were 
stimulated with anti-CD3 and anti-CD28 (both plate-bound at 1µg/ml) for 48 hours in the presence of different 
cytokines (all at 20ng/ml) ± IL-4 (20ng/ml).  RT-PCR was performed for IL-31 (a), IL-4 (b) and IFNγ (c). Data shown are 
relative to media control and normalised to EF1a expression. Any significant differences by Wilcoxen test shown 
*=P<0.05 
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In addition to IL-4, Th2 cells produce the cytokines IL-5, IL-9, IL-10 and IL-13. CD4+ T-cells were 
stimulated with a panel of Th2 cytokines ± IL-4 for 48hrs before IL-4, IL-31 and IFNγ gene expression 
was calculated (Figure 4.4.1.2). In line with the previous figure, IL-4 induced a 4.02 ± 1.6 SEM fold 
increase in IL-31 expression. Singly, none of the alternative Th2 cytokines had any effect on IL-31 
expression from T-cells.  
When combined with IL-4 these cytokines show a trend towards boosting IL-31 expression from that 
observed with IL-4 alone, however there were no significant differences between any of the groups 
where IL-4 was present. IFNγ did not induce IL-31 when compared to the media control.  
IL-4 gene was measured in these conditions as a marker of Th2 induction, but none of the conditions 
induced a significant fold change of IL-4 expression, with most results remaining within a margin of 
0.5 fold change ± media control. 
None of the Th2 cytokines could induce IFNγ expression from the cells above the media control, 
however there was a significant suppression of IFNγ in the presence of IL-4 when compared to the 
media control (p=0.0011, IL-4 fold change 0.37 ± 0.074 SEM vs. media control set at 1). This 
suppression of IFNγ by IL-4 was consistent and was not influenced by the other Th2 cytokines. 
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4.4.1.2 IL-33 can synergise with IL-4 to induce IL-31 from memory and naive CD4+ T-cells.  
 
 
Figure 4.4.1.3 IL-33 can synergise with IL-4 to induce IL-31.CD45RA
+
 and CD45RO
+ 
CD4
+
 T-cells from atopic donors 
(n=3) were stimulated with anti-CD3 and anti-CD28 (both plate-bound at 1µg/ml) for 48 hours with combinations of 
IL-4 (20ng/ml) and IL-33 (20ng/ml). RT-PCR was performed for IL-31 (a) and IL-4 (b), data shown are relative to media 
control and normalised to EF1a housekeeping gene expression. 
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Naive and memory T-cells were isolated from 3 atopic donors and stimulated with anti-CD3 and anti-
CD28 and combinations of IL-4 and IL-33 (both 20ng/ml) for 48hrs. RT-PCR was then used to analyse 
the gene expression of IL-31, IL-4 and IFNγ, relative to the media control. When combined with IL-4, 
IL-33 could significantly upregulate IL-31 expression from CD45RA+ naive T-cells (1 vs. 13.6 ± 2.6 SEM 
fold change, p=0.044) and from CD45RO+ T-cells (1 vs. 19.73 ± 13.18 SEM, p=0.29) in comparison to 
the media control (Figure 4.4.1.3). IL-33 alone had no real effect on IL-31 expression but the 
combination of IL-4 and IL-33 showed a synergy that boosted IL-31 expression beyond an additive 
effect of the two separate cytokines. There was no consistent effect of IL-4 and IL-33 on IL-4 
expression. 
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4.4.1.3 IL-31 expression induced by IL-4 is resistant to suppression by regulatory cytokines 
 
 
Figure 4.4.1.4 IL-31 expression induced by IL-4 is resistant to suppression by regulatory cytokines. CD4
+
 T-cells from atopic 
donors (n=3) were cultured for 6 days with Th2 polarising conditions (IL-4 20ng/ml, anti-IFNγ 5µg/ml) or IL-35 or IL-10 (both 
at 20ng/ml). All cultures were restimulated with soluble anti-CD3 and anti-CD28 (both at 1µg/ml) for 24 hours and IL-35 
and IL-10 was added to the Th2 cultures before RT-PCR performed for IL-31.Data shown are relative to media control and 
are normalised to EF1a housekeeping gene expression. 
 
neu IL-35 Th2 Th2 IL-35
0
10
20
30
40
50
ns
A
IL
-3
1
 m
R
N
A
 e
x
p
re
s
s
io
n
 [
fo
ld
]
neu IL-10 Th2 Th2 IL-10
0
10
20
30
40
50
nsB
IL
-3
1
 m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
neu IL-35 Th2 Th2 IL-35
0
2
4
6
8
C
ns
IF
N
 
e
x
p
re
s
s
io
n
 [
fo
ld
]
neu il-10 Th2 Th2 il-10
0.0
0.5
1.0
1.5
2.0
2.5
D
P=0.06
IF
N
 
e
x
p
re
s
s
io
n
 [
fo
ld
]
neu IL-35 Th2 Th2 IL-35
0
1
2
3
4
5
E ns
fo
xP
3
 m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
IL-35 IL-10
IL-31
IFNγ
FoxP3
neu IL-10 Th2 Th2 IL-10
0
1
2
3
4
F
p=0.1
fo
xP
3
 m
R
N
A
 e
xp
re
s
s
io
n
 [
fo
ld
]
115 
 
While most Th2 cytokines have an activating effect on their target cells, IL-10 has an alternative 
function which is to suppress the secretion of cytokines. In Figure 4.4.1.2, it was observed that IL-10 
showed no suppressive effect on the expression of IL-31 induced by IL-4. This experiment was 
repeated but with the stronger IL-31 induction of Th2 polarising conditions, IL-4 plus anti-IFNγ. The 
effect of IL-35, a cytokine that can induce regulatory T-cells, was also tested. 
As demonstrated in Figure 4.4.1.4, IL-35 and IL-10 have no suppressive effect on IL-31 induced by 
Th2 conditions after 1 week culture. The Th2 conditions did induce a strong IL-31 expression, a 27.69 
± 11.4 SEM fold increase over neutral conditions. Neither IL-10 nor IL-35 had any significant 
influence on IL-31 expression, although they could not induce IL-31. IFNγ was measured as a marker 
of Th2 differentiation suppression. 
As shown in Figure 4.4.1.4.b-c, Th2 conditions suppressed IFNγ expression. IL-35 had no influence 
over this suppression of IFNγ, but IL-10 was able to inhibit the Th2 differentiation and subsequent 
suppression of IFNγ expression, a near significant change of p=0.06. FoxP3 was measured as a 
marker of regulatory T-cell differentiation and a sign of active IL-35 recombinant protein. In this 
experiment IL-35 was unable to significantly induce FoxP3 therefore we cannot conclude that IL-31 is 
resistant to regulation by IL-35. IL-10 and IL-35 did however permit a trend towards an increased 
FoxP3 expression when combined with Th2 conditions. 
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4.4.2 Transcription factors associated with allergic disease can potentially bind the IL-31 
promoter. 
Table 4.4.2.1. Transcription factors that can potentially bind the IL-31 promotor as determined by MatInspector software. 
Highlighted rows are transcription factors important to immune response. 
 
TF Family name  Function/association  Matrix (TF name)  
Matrix 
similarity  
1  Vertebrate steroidogenic factor Regulates expression of hormones  SF1.01  1 
2  Vertebrate steroidogenic factor “                      “                      “  SF1.01  0.996 
3  
Vertebrate SMAD family of 
transcription factors TGFbeta signalling  SMAD4.01  0.995 
4  C2H2 zinc finger transcription factors 2 Multiple  ZNF300.01  0.994 
5  GATA binding factors Haematopoeisis  GATA2.03  0.99 
6  NeuroD, Beta2, HLH domain Neurogenesis and pancreas development  NGN_NEUROD.01  0.988 
7  
SWI/SNF related nucleophosphoproteins 
with a RING finger DNA binding motif multiple  SMARCA3.02  0.986 
8  Human and murine ETS1 factors Apoptosis and protein degradation  ETV1.02  0.984 
9  NeuroD, Beta2, HLH domain Neurogenesis and pancreas development  NGN_NEUROD.01  0.982 
10  AP1, Activating protein 1 
Responds to cytokines, stress, bacterial 
viral infections, multiple effects.  AP1.03  0.979 
11  GATA binding factors multiple  GATA1.06  0.978 
12  Human and murine ETS1 factors Apoptosis and protein degradation  ELK1.02  0.977 
13  Zinc finger protein ZNF35 multiple  ZNF35.01  0.976 
14  
Testis-specific bHLH-Zip transcription 
factors multiple  SPZ1.01  0.974 
15  
SWI/SNF related nucleophosphoproteins 
with a RING finger DNA binding motif multiple  SMARCA3.01  0.973 
16  Heat shock factors Induce heat shock factors  HSF2.02  0.972 
17  
Vertebrate homologues of enhancer of split 
complex Multiple during embryogenesis  DEC2.01  0.972 
18  Nuclear factor of activated T-cells Regulate t-cell development and function  NFAT.01  0.971 
19  Winged helix binding sites multiple  WHN.01  0.971 
20  
Krueppel-like C2H2 zinc finger factors 
hypermethylated in cancer Multiple/metabolism  HIC1.02  0.97 
21  EVI1-myleoid transforming protein embryogenesis  EVI1.07  0.968 
22  
AHR-arnt heterodimers and AHR-related 
factors Regulates Th17 differentiation  AHRARNT.03  0.966 
23  
 Twist subfamily of class B bHLH 
transcription factors multiple  MESP1_2.01  0.964 
24  
Vertebrate SMAD family of transcription 
TGFbeta signalling SMAD.01  0.963 
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factors 
25  PAX-2/5/8 binding sites embryogenesis  PAX2.02  0.96 
26  
Signal transducer and activator of 
transcription T-cell expressed, IL-6 signalling  STAT3.02  0.958 
27  
Signal transducer and activator of 
transcription 
Growth factor, IL-2,3, 4,7 GM-csf 
signalling  STAT5.01  0.957 
28  Myoblast determining factors Haematopoeisis  TCFE2A.02  0.957 
29  AP1, Activating protein 1 Response to multiple immune attack  AP1.01  0.955 
30  MEF3 binding sites embryogenesis  SIX.01  0.955 
     
57  
Signal transducer and activator of 
transcription IL-4 signalling, Th2 differentiation  STAT6.01  0.924  
66  Nuclear factor kappa B/c-rel  
Regulates B-cell Ab production, 
activated by TLR signals  CREL.01  0.912  
91  Ikaros zinc finger family Regulates Th2 differentiation  IK3.01  0.873  
 
 
Figure 4.4.2.1 Potential transcription factor binding sites of the IL-31 promoter region  
  
Start of IL-31 gene
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The IL-31 promoter region on chromosome 12 is -582 to +245 base pairs around the start codon. 
This region was analysed by MatInspector software (Genomatix) for the probability of known 
transcription factors binding Figure 4.4.2.1. This was carried out to identify whether the IL-31 gene 
was regulated in a similar manner to other Th2 cytokines. Alternatively, this analysis could reveal a 
new pathway to IL-31 induction such as a transcription factor that is specifically linked to a certain 
receptor. 142 potentially binding transcription factors were identified and ranked according to the 
similarity of binding sequences on the promoter. At the top of this list with the only perfect matrix 
similarity score of 1 was Vertebrate steroidogenic factor (VSF1), a common nuclear transcription 
factor which has been shown to regulate expression of hormones during puberty.  In the top 30 of 
this list (Table 4.4.2.1), 6 transcription factors were identified that have previously been shown to 
play a prominent role in allergic and immunological disorders.  Gata2 and the Stats 3,5,6 in particular 
are crucial in activating T-cell differentiation pathways. 
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4.4.3 Ex Vivo expression of IL-31 from T-cell clones 
 
We have shown that IL-31mRNA can be induced from T-cells treated with IL-4 in vitro. However, 
immunohistochemistry failed to show any IL-31 co-localised to T-cells. In order to study the 
expression of IL-31 from T-cells that had differentiated in vivo, ideally one would use flow cytometry 
to quickly identify IL-31 positive cells and allow a characterisation of these cells on the basis of 
cytokine co-expression and cell surface marker expression. As detailed in the methods section, flow 
cytometric detection of IL-31 was hampered by poor quality antibodies and rejected as a technique.  
T-cell cloning was developed as an alternative approach to characterising IL-31 expression on a 
single cell level. T-cell clones (TCC) were set up from 3 grass pollen allergic donors (although n=2 for 
most experiments as the first batch of clones died rapidly) but were polyclonal in terms of allergen-
specificity and stimulated with feeder cells, PHA and IL-2 as opposed to grass pollen allergen as to 
not bias the T-cell phenotype that would proliferate and grow into a clone culture.   
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4.4.3.1 T-cell clones are phenotyped on the expression of cytokines.  
 
 
 
 
 
 
Figure 4.4.3.1. Characterisation of T-cell clones (TCC).A) TCC were stimulated by PMA (20ng/ml) and Ionomycin  
(1µg/ml) for 6 hours with protein transport inhibitors before being stained intracellularly with fluoresecent  
antibodies.Th1 and Th2 clones were assigned as such based on sole expression of IFNγ and IL-4 respectively. Non-Th1 
or Th2 clones were checked for IL-17 and IL-22 and multiexpressors termed Th0. B) Clones were also screened by 
ELISA following a 48 hour stimulation. C) Shows IL-4/IFNγ protein production from these clones from a subsequent 
stimulation 
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TCC derived from a single CD4+ T-cell could be naive, or a fully differentiated memory cell with 
characteristic cytokine expression. The specific expression of IL-4 and IFNγ is the defining features of 
the major T-cell sub groups Th2 and Th1 respectively. The pattern of cytokine expression was 
analysed by both ELISA or flow cytometry from clones for the cytokines IL-4, IFNγ, IL-17 and IL-22. IL-
31 was measured by ELISA only.  
Figure 4.4.3.1a.  shows a representative FACS plot for Th2, Th1 and an undifferentiated Th0 clone. 
Although not 100% of the cells in the clone culture were stimulated enough to express cytokine, it 
can be observed that Th2 clones produced solely IL-4 and no IFNγ and the converse for Th1 clones 
which expressed no IL-4 but strongly expressed IFNγ. IL-22 and IL-17 were also stained for but were 
both negative for these clones. 
Clone cultures were adjusted to 1million cells/ml and stimulated 48 hours before analysing the 
supernatant by ELISA. Although flow cytometry is the superior technique because it can reveal 
polyclonal clones, ELISA was used for the majority of screening due to the supernatants being 
generated anyway for IL-31 detection. When IL-4 and IFNγ absorbance values were plotted against 
each other, the clones sort into 4 groups, Th1, Th2, double positive (Th0) and double negative which 
could be Th22 or Th17 depending on the sole expression of these two cytokines (Figure 4.4.3.1b) 
Absorbance values accurately assigned phenotypes, Figure 4.4.3.1.c  shows ELISA data from these 
clones stimulated for another experiment and the Th1 and TH2 clones have grouped together with 
respect to IL-4 and IFNγ protein production. In total, 56 clones were generated from 3 donors and of 
these 14 were Th2, 16 were TH1, and 26 were other (Th0, Th17 and Th22). Although varying 
numbers of these were used in assays depending on whether they survived that long or expanded 
sufficiently. 
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4.4.3.2 Th2 clones show elevated expression of IL-31. 
 
 
 
Figure 4.4.3.2 Th2 clones show elevated expression of IL-31 TCC were adjusted to 1 million/ml and stimulated with 
plate-bound anti-CD3 and anti-CD28 (both at 1µg/ml) for 48 hours. The supernatants were then assayed for IL-31 An 
unpaired T-test was applied to show differences between groups (*** p=<0.0005) where significant. 
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Once the clones were sorted into phenotypes, IL-31 production was measured by ELISA (Figure 
4.4.3.2). There was a strong correlation between IL-31 expression and Th2 phenotype with these 
clones showing a 520pg/ml (676.7 SD) IL-31. Th1 clones showed the lowest mean IL-31 secretion 
(45pg/ml 73.8 SD). Interestingly, two of the three Th22 clones showed elevated IL-31 despite 
secreting minimal IL-4. Th0 were excluded from this figure due to their variance in phenotype but 
expressed a range of IL-31 values (mean 584pg/ml, standard deviation 1667pg/ml). 
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4.4.3.3 Expression of IL-31 correlates with IL-13. 
 
 
 
 
Figure 4.4.3.3 Expression of IL-31 correlates with IL-13.  TCC were adjusted to 1 million/ml and stimulated with plate-
bound anti-CD3 and anti-CD28 (both at 1µg/ml) for 48 hours. The supernatants were then assayed for IL-31 , IL-13, IL-
4, IFNγ and IL-22 Correlation of cytokine expression was calculated by linear regression and r
2
 denotes the goodness 
of fit of the scatter to the line of best fit. 
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ELISA was employed to measure a panel of cytokines expressed by TCC from one donor. The 
expression of IL-31 was plotted against these cytokines to investigate whether IL-31 was 
preferentially co-expressed with them. When TCC are examined, in contrast to cultures of Th2 or Th1 
polarised cells, the variances of these broad phenotypes emerge and a number of subtypes of Th2 
cells can be identified such as IL-13 high or very pure IL-4 specific expression. Figure 4.4.3.3 showed 
that expression of IL-31 did not correlate with the expression of IL-4, with IL-31 expression occurring 
at any expression of IL-4, although there were practically no IL-31 positive clones that were also 
negative for IL-4. Previous studies suggested that Th1 cytokines may inhibit IL-31 expression, there 
was a trend towards a negative expression of IFNγ with IL-31 and the clones that highly expressed 
IFNγ were IL-31 negative. IL-22 positive clones were nearly always IL-31 negative, although of the 3 
pure Th22 (IL-22 but no IL-4 and IFNγ) 2 of these clones expressed IL-31. IL-22 is often co-expressed 
with IFNγ which may explain this result.  
The only cytokine whose expression increased with IL-31 was IL-13, showing a significant positive 
correlation (r=0.19) strengthening the link with Th2 phenotype. 
4.4.3.4  Transcription factors expressed by different clone phenotypes. 
 
A selection of clones from each phenotype, plus the three greatest IL-31 expressing clones (various 
phenotype) were analysed by RT-PCR for a range of transcription factors that are known to be up-
regulated for certain T-cell phenotypes.  GATA3, GFI-1, IKAROS are all associated with Th2 cells, T-
bet is a specific marker of Th1 and RorC2 is a marker of Th17. Cytokine mRNA was also measured as 
a secondary confirmation of clone phenotype. As there was not a clear negative control, all data was 
normalised first to a house-keeping gene and then made relative to one of the IL-31 high clones, 
clone 4.02 which was a classic Th2 clone. The remaining IL-31 high clones were Th0 (IL-4 IFNγ co-
expressor) and an IL-22 high Th0. 
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Figure 4.4.3.4. Transcription factors expressed by different clone phenotypes and the three highest IL-31 expressing 
clones. A selection of TCC phenotypes were stimulated for 8 hours with PMA and  ionomycin (20ng/ml and 1µg/ml 
respectively) before RT-PCR performed for IL-4, IL-22, IL-31, Gata-3, GFI-1, Ikaros, RorC2, AHR and T-bet. Results are 
normalised against Ef1a expression and are shown relative to one of the IL-31 high clones. 
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Figure 4.4.3.4highlights the variance between apparently similar clone phenotypes so none of the 
results were significant although trends were observed. IL-4 was expressed by 2 out of 3 IL-31 clones 
but not more or less than by Th2 clones (mean 0.85 fold change). The highest expression of IL-4 was 
by a Th1 clone which has been shown by ELISA to secrete very little IL-4 protein. 
IL-22 was overexpressed by Th22 clones (mean 23.21 fold increase) and not expressed by Th1 (mean 
0.54 fold change) or, to a lesser extent, Th2 (mean 3.82 fold change). Interestingly, the Th17 clone 
expressed very high IL-22, much higher than the pure Th22 clones. The highest expression of IL-22 
was from an IL-31 high clone, although ELISA had previously revealed this co-expression of IL-22 and 
IL-31, this was an unexpected result. This clone however, showed a down-regulation of IL-31 mRNA 
of levels similar to Th1 basal expression.  
IL-31 was only detectable in the three IL-31 high clones, but because the data has been normalised 
to one of these clones this has resulted in all of the other phenotypes showing a down-regulation of 
IL-31. However, in terms of expression fold change of IL-31, only minor expression of IL-31was 
observed from all clones with the maximum fold increase 1.87. 
Gata 3 was up-regulated in only Th2 clones (mean 2.26 fold change) and IL-31 high clones (2.59 
mean fold change). In contrast, GFI-1, another Th2 associated transcription factor, was slightly up-
regulated in Th2 clones (1.63 fold increase) but not IL-31 high clones (0.75 mean fold increase). 
These data correlate with the IL-31 promotor analysis (Table 4.4.2.1) where Gata 2, a transcription 
factor related to Gata 3, was predicted to be highly likely to bind and promote transcription of the IL-
31 gene but not GFI-1. 
AHR, a marker of Th22 cells and Ikaros, a Th2 associated marker and T-bet, a marker of Th1 cells all 
showed broadly the same expression between the groups. 
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4.4.3.5  Chemokine receptors expressed by different clone phenotypes 
 
In addition to cytokine and transcription factor expression, T-cells can also be characterised on the 
basis of chemokine receptor expression.We wanted to investigate whether any chemokine receptors 
associated with IL-31 expression from clones. A sample of Th1 and Th2 clones (n=3) in addition to 
the three highest IL-31 expressing clones were stained for various chemokine receptors. The 
increase in mean fluorescence intensity over the isotype matched negative control is summarized in 
Table 4.4.3.1.
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Table 4.4.3.1 Chemokine receptor expression of T-cell clones 
  
% Cells with higher mean fluorescence Intensity than Isotype control 
Chemokine Receptor 
Biological 
Significance Th1 Clones Th2 clones IL-31 High Clones 
CXCR3 
expressed on Th1 
cells 58% 56.1% 0.6% 15.8% 28.8% 52.5% 28.8% 23.2% 11.4% 
CCR3 
Th1 and Th2 cells. 
Up-regulated in 
Allergy. 0.50% 4.60% 41% <0.5% 1.70% 2.80% 1.80% 2.40% 2% 
CCR10 
Skin homing T-
cells <0.5% 0.75% 2% <0.5% <0.5% <0.5% 1.40% 1.20% 0.80% 
CCR8 Th2 cells and  0.90% 1.40% 2% <0.5% 1.15% 2.40% 4.70% 3.40% 1.80% 
CCR4 Th2 cells 51% 38.90% 80.70% 16.40% 24.30% 63.20% 65.80% 18.20% 73% 
CRTh2 
Prostaglandin D2 
receptor, marker 
of Th2 cells 40.90% 36.50% 32.30% 35.80% 27.50% 46.90% 59.10% 36.20% 32.50% 
CCR5 
T-cells, 
macrophages, 
dendritic cells <0.5% <0.5% <0.5% <0.5% <0.5% <0.5% <0.5% <0.5% <0.5% 
CD124 
IL-4 receptor, 
over-expressed on 
Th2 cells 20.10% 0.80% 1% 1.40% 0.60% 1% 2.40% 1% 1% 
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As observed in previous studies with clones, the expression of these chemokine receptors was quite 
varied within groups of the same phenotype (as determined by cytokine expression).  As such, no 
significant differences were observed between Th1, Th2 or the IL-31 high clones. CXCR3 was highly 
expressed on two Th1 clones but almost absent on the third (mean 57.05% if third clone is 
excluded). Th2 clones did express less CXCR3 (mean 32.36%) thanTh1 but more than IL-31 high 
clones (mean 21.13%). 
CCR3 can be enhanced in Th2 cells but there was little difference between the groups with average 
expression of 2.55%, 2.1% and 2% for Th1, Th2 and IL-31 respectively. The Th1 clone that had little 
expression of CXCR3 showed very high CCR3 expression of 41% (this figure was excluded from the 
mean Th1 value of CCR3 expression) perhaps suggesting a reciprocal expression of these chemokine 
receptors. 
There was no significant difference between CRTH2 expression by Th1 or Th2 clones (36.6% and 
36.7% respectively). CRTH2 was slightly up-regulated by IL-31 high clones with a mean expression of 
42.6%. CCR4 is also enhanced in Th2 lines,but was not in this experiment, nor by the IL-31 high 
clones. 
CCR10 is a marker associated with skin homing T-cells and enhanced IL-31 is associated with skin 
disorders. Unfortunately, this chemokine receptor was not enhanced in IL-31 expressing clones.  
CD124 is also known as IL-4 receptor, this was measured on the clones because IL-31 is dependent 
on external IL-4. With the exception of one Th1 clone, the remaining clones showed very low CD124 
expression with no elevation of expression observed in any group. 
CCR8 is a chemokine receptor for the chemokine CCL1 and is important for the correct postioning of 
T-cells within lymphoid tissue and has been shown to be enhanced in Th2. Although there was no 
difference between Th1 and Th2 clones for CCR8 expression (1.4% 1.35% respectively), the IL-31 
high clones did show a slightly augmented expression of 3.3%.
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4.4.4 Regulation of IL-31 expression by IL-4 
 
IL-4 is the primary cytokine to drive and maintain the Th2 phenotype. This set of experiments 
examined whether IL-4 is also an important regulator of IL-31 expression. 
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4.4.4.1 Neutralisation of IL-4 during clone restimulation reduces IL-31 expression. 
 
 
 
 
Figure 4.4.4.1 IL-31 expression is dependent on IL-4. TCC were restimulated with plate-bound anti-CD3 and anti-CD28 
(both at 1µg/ml) ± blocking antibody to IL-4 (5µg/ml). IL-31 was then measured in the supernatants by ELISA. (a) 
shows the percentage change in IL-31 expression  from just Th2 clones. Different symbols represent different donors. 
(b) shows the actual change in IL-31 expression from all TCC phenotypes due to blocking IL-4. (c) shows the 
percentage change in IL-31 expression between anti-IL-4 and an isotope control.(d) shows the IL-13 production from 
Th2 clones A Wilcoxen test was employed to show significant differences between groups, *p<0.05, **P<0.005 
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Experiments so far have demonstrated that T-cell clones co-express IL-4 and IL-31. Whether this is 
due to co-activation of the IL-4 and IL-31 genes on a transcriptional level or that IL-4 receptor 
stimulation from autologous IL-4 expression is driving IL-31 expression is unclear.  
Th2 clones were washed and restimulated for 48 hours in the presence of a blocking/neutralising 
antibody to IL-4. IL-31 was then measured in the supernatants and compared with supernatants 
from the media control and isotype-matched control (Figure 4.4.4.1). There was a significant 
difference in IL-31 expression between Th2 clones treated with anti-IL-4 and untreated, with mean 
expression of anti IL-4 treated clones 66.18%  of baseline IL-31 expression, a 1.5 fold decrease. When 
this figure is expanded to show all non-Th2 clones (Th1, Th17, Th22, Th0), a 1.7 fold decrease in IL-31 
expression was observed.  To account for any effect caused by immunoglobulin, an isotype control 
was used in place of the media control for a preliminary experiment. As demonstrated in Figure 
4.4.4.1.c the isotype control had minimal effect on IL-31 expression. Blocking IL-4 specifically 
reduced IL-31; as shown in Figure 4.4.4.1d, IL-13 expression was not affected by anti IL-4 from Th2 
clones. 
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4.4.4.2 Addition of IL-4 during clone restimulation can induce IL-31 from Th1 clones. 
 
 
 
 
 
 
 
Figure 4.4.4.2. IL-4 can induce IL-31 from Th1 clones . Th1 clones were restimulated for 48 hours with plate-bound 
anti- CD3 and anti-CD28 (both at 1µg/ml) ± IL-4 (20ng/ml) before IL-31 (a), IFNγ (c) and IL-13 (d) was measured in the 
supernatants by ELISA. (b). Significant differences between treatments were determined by a Wilcoxen test. 
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Following the observation that IL-31 is induced by exogenous IL-4 and not constitutively expressed 
by Th2 cells, we examined the effect of IL-4 on Th1 cells. Th1 and Th2 clones were washed and 
restimulated for 48hrs in the presence of recombinant IL-4. IL-31 protein was then measured in the 
supernatant by ELISA. As seen in Figure 4.4.4.2.a, IL-4 could induce a marginal but significant 
increase in IL-31 from Th1 clones from 47.85pg/ml mean to 94.97pg/ml mean. Although the quantity 
of IL-31 produced by Th1 clones was still very low in comparison with Th2 clones, these data suggest 
that Th1 cells are receptive to IL-4. When IL-4 receptor expression on clones was analysed by flow 
cytometry, there was a small but detectable expression of IL-4 receptor on Th1 cells as well as Th2 
cells (Figure 4.4.4.3). When recombinant IL-4 was added to Th2 clones, no further IL-31 expression 
was observed (Figure 4.4.4.2.b) with a non-significant change from 2115pg/ml to 1596pg/ml IL-31 in 
the presence of IL-4. 
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Figure 4.4.4.3 IL-4 receptor (CD124) expression on different T-cell clone phenotypes. Resting T-cell clones were 
stained with either CD124 PE or PE isotype matched control before being analysed by flow cytometry
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control  before being analysed by flow cytometry.
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4.4.4.3 IL-31 expression by Th1 clones is temporary and is not indicative of T-cell plasticity. 
 
 
Figure 4.4.4.4 IL-31 expression by Th1 clones is temporary and not indicative of T-cell plasticity. A) Th1 TCC were 
stimulated with anti-CD3 and anti-CD28  (1µg/ml both) and either media or IL-4 (20ng/ml) and then cultured for 2 
weeks before being washed and restimulated  for 48 hours with no additional IL-4. IL-31 was measured in the 
supernatant by ELISA, different symbols represent different donors. (b,c) IFNγ and IL-13 were measured by ELISA in 
the supernatants of Th1 clones stimulated  as before but +/- IL-4 (20ng/ml) 
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The observation that IL-4 can induce IL-31 from Th1 cells was novel, unexpected and distances IL-31 
from other Th2 cytokines. The Th1 phenotype is considered to be fixed whereas this result suggested 
that a plasticity of cytokine expression is possible. Two questions were raised; for how long can Th1 
clones express IL-31 when treated with IL-4 and is IL-4 deforming the Th1 phenotype to Th2?  
To answer the first question, Th1 clones were restimulated with IL-4 or media alone, as previously 
shown, IL-31 secretion was enhanced. They were then cultured for 2 weeks before being washed 
and restimulated with no additional IL-4. IL-31 was measured in these supernatants by ELISA. This 
time there was no difference between the IL-31 expression from Th1 clones that had previously 
been treated with IL-4 or not, with levels from both groups at the same base level of <100pg/ml IL-
31 observed at the first stimulation. 
When Th1 clones were treated with IL-4, in addition to IL-31, IFNγ and IL-13 were measured as 
markers of Th1 and Th2 differentiation. As can be seen in Figure 4.4.4.4 IL-4 had no impact on the 
expression of these cytokines suggesting that IL-4 was not converting Th1 clones to Th2.  
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4.4.5 Effect of IL-4 on IL-31 expression from non-CD4 PBMC 
 
Figure 4.4.5.1IL-31 can be induced by IL-4 in non-CD4
+
 cells. PBMC from two atopic donors were depleted of CD4
+ 
T-
cells and stimulated for 16hrs with PMA and ionomycin  in the presence of  IL-5, IL-13, IL-9, IL-10, IFNγ (all at 20ng/ml) 
± IL-4 (20ng/ml). RT-PCR was performed for the genes IL-31, IL-4 and IFNγ. Data shown are relative to the media 
control and have been normalised to 18s gene expression. No significant differences were detected by a Wilcoxen 
test. 
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Following the observations that cells other than T-cells can express IL-31 and that allergen 
stimulation can induce IL-31, the effect of Th2 cytokines associated with allergen stimulation on 
CD4+ T-cell depleted PBMC was investigated. PBMC were depleted of CD4+ T-cell and then 
stimulated with IL-4 ± a panel of Th2 cytokines. It can be seen in Figure 4.4.5.1 that IL-4 can induce 
IL-31 from non-CD4 PBMC (mean fold change 4.5 vs. 1 of media control). The addition of further Th2 
cytokines to IL-4 does not enhance the effect that IL-4 has on IL-31 induction, nor do any of these 
cytokines induce IL-31 alone either. IL-4 could not induce IL-4 from non-CD4 PBMC, nor could any of 
the Th2 cytokines. Th2 cytokines could not induce any IFNγ from non-CD4 but the presence of IL-4 
suppressed IFNγ expression to approximately half of that observed from the media control. These 
data suggest that IL-31 can indeed be expressed by cells other that CD4+ T-cells. 
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4.4.6  IL-31 can be induced by IL-4 in CD4+, CD8+ and B-cells 
 
 
Figure 4.4.6.1 IL-31 can be  induced by IL-4 in non-CD4+ cells. CD4, CD8 and CD20 (B-cell) positive cells from 3 atopic 
donors were stimulated for 24hrs with PMA and ionomycin ± IL-4 (20ng/ml) before RT-PCR measured IL-31 (a), IL-4 (b) 
and IFNγ  (c) gene expression. Data have been normalised to 18s expression and are relative to the media control at 
4hrs. No significant differences were detected by a Wilcoxen test. 
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CD4+, CD8+ and B-cells were isolated from the PBMC of atopic individuals (n=3) and stimulated for 8 
and 24 hours with PMA/ionomycin ± IL-4. IL-31, IL-4 and IFNγ expression was measured by RT-PCR. 
Data were normalised to the CD4 media 8 hour result. Only the 24 hour result is shown because 
there were not enough B-cells for the 8 hour time point (Figure 4.4.6.1). None of the results were 
significant due to the small n number. In concordance with Figure 4.4.1.1. IL-4 had no consistent 
effect on IL-4 expression but did appear to suppress IFNγ expression from all three cell types. 
4.5 Discussion 
 
Through the use of a number of approaches, this section has set out to test the hypotheses and aims 
set out at the start (page 41). The title of this thesis “The role of Interleukin-31 in allergic airway 
disease” was deliberately broad and was necessary for a cytokine with so little known about it. With 
the majority of literature about IL-31 focusing on the detection of IL-31 in various skin diseases, this 
section aimed to investigate the conditions under which IL-31 is expressed. The relationship 
between IL-31 and allergy was a question that ran through these experiments to identify the 
importance of IL-31 in allergic airway diseases.  
4.5.1 Investigation into IL-31 expression in vitro in allergen- stimulated cultures of peripheral 
blood mononuclear cells (PBMC) from atopic grass pollen allergic individuals and healthy non-
atopic controls. 
IL-31 expression has been detected in skin diseases such as dermatitis and eczema (Neis, Peters et 
al. 2006) that are allergen driven and conversely, shown to be down-regulated in Th1-driven non-
allergic psoriasis (Sonkoly, Muller et al. 2006). This potential association of IL-31 with allergy has not 
been fully examined and it is not known whether allergen stimulation can directly induce IL-31 
expression or whether a secondary factor such as bacterial infection or scratching upregulates IL-31. 
In Figure 4.1.2.1 we were able to show that stimulating PBMC from grass pollen allergic donors with 
Phlp protein (derived from the pollen from Timothy grass) strongly and directly induced a significant 
IL-31 mRNA expression. Not only was the expression of IL-31 up-regulated in donors that were 
allergic to Phlp compared to non-allergic donors but the there was a greater upregulation of IL-31 
from the atopic donors than there was of IL-4, a cytokine that is classically over-expressed by allergic 
subjects (Chan, Brown et al. 1996). These data show a strong link between allergen stimulation and 
IL-31 which was corroborated by the negative control of the alternative antigen stimulation by PPD 
and the complete lack of IL-31 induction. The PPD result also demonstrates the bias of IL-31 
expression favouring Th2 over Th1 as PPD specific cells are usually Th1 (Del Prete, De Carli et al. 
1991)and aero-allergen-specific T-cells are usually Th2 (Crack, Chan et al.). In addition, there should 
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be no difference in PPD responses between atopic and non-atopic donors in, so long as the donor 
has been immunised against Tuberculosis, which we observed. There was no additional artificial 
stimulus such as PMA or PHA used so the IL-31 gene expression observed represents a biologically 
relevant response to allergen.  
An unexpected result was from the polyclonal stimulation by anti-CD3 and anti-CD28 that was 
included in the experiment as a positive control and as a reference to calculate the relative 
expression of genes induced by Phlp protein and PPD. Instead of stimulating just the antigen specific 
portion of the T-cells, this combination of antibodies should have activated all of the T-cells and 
induced a large gene expression. The polyclonal stimulation was in fact, apparently less potent than 
both the PPD and Phlp stimulation for both atopic and non-atopic PBMC. One explanation could be 
that the timepoint of 7 days was too late to measure peak gene expression induced by the 
polyclonal stimulation compared with the antigen driven reactions. It is unlikely that the antibodies 
used were at fault because the different replicates for this experiment were performed over a large 
time frame and therefore different batches of antibodies would have been used. 
A caveat with this experiment is that measuring IL-31 by RT-PCR in a mixed population of cells does 
not allow the IL-31 producing cell to be identified. Due to the fact that IL-31 was not detectable after 
5 hours allergen stimulation but was after 7 days suggests that the cells producing IL-31 had 
undergone an expansion in that time to cross the threshold into detection. Alternatively the IL-31 
producing cells may have been induced by a factor produced by the allergen stimulated cells. The 
primary cell that proliferates in response to allergen is an allergen-specific memory T-cell. Other cells 
within the PBMC population such as dendritic cells or basophils, may have been activated by the 
presence of allergen, and thereby express IL-31, but they would also be activated by PPD and the 
effect observed in this experiment was allergen-specific. If the source of IL-31 was from memory T-
cells, then this would also account for IL-31 being undetectable at 5 hours; it is likely that the 
allergen-specific T-cells had been activated and were producing IL-31 by that time but were at too 
low a frequency.  
Previous literature (Dillon, Sprecher et al. 2004) had suggested that the predominant source of IL-31 
is from memory CD4+ T-cells. When the IL-31 expression from memory and naïve T-cells was 
compared, Figure 4.1.1.1, there was a big trend towards increased IL-31 expression from the 
memory T-cells in agreement with the literature. The difference between memory and naïve T-cell 
expression of IL-31 expression was similar to the difference observed in the expression of IL-4 and 
IFNγ, both markers of fully differentiated memory Th2 and Th1 cells. All donors in this experiment 
were allergic to aeroallergens such as timothy grass pollen and house dust mite and this fact was 
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represented by the relative expression of IL-4 and IFNγ which is biased towards allergy and Th2 
related IL-4. The expression of all of these genes should be maximal due to the strong stimulation by 
PMA and ionomycin. Taken together, these data would suggest that IL-31 maybe is a cytokine 
expressed by fully differentiated memory T-cells, particularly those specific to Th2 biased antigens. 
4.5.1.1 Future work  
The current work is all based on mRNA expression and it would be optimal to validate these results 
on a protein level. Unfortunately, ELISA was unable to detect IL-31 in supernatants of PBMC culture 
but an alternative, more sensitive technique to develop could be western blotting of the PBMC 
lysates although this is only a semi-quantitative assay. Another experiment to carry out could be to 
compare different antigens that target different receptors on antigen presenting cells such as 
helminth extracts or toll-like receptor agonists imitating viral infection. Hopefully this would confirm 
the link between IL-31 and allergen stimulation. 
4.5.2 Immunofluorescence microscopy examination into the expression and co-localisation of 
IL-31 in vivo after allergen provocation in human skin and nasal mucosa.   
 
In order to confirm the importance of IL-31 in allergic airway disease, first it is necessary to confirm 
that IL-31 is actually present in the relevant tissues. Prior to this thesis, there were no published 
reports of successful immunological staining of IL-31 with most studies detecting ex vivo IL-31 with 
RT-PCR. This was probably due, in part, to the dearth of good quality antibodies available to detect 
IL-31 protein which hampered development of an IL-31 flow cytometry protocol. The aim of this 
section of the study was to investigate the frequency of IL-31 producing cells in skin and nasal tissue 
and confirm the identity of IL-31 producing cells. 
By developing a three layer, biotin-avidin amplification immunofluorescent staining protocol we 
were able to detect IL-31 in skin and nasal tissue. This permitted an investigation into the localisation 
and conditions surrounding IL-31 expression in tissue. In order to maximise the chances of detecting 
IL-31, all staining was performed on sections from atopic donors. As mentioned in the results 
section, staining was performed on sections generated by the study by Graham Banfield (Banfield, 
Watanabe et al. 2010). These sections, nasal and dermal, were from donors allergic to either timothy 
grass or house dust mite. The sections were of intradermal or nasal challenges of allergen, PPD or 
diluent taken at 8 and 48 hours. A set of sections from 8 atopic donors stimulated for 8 hours with 
allergen or diluent were stained for IL-31 and CD3 (T-cells) and the frequency of the positive cells 
quantified. IL-31 positive cells were relatively frequent with few slides containing no IL-31 at all. As 
previously determined by G. Banfield et al the frequency of CD3 positive cells increased with allergen 
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challenge in comparison to diluent. Unfortunately, there was no difference between allergen and 
diluent challenge in terms of IL-31 expression which did not support the results generated in vitro 
from PBMC. Although with a much smaller n-number than the allergen study at 8 hours, a count of 
IL-31+ cells at 48hrs of biopsy sections that had been stimulated with allergen, PPD or diluent was 
also made. This demonstrated the different timescales of the responses to the different antigens as 
there were enhanced numbers of T-cells infiltrating in response to PPD in comparison to allergen 
challenge at this timepoint. There were no significant differences between IL-31+ cell numbers in 
diluent and PPD challenged sections but one of the donors showed a strong increase of IL-31+ cells in 
response to allergen at 48 hours. 
 The primary experiment was performed on skin sections which one may consider unrelated to 
allergic airway diseases. However, all donors responded clinically to challenges with the same 
allergen in the skin and nose (Banfield et al 2010) with similar patterns of cellular infiltration. The 
nasal sections were stained successfully for IL-31, which is a first for the technique, but the nasal 
biopsies were a lot smaller and more fragile than the skin sections which meant they were not as 
reliable to count because many of the sections had such poor morphology that clear bright cells 
were relatively rare. 
An unexpected result was that IL-31 was never observed to co-localise with CD3 positive cells. This 
contrast with the experiments where T-cell clones isolated from atopic donors expressed IL-31 with 
no other stimulation than by anti-CD3 and anti-CD28. However, cytokines known to be produced by 
T-cells have proven difficult to co-localise to T-cells by immunohistochemistry in the past. This is due 
to a number of factors; firstly, T-cells may synthesise large amounts of cytokine but they do not store 
any. A T-cell response is not as rapid as say, mast cell degranulation where a large quantity of 
histamine is stored up and then all released at once. This means the actual amount of cytokine in a 
T-cell will be limited to what is in the endoplasmic reticulum and secretory vesicles. Standard 
histology shows that T-cells have very little cytoplasm where the cytokines could be and potentially 
only a proportion of the protein will be sufficiently folded with the correct post-translational 
modifications to have the correct epitopes for the antibody to bind. Secondly, the slides were fixed 
in acetone which is a relatively weak fixative, although good for preserving epitopes, and may have 
allowed the small amount of IL-31 in T-cells to diffuse away. Thirdly, the visualisation method used 
may not have been sufficient and if an even brighter fluorophore or more amplification was used 
then perhaps IL-31 on T-cells may have been observed.  A method for confirming T-cell synthesis of 
IL-31 would be to use fluorescent in-situ hybridisation (FISH) with probes for IL-31 mRNA but there 
was insufficient time to develop this technique. As mentioned earlier, literature suggested that CD4 
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memory T-cells are the predominant source of IL-31 but as shown in Figure 4.4.6.1 CD8 and B-cells 
were also able to express IL-31 especially when provided with additional IL-4. 
The phenotype of the IL-31 producing cells that were detected, remain unidentified. The cells were 
found alongside and looked similar to the T-cells that were found in the infiltrates of immune cells 
induced by the allergen challenge with a rounded shape, large nucleus and small cytoplasm. There 
were some IL-31+ cells spread throughout the dermis as well as in the infiltrate suggesting that tissue 
resident cells such as mast cells or Langerhans dendritic cells could express IL-31 but no-
colocalisation with these cell types was observed. One explanation for the localisation of IL-31 could 
have been that it was bound to IL-31 receptor on its target cells. However, IL-31 receptor was also 
not found to co-localise with IL-31.  
Granulocytes were stained with IL-31 to test the theory that IL-31 is only detectable in cells that 
store cytokines. One study had shown weak IL-31 staining co-localising with mast cells (Niyonsaba, 
Ushio et al. 2010). Unfortunately, mast cells, neutrophils and eosinophils all proved negative for IL-
31 in our hands. Macrophages and dendritic cells also proved negative for IL-31 suggesting that the 
IL-31 positive cells detected were structural cells such as stromal cells. This may seem unlikely but 
the participation of the tissue in immune responses is becoming more and more important with the 
epithelium especially being pivotal to drive immune cell activation and migration.  
Although not the focus of this study, the distribution of IL-31RA was also investigated with a range of 
skin sections from allergic and non-allergic donors that had undergone allergen or diluent challenge. 
IL-31RA expression in tissue has been regularly published and it is known that keratinocytes and 
epithelial cells in the skin express IL-31RA (Heise, Neis et al. 2008). When skin sections were stained 
for IL-31RA, a large number of cells were positive for IL-31RA and were localised to endothelial and 
epithelial cells. In agreement with the literature we did not observe IL-31RA on T-cells, and the 
majority of IL-31RA was not in the infiltrates that appear with allergen challenge. Some reports 
suggested that IL-31RA could be induced by IFNγ on macrophages (Dillon, Sprecher et al. 2004). 
Although there may not have been much IFNγ present in the skin sections that had undergone 
allergen challenge, there was no colocalisation of IL-31RA and the macrophage marker CD68.  The IL-
31RA staining was performed on a range of sections and although the individual groups had a very 
small n-number and the cells were not quantified, there appeared to be very little difference 
between all of the sections. This would suggest that IL-31RA is constitutively expressed and not 
enhanced by the donor being allergic. If IL-31RA is considered to be a constant than this means that 
the change in the levels of IL-31 expression is the most important factor in the magnitude of 
response to IL-31. The distribution of IL-31RA did suggest that the target of IL-31 is the tissue as 
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opposed to other immune cells. This possibly categorises IL-31 as a cytokine more similar to IL-22 or 
IL-17 than the Th2 roster of IL-4, IL-5 and IL-9. The only other Th2 cytokine that acts on tissue is IL-
13, which is well known as an inducer of goblet cell differentiation (Whittaker, Niu et al. 2002) and 
matrix metallo-protease production (Zheng, Zhu et al. 2000) from lung epithelial cells so perhaps IL-
31 can act in concert with IL-13  
To summarise, immunofluorescent staining of IL-31 in skin and nasal tissue was successfully 
achieved but the identity of the IL-31 positive cells has yet to be elucidated. Although T-cells did not 
appear to express IL-31, this could be due to them not storing IL-31 and secreting all the cytokine 
they synthesise. IL-31 was definitely present in the tissue of allergic rhinitis patients and in some 
cases increased in response to an allergen challenge strengthening the link between IL-31 and 
allergy. In contrast, a challenge with PPD did not induce significant numbers of IL-31+ cells. IL-31RA 
was detected on the epithelium and endothelium suggesting that the target of IL-31 is these tissues. 
4.5.2.1 Future work 
 
The main aim of the immunohistochemistry was to identify any cells that produce IL-31. Although IL-
31 staining was achieved in skin and nasal tissue, co-staining with a panel of different cell 
phenotypes failed to identify the source of the IL-31 so this is obviously an area that needs further 
work with the panel expanded to include more tissue specific cells such as fibroblasts, stromal cells, 
nerve tissue or even stem cells. Another technique to be developed is FISH and this could be used to 
detect IL-31 mRNA sites of IL-31 synthesis hopefully co-localised to CD3 staining. 
 
4.5.3 Investigation into IL-31 expression in CD4+ T cells derived from peripheral blood 
cultured under Th1/Th2 polarising conditions.  
 
Th2 cells are arguably the most important cells in the allergic response, secreting a range of 
cytokines that can counteract the allergen challenge such as IL-4 to stimulate the production of 
allergen neutralising antibodies, IL-13 to induce aeroallergen trapping mucus and IL-9 and IL-5 to 
activate mast cells and eosinophils to further promote allergen clearance. In Figure 4.1.2.1 it was 
shown that allergen-specific cells express IL-31 and coupled with literature demonstrating enhanced 
IL-31 from mouse T-cells polarised towards Th2 (Dillon, Sprecher et al. 2004) it was important to 
determine IL-31 expression from human Th2 cells. The first experiment to compare IL-31 expression 
from Th1 and Th2 cells was shown in Figure 4.3.1.1 and showed a significant augmentation of IL-31 
148 
 
protein induced by the Th2 conditions of IL-4 and anti-IL12 after 7 days. This result was enhanced by 
the fact that the donors in the experiment were healthy non-atopics so the IL-31 expression 
observed may have been lower than that expressed by an atopic donor. The Th1 conditions of IL-12 
and anti-IL-4 showed a slight downregulation of IL-31 expression compared to the neutral 
conditions. These data suggest that either IL-12 inhibits IL-31 or that the lack of IL-4 has removed the 
stimulus for IL-31 expression. Alternatively, the IL-31 induced by the Th2 conditions may have either 
been induced by IL-4 or permitted by the lack of inhibiting IL-12. Either way, the data show for the 
first time that human CD4+ T-cells can be induced to produce IL-31 with 7 days of Th2 polarising 
cytokines. The degree of polarisation achieved in this timeframe can be seen by the difference in T-
bet and Gata3 transcription factor mRNA expression from the two conditions, although not a 
significant difference there was a definite trend towards the respective markers of Th1 and Th2 
differentiation. A caveat with this experiment is that it was performed on CD4+ T-cells instead of 
purely naïve T-cells. This means within the population, the naïve T-cells would polarise towards Th2 
and the memory Th2 cells would have been expanded by IL-4 acting as a growth factor so the 
resulting culture was not strictly purely in vitro generated Th2 cells and would have contained some 
existing memory Th2 cells. However, any existing Th1 cells would not thrive in the Th2 conditions 
with the anti-IL-12 neutralising the IL-12 Th1 growth factor so the IL-31 detected would not be due 
to Th1 cells. 
A slightly modified Th2 differentiation protocol was used to generate Th1 and Th2 lines in Figure 
4.3.2.1 as designed by D. Cousins (Cousins, Lee et al. 2002). In addition to IL-4 and anti-IL-12, this 
protocol also included blocking antibodies to IL-10 and IFNγ were also included to comprehensively 
inhibit Th1 differentiation. The Th1 lines were generated with the same combination of IL-12 and 
anti-IL4. The IL-31 production by these cells, which were from atopic donors, was monitored over a 
four week period and should have increased as the proportion of Th2 cells increased. Although the 
IL-31 expression from the Th2 cultures was consistently higher than the Th1 cultures, the expression 
from the Th2 cultures was sometimes lower than seen from the neutral cultures. This difference in 
IL-31 expression compared with the differentiation conditions used in Figure 4.3.1.1 must be to do 
with blocking either IL-10 or IFNγ. It is unlikely that IFNγ would be essential for inducing IL-31 as Th1 
cultures produce a lot of IFNγ and IL-31 levels were consistently low in the Th1 cultures. This leaves 
IL-10 being potentially important to induce IL-31. IL-10 is a contradictory cytokine; despite being a 
regulatory cytokine that can down-regulate the cytokine secretion of T-cells (Sabat, Grutz et al. 
2010) it is also expressed by pro-inflammatory effector T-cells (Del Prete, De Carli et al. 1993). A 
relationship between IL-10 and IL-31 does not necessarily mean that IL-31 is also a regulatory 
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cytokine but it could hint that IL-31 is resistant to suppression by IL-10 and circumvents normal 
regulatory mechanisms.   
Epigenetic studies of Th1 and Th2 lines generated with the same anti-IL-10 protocol measured the 
methylation status of the histone proteins H3 and H27 (Santangelo, Cousins et al. 2002). This was 
able to show the genome wide differential silencing and activation of genes in cell lines polarised 
towards Th1 and Th2.   
 
Figure 4.5.3.1 Chromatin architecture of the IL-31 locus. A custom track view (Hg 18 build) is shown of the Th1 and Th2 
specific DHS sites
40
, histone modifications H3K4me1, me3 and H3K27me3 in Th1 and Th2 cells and positions of CpG islands 
in this region of chromosome 12. Image used with permission from Paul Lavender. 
When focused on IL-31 (Figure 4.5.3.1), there was little difference between H3K4 trimethylation 
status on both Th1 and Th2 cells at the transcriptional start site of the IL-31 gene suggesting there is 
little difference in the activation (Heintzman, Stuart et al. 2007) of the gene between Th1 and Th2 
cell lines. However there was a peak of H3K27 trimethylation, a marker of gene silencing (Barski, 
Cuddapah et al. 2007), over the IL-31 gene in the Th1 cultures that was absent in the Th2 lines 
suggesting that IL-31 may not be enhanced by Th2 differentiation but is at least not inhibited. 
Another factor to consider is that the core Th2 cytokines IL-4, IL-5 and IL-13 are adjacent on 
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chromosome 10, which means they are generally all transcriptionally active at the same time due to 
the DNA in that area being unwound slightly. IL-31 is on a different chromosome entirely and 
therefore it expression would probably be regulated entirely separately from the Th2 cytokines. 
To summarise, IL-31 protein expression is enhanced to levels detectable by ELISA from human T-cells 
that have been cultured towards Th2 for at least 1 week via the presence of IL-4 and anti-IL-12. This 
expression is inducible in both atopic and non-atopic donors to a similar degree. IL-31 expression 
was inhibited by Th1 inducing conditions thereby controlling for any induction by the anti-CD3 and 
anti-CD28 stimulation. These data partially support hypothesis 1 in chapter (CROSSREF) that IL-31 is 
a pro-allergic Th2 cytokine, IL-31 is certainly expressed by in vitro polarised Th2 cells and is induced 
by allergen stimulation but these data cannot answer whether IL-31 is driving allergic reactions or 
expressed at the resolution stage to dampen down the allergic reaction. 
4.5.3.1 Future work 
The present data show Th2 conditions induce IL-31 and Th1 conditions inhibit IL-31 but perhaps 
further work could investigate the importance of IL-10 in IL-31 induction. What is unknown is the 
kinetics of IL-31 expression within an allergic reaction. T-cells expressed IL-31 by day 7 but whether 
IL-31 is expressed the moment T-cells start to differentiate to Th2 or whether IL-31 expression 
comes in later along with regulatory cells is as yet undetermined. The importance of IL-10 in IL-31 
expression also warrants further investigation. 
 
4.5.4 Examination of the regulation of IL-31 expression in CD4+ T cells, lines and clones 
derived from peripheral blood. 
 
Following the observation that IL-31 is induced by Th2 conditions, a more thorough investigation 
into the regulation of IL-31 expression was performed. This was an area that was very novel with no 
published data beyond mouse T-cells stimulated with IL-4 and anti-IL-12 (Dillon, Sprecher et al. 2004) 
to induce IL-31. By understanding the conditions that regulate IL-31 expression we can further 
understand the role IL-31 plays in the allergic reaction. This work focussed on CD4+ T-cells and aimed 
to identify the optimal stimuli to induce IL-31 and the characteristics of IL-31 expression. 
The first experiment (Figure 4.4.1.1) investigated the effect of IL-4 on the induction of IL-31 mRNA 
and compared this effect on naïve CD45RA and memory CD45RO T-cells. IL-4 drives Th2 
differentiation and we have previously shown Th2 cells have up-regulated IL-31. An increasing dose 
of IL-4 showed a strong trend towards increasing IL-31 expression with a peak at 50ng/ml IL-4 which 
151 
 
tailed down again at 100ng/ml possibly due to IL-4 receptors becoming saturated.  There was fairly 
high variance between the donors which meant that the fold changes did not reach significance. This 
experiment confirmed the importance of IL-4 but the most interesting result was that there was no 
difference between the effect of IL-4 on naïve and memory T-cells. Fully differentiated memory T-
cells usually strongly express their characteristic cytokines when stimulated, in contrast to naive T-
cells which are uncommitted to a particular cytokine expression pattern and therefore typically 
express lower levels of cytokines than memory (De Rosa, Herzenberg et al. 2001). This suggests that 
IL-31 is directly induced by IL-4 and not necessarily as a result of Th2 differentiation.  The relatively 
short timepoint of 48hrs would not allow the majority of the naïve t-cells to be fully differentiated to 
Th2 so the IL-31 expression observed would therefore be due to just IL-4. The naïve T-cells would 
have had equivalent responsiveness to IL-4, with the potential to become any T-cell phenotype but 
the memory cells would have been a mixture of phenotypes with differing responses to IL-4. 
Although IL-4 expression was unaffected by IL-4 treatment, IFNγ was reduced from the memory T-
cells by IL-4 suggesting that the recombinant protein was acting as expected. The similarity between 
the naïve and memory T-cell response to IL-4 suggests that IL-31 expression is distinct from the 
expression of cytokines associated with differentiated T-cells.  
In addition to IL-4, Th2 cells produce a number of cytokines that would be present during allergen 
stimulations and Th2 polarising experiments and therefore could have an influence on IL-31 
expression. We tested the panel of IL-5, IL-9, IL-10 and IL-13 in combination with IL-4 to determine 
their effect on IL-31 expression but none were able to boost the IL-31 induced by IL-4. This highlights 
the importance of IL-4 as the main driver of IL-31 expression. There was a possibility that IL-10 was 
important for IL-31 expression, as its neutralisation during Th2 polarisation appeared to reduce IL-31 
expression. However, IL-10 did not enhance the effect of IL-4 and definitely did not induce IL-31 by 
itself.  
The negative control for this experiment was treatment with IFNγ, a Th1 cytokine, and was unable to 
induce any IL-31. Unfortunately, there was not an IFNγ + IL-4 group, due to a shortage of cells. 
IL-33 is a newly described cytokine that can induce Th2 cells independent of IL-4 (Chen, Carroll et al. 
2006). When combined with IL-4, IL-33 was highly effective at inducing IL-31 from both memory and 
naïve T-cells.  IL-33 was the only cytokine tested that was able to induce IL-31 in the absence of IL-4 
and this result is significant as it provides another situation in which IL-31 could be generated. IL-33 
is derived from high endothelial venules (Baekkevold, Roussigne et al. 2003) and could therefore 
induce IL-31 from naïve T-cells in the absence of allergen stimulation in the lymphoid tissue. This 
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experiment was preliminary and requires further optimisation to ascertain a suboptimal dose of IL-
33 and IL-4 and thereby demonstrate true synergy. 
IL-35 is even newer than IL-33 and has shown a strong role at promoting regulatory T-cells. Similar to 
IL-10, the other regulatory cytokine tested, IL-35 had no effect on IL-31 induced by Th2 conditions. 
This could suggest that IL-31 is resistant to inhibition by regulatory cytokines.  To confirm the activity 
of IL-10 and IL-35 the expression of IFNγ and FoxP3 were measured. IL-10 was able to inhibit Th2 
differentiation thus permitting the expression of IFNγ. Both cytokines showed a trend of promoting 
FoxP3 expression in combination with Th2 cytokines suggesting they were promoting regulatory T-
cells. A preliminary experiment (data not shown) also looked at the effect of steroids 
(dexamethasone) and TGFβ and found that IL-31 was not inhibited by TGFβ but was by 
dexamethasone, so if IL-31 is pro-allergic at least its effects could be treated with steroids. 
An investigation into the IL-31 promoter strengthened the link with allergy as it revealed that the IL-
31 gene was likely to be transcribed by the same transcription factors that are up-regulated in 
allergic inflammation such as factors from the GATA and STAT families that link IL-4 receptor 
signalling to target genes and control T-cell differentiation (Tsai, Keller et al. 1994; Grimley, Dong et 
al. 1999; Cheng, Wang et al. 2003). AP1 and NFAT also have well described roles in inflammation 
(Hess, Angel et al. 2004; Macian 2005) and were shown to have strong likelihood of binding and 
promoting the expression of IL-31. The transcription factor with the greatest degree of fit to the IL-
31 promoter was vertebrate steroidogenic factor 1 (VSF1), a transcription factor more commonly 
researched in the field of developmental biology as it regulates the expression of growth factors 
during puberty (Parker, Rice et al. 2002). VSF-1 has not been previously linked with allergic 
inflammation but its expression can induced by T-cell factor 4N (Kennell, O'Leary et al. 2003) that is 
in turn up-regulated in activated T-cells. Although unvalidated, this in silico analysis highlights the 
relationship between IL-31 and allergy and shows the similarities between IL-31 and other Th2 
cytokines such as IL-4.  
4.5.5 T-cell clones 
 
In addition to the relatively artificial conditions of in vitro stimulated and differentiated T-cells, we 
also examined T-cells that had differentiated in vivo using limiting dilution to create T-cell clones. T-
cell clones provided a means to look at IL-31 expression on a single cell level as each cell in the clone 
culture would have originated from one cell. This is also achievable by flow cytometry but, as 
described in the methods section, attempts to stain IL-31 for flow cytometry all failed.  The clones 
were characterised by ELISA on the basis of cytokine expression. IL-31 positive clones were not rare 
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and not restricted to the pure Th2 clones, although the vast majority of Th2 clones did express IL-31. 
Although IL-4 and IL-31 were always co-expressed, the magnitude of IL-31 secretion did not correlate 
with IL-4. However, there was a positive correlation between IL-31 and IL-13. These data really 
reinforce the view that IL-31 is a Th2 cytokine as these cells were natural Th2 cells that had 
differentiated in vivo and had received no additional polarising cytokines. The analysis of the clones 
highlighted the variation of T-cells that can be generated, with combinations of cytokines much 
more subtle than the standard Th1 and Th2 phenotype, e.g. Th2 cells that are high or low IL-13 and 
all of the differing combinations of IL-22, IL-17 and IFNγ expression. T-cell clones with very high IFNγ 
expression were nearly always negative for IL-31 which supports the in vitro suggestions that IL-31 
expression could be inhibited by IFNγ. An unexpected finding was the co-expression of IL-31 and IL-
22 in two out of the three Th22 (IL-22 sole expression) but this hints that IL-31 may not be as 
restricted to Th2 as thought. 
As shown in Figure 4.4.3.4 and Table 4.4.3.1, attempts to characterise IL-31 expressing clones on the 
basis of cytokine, transcription factor and chemokine receptor expression were inconclusive. This 
may have been because the experiment only took three of each phenotype to analyse and there was 
too high variance between the apparently same phenotype clones. Also, the clones were 
characterised by ELISA but then studied by RT-PCR which is a far more sensitive technique and would 
highlight any differences between the clones. The only result that was reliable was that the clones 
with the three highest IL-31 protein expression values did still have the three highest IL-31 mRNA 
expression values. Another result, although not significant, was the IL-31 high clones had increased 
Gata3 expression to levels similar of the Th2 clones. Gata3 is the prime transcription factor for 
directing Th2 differentiation (Yamashita, Ukai-Tadenuma et al. 2004) and there was a likely binding 
site for the Gata family on the IL-31 promoter as predicted by the promoter analysis carried out in 
Table 4.4.2.1. In contrast, Ikaros and GFI-1 are also markers of Th2 differentiation but their 
expression was not markedly different in any group. T-bet is a key director of Th1 expression (Szabo, 
Kim et al. 2000 but there was very little difference in expression between the groups although the 
lowest expression was from the clones with the highest IL-31 expression. This experiment may have 
not have used the optimal timepoint for detecting transcription factor expression or perhaps the 
expression of these factors are only induced during differentiation and in fully mature clones we 
were never going to detect big changes. 
Using flow cytometry to detect chemokine receptors on clones of different phenotypes (Table 
4.4.3.1) also proved inconclusive due to the high variance and low n-number of clones of each 
phenotype. This experiment was carried out with the aim of identifying where IL-31 positive cells 
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would migrate to and therefore function of these cells. A marker of skin homing T-cells CLA 
(cutaneous lymphocyte antigen) had been found to have up-regulated IL-31 expression (Bilsborough, 
Leung et al. 2006) over non-CLA positive T-cells. We expanded the panel of chemokine receptors 
measured but found no significant bias in expression between the groups. The only chemokine 
receptor that was up-regulated by the IL-31 high clones was CCR8, which has been shown to be up-
regulated in lung-infiltrating T-cells of asthmatics (Panina-Bordignon, Papi et al. 2001). Although not 
a significant result, this could suggest IL-31 positive cells may migrate to the lungs to promote 
inflammation. 
4.5.6 Regulation of IL-31 by IL-4 
 
Although we had determined that IL-31 was expressed by Th2 cells and was induced by IL-4 it was 
still unclear whether IL-31 was constitutively expressed by Th2 cells or expressed as a response to 
exogenous IL-4. When Th2 clones were restimulated in the presence of a blocking antibody to IL-4 
we observed a significant drop in IL-31 expression. This result was also replicated by the rest of the 
clone phenotypes even Th1. This suggests that IL-31 is expression is not limited to Th2 clones but any 
clone that produces even the tiniest amount of IL-4 could induce IL-31 and that IL-31 could be 
inhibited via an IL-4 blockade. The levels of IL-31 from non-Th2 clones were a lot lower than those 
observed from Th2 clones. Although Th1 clones may have been designated IL-4 negative, there may 
have been a marginal expression of IL-4 that fell below the detection threshold of the ELISA. This 
experiment was novel and significant because it highlights that IL-31 can be expressed by any T-cell 
where IL-4 is present whatever the phenotype. The result seen was not due to an inhibitory effect by 
the presence of antibody because an isotype-matched control had no effect on IL-31 expression. 
Interestingly, blocking IL-4 on the Th2 clones had no effect on the expression of IL-13 showing that 
this cytokine is constitutively expressed once the cell has differentiated to Th2.  
The chance that Th1 clones may produce enough autologous IL-4 to induce IL-31 suggested that they 
may be responsive to IL-4. Indeed, treatment with IL-4 did enhance IL-31 expression significantly. 
Again levels were much lower than those observed by the Th2 clones but the fact that IL-31 levels 
did not change when IL-4 was added to Th2 clones suggests that their IL-31 expression was already 
maximal.  
It was perhaps surprising that Th1 clones responded to IL-4 in the first place but when we analysed 
the IL-4 receptor expression of a range of clones of differing phenotypes we consistently found IL-4 
receptor expressed on all clones. The lack of responsiveness to IL-4 observed by Th1 clones normally 
must therefore be due to transcriptional or epigenetic controls. Although Th1 cells responded to IL-4 
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to produce IL-31, they did not upregulate IL-13 expression or downregulate IFNγ expression 
indicating that plasticity of the T-cell phenotype was not occurring. The data suggested that IL-31 
was not a Th2 cytokine but could be more accurately thought of as a cytokine induced as a response 
to IL-4. When IL-4 was removed from the Th1 clones they resumed baseline levels of IL-31 after two 
weeks with no difference observed between the clones that had been restimulated with IL-4 or had 
never encountered IL-4 previously. 
This work raised the question; could any cell with an IL-4 receptor responds to IL-4 and produce IL-
31? Preliminary experiments started to explore this but were hampered by difficulties in isolating 
sufficient cells and a lack of time. However, in Figure 4.4.5.1IL-31 can be induced by IL-4 in non-CD4+ 
cells. PBMC from two atopic donors were depleted of CD4+ T-cells and stimulated for 16hrs with 
PMA and ionomycin  in the presence of  IL-5, IL-13, IL-9, IL-10, IFNγ (all at 20ng/ml) ± IL-4 (20ng/ml). 
RT-PCR was performed for the genes IL-31, IL-4 and IFNγ. Data shown are relative to the media 
control and have been normalised to 18s gene expression. No significant differences were detected 
by a Wilcoxen test. we investigated the responses of PBMC that had been depleted of CD4 T-cells to 
IL-4 and other Th2 cytokines. Although the other Th2 had no additional effect, in corcordance with 
our previous studies, IL-4 was able to induce IL-31 from these cells, unfortunately not significantly 
due to high variance between the donors. The relative induction of IL-31 by IL-4 was around 4-fold 
and very similar to the size of induction produced by T-cells perhaps implying that the IL-31 response 
to IL-4 is the same for any cell that can respond to it. An obvious problem with this experiment was 
that you cannot identify the cell type that is producing the IL-31. We isolated CD4 and CD8 T-cells 
and B-cells from 3 donors and stimulated them with IL-4. The results were inconclusive but there 
was a hint that CD8 T-cells and B-cells could respond to IL-4 to produce IL-31. If the range of cells 
that can produce IL-31 is expanded then the role IL-31 plays in an allergic reaction becomes much 
more important with IL-31 potentially being induced from the early IL-4 from a dendritic cell or 
basophil by different cells before T-cells have arrived and then throughout the t-cell driven late-
phase. 
4.5.6.1 Future work 
There are a number of avenues to explore that have been revealed by these studies. Firstly, an 
examination into the transcription factors involved with IL-31 expression to validate the 
Matinspector software analysis and determine what signalling pathway is crucial to induce IL-31. The 
experiments with clones could be repeated to generate allergen-specific clones and compare the IL-
31 expression induced by aeroallergens with food or contact allergens like nickel. There is a focus on 
research into IL-31 in the skin and it may be the case that allergens associated with the skin can 
induce higher levels of IL-31 than others. On a similar note, identifying a bias towards skin homing or 
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lung homing IL-31 positive T-cells may hint towards the tissue in which the function of IL-31 is most 
important. 
Further studies on the effect of IL-4 on non-T-cells are needed to confirm whether IL-31 can induce 
IL-31 from any cell with an IL-4 receptor and whether different cells can express various amounts of 
IL-31 in response to IL-4.  
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5 An investigation into the function of IL-31 
The following section examines the function of IL-31 with the aim of proving the hypothesis that IL-
31 is a pro-allergic cytokine that affects the function of the airway epithelium. The objectives of this 
chapter were to investigate whether IL-31 can induce responses from lung epithelium that would 
promote inflammation in vivo such as chemokine, cytokine or growth factor expression or cell 
proliferation. Th2 cytokines affect the epithelium in a number of ways to promote an allergic 
reaction, for example IL-31 promotes the expression of chemokines and differentiation of mucus 
producing goblet cells from epithelium. Due to the relative scarcity of research into the function of 
IL-31 we also took an unbiased approach and performed a microarray to search for epithelial genes 
regulated by IL-31. 
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5.1.1 IL-31 can enhance the proliferation of peripheral blood mononuclear cells from grass 
pollen allergic donors.  
 
 
Figure 5.1.1.1 . IL-31 can enhance the proliferation of PBMC from atopic subjects (a) PBMC from 3 atopic donors were 
stimulated for 48hrs with recombinant IL-31 or PHA (1µg/ml). Tritiated thymidine was added for the final 18hrs and tritium 
incorporation measured. (b) PBMC from 1 atopic donor were stimulated for 5 days with PPD (1µg/ml) or whole Phlp 
protein ± blocking antibodies to IL-31 or IL-4 (both 5µg/ml). An isotype matched control was added to the Phlp 10µg/ml 
condition. Tritiated thymidine was added for the final 18hrs before incorporation measured. Symbols represent 
experimental replicates. A Wilcoxen test was used to show significant differences between groups relative to the media 
control 
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 Experiments up until this point have focused on the induction of IL-31 from Immune cells and 
ignored whether IL-31 itself has any effect on these cells. In this experiment, PBMC from grass pollen 
allergic donors (n=3) were cultured with an increasing dose of IL-31 for 48 hours and were pulsed 
with tritiated thymidine for the final 18 hours and any tritium incorporation was then measured by 
scintillation counting. PHA was used as a positive stimulation control. As demonstrated in Figure 
5.1.1.1.a, PHA induced a robust proliferative response from all three donors, with significantly more 
tritium being incorporated than seen in the media control (821 vs 58 mean counts per minute (cpm) 
respectively). A very slight but significant increase in cpm was observed with the higher 
concentrations of IL-31. This result was unexpected as these cells were assumed to be unresponsive 
to IL-31 due to a lack of IL-31RA expression.  
IL-31 has been shown to be up-regulated by PBMC stimulated by allergen. If IL-31 were stimulating 
the proliferation of PBMC, then neutralising it during an allergen stimulation may reduce the 
proliferation of these cultures. PBMC from grass pollen allergic donors were stimulated with Phlp 
protein or PPD, a positive control that usually induces a strong proliferative response. Blocking/ 
neutralising antibodies to IL-31 and IL-4 were added in excess to these cultures (Figure 5.1.1.1.b) 
Tritiated thymidine was added 18hrs prior to the 5 day timepoint before cells were harvested and 
tritiated thymidine incorporation measured by scintillation counting. Phlp protein induced significant 
proliferation from all three donors, with PPD also inducing a strong proliferation. The addition of 
anti-IL-31 and anti-IL-4 however, made no impact to the proliferation of these cultures. This suggests 
that IL-31 and IL-4 have minimal influence on the proliferation of PBMC. 
 
5.1.2 Effects of IL-31 on human airway epithelium gene expression, proliferation and on 
epithelial wound healing. 
 
The airway epithelium is the point of contact between the environment and the body. Much more 
than just a physical barrier, the epithelium interacts with the immune system to mediate responses 
to immune challenges. Immunohistochemistry had suggested that skin epithelium expressed IL-31 
receptor (IL-31RA) so we examined whether IL-31 had any effect on the airway epithelium. Although 
IL-31 and IL-31RA have been detected in many allergic and inflammatory conditions, very little is 
known of the function that this interaction provides. We wanted to test the hypothesis detailed on 
page 41 that airway epithelium is responsive to IL-31 and that the function of IL-31 is due to its 
interaction with the epithelium. 
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This investigation focused on the effects of IL-31 on primary airway epithelium, using cultures of 
primary cells from one healthy donor, all statistics are based on experimental repeats as opposed to 
replicates of donors. 
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5.1.2.1 Normal human epithelial cells express IL-31 receptor. 
 
 
Figure 5.1.2.1 Normal human epithelial cells express IL-31 receptor. NHBE grown on cover slips were stained for IL-
31RA with a goat polyclonal Ab or a normal Ig control and visualised with biotin- avidin alexafluor 488. Nuclei were 
counterstained with DAPI 
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Cultures of normal human bronchial epithelium were established on cover slips which were then 
stained for the IL-31 receptor. As shown in Figure 5.1.2.1, the cell membranes stained strongly for IL-
31RA. The staining was specific when compared to secondary antibody only. The isotype control of 
normal goat immunoglobulin, resulted in a bright random staining that was judged to be non-
specific.
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5.1.3 IL-31 does not affect proliferation of epithelial cells 
 
  
 
 
 
 
 
Figure 5.1.3.1 . IL-31 does not affect proliferation of normal human bronchial epithelial cells (NHBE) 50% confluent 
NHBE were treated with increasing concentrations of IL-31 for 48 hours in a growth media (BEGM) and a neutral 
serum free media (AIMV). Cells were pulsed with tritiated thymidine for the final 16 hours before tritium 
incorporation was measured. No significant differences between groups were observed. 
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We wanted to investigate whether IL-31 had any effect on the proliferation of NHBE and therefore 
whether this is part of the function of IL-31. 70% confluent NHBE were washed and either growth 
media or AIM V, a serum free non-stimulatory media was added. A range of concentrations of 
recombinant IL-31 was added in addition to tritiated thymidine over-night. Cells were harvested and 
the lysates analysed for tritium incorporation. As shown in Figure 5.1.3.1 IL-31 had no effect on the 
proliferation of NHBE, with no concentration of IL-31 inducing a change in proliferation over that 
seen with media only. There was a noticeable but statistically insignificant difference between the 
two media types with the serum free AIM V inducing a lower basal proliferation than the growth 
factor containing BEGM.  
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5.1.4  IL-31 does not affect the migration of NHBE in a wound-healing assay. 
 
 
 
 
 
 
Figure 5.1.4.1 IL-31 does not affect wound healing of epithelial cells wound healing assay was performed on confluent 
NHBE in the presence of increasing concentration of recombinant IL-31. 9 scratches per concentration were 
measured. The area of the scratch was calculated at 5, 16 and 24 hours with 100% being maximum area. No 
significant differences between groups were found with a wilcoxen test 
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One possible function of IL-31 could be to promote the migration of NHBE when the epithelial 
monolayer is damaged and cells need to be stimulated to migrate and fill in the damaged area. This 
is one of the functions of the T-cell cytokine IL-22, which is also a tissue acting cytokine.  
The wound-healing scratch assay is fully described in the methods, but briefly, a monolayer of 
confluent NHBE are scratched with a p-200 pipette tip to make a uniform cell-free gap. Cells are then 
washed to remove the dislodged cells and fresh media containing IL-31 was added. The area of the 
scratch was then monitored at the same position at regular intervals in order to quantify the % 
change over time. As shown in Figure 5.1.4.1, various concentrations of IL-31 did not have a 
significant effect on wound healing compared to the media control. In 25 hours, most of the wounds 
had completely closed up naturally but at 16 hours there was a greater difference between the 
media control and 25ng/ml IL-31, although not significant. 
The morphology of cells treated with IL-31 did not appear to change during this 24 hour observation, 
nor did they show signs of death or lifting off the plate.  
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5.1.5  IL-31 affects the gene expression of normal human bronchial epithelial cells (NHBE) 
 
IL-31 did not appear to have an effect on the physical functions of NHBE so we next investigated 
whether IL-31 could induce genes that are often up-regulated in allergic inflammation 
5.1.5.1 IL-31 induces a panel of inflammatory genes from NHBE. 
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C. 
 
Gene detected 
Fold change following cytokine treatment relative to media control 
(8hrs) 
IL-31 IL-4 IL-13 
CCL2 12.35 15.37 16.7 
CCL5 0.82 0.67 2.2 
CCL11 0.33 0.38 0.28 
CCL17 0.44 0.65 0.52 
CCL22  0.64 0.49 0.47 
CXCL1 0.93 1.66 1.2 
EGF 1.15 0.29 0.52 
G-CSF 2.16 2.15 2.86 
GM-CSF 1.67 0.69 0.98 
IL-6  0.9 0.24 0.52 
IL-8 1.3 1.96 1.96 
IL-25 sv2 0.47 0.49 0.37 
IL-33 1.54 0.33 0.6 
IL-31RA 0.73 1.12 0.69 
Muc5AC 2.11 0.83 1.13 
TGFβ 1.06 0.7 0.44 
TSLP 0.46 0.96 - 
 
Figure 5.1.5.1 IL-31 has an effect on gene expression of NHBE. (a) 70% confluent NHBE were treated with 50ng/ml IL-31 for 
8 hours. RT-PCR was performed for a range of genes. Data shown are relative to a media control and have been normalised 
to 18s expression. (b) A dose response to IL-31 at 8 hours. Data shown are relative to the media control and relative to 18s 
housekeeping gene expression.(c) table to show full panel of genes tested in response to 50ng/ml IL-31, IL-4 or IL-13. 
Orange denotes upregulation, blue downregulation. 
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Figure 5.1.5.1.a shows a preliminary experiment of gene expression from NHBE following an 
arbitrary dose of 50ng/ml IL-31, IL-13 or IL-4 for 8 hours. These data were encouraging as some 
genes tested showed slight upregulation of around 1.5-2.5 fold increase when compared to media 
control in response to IL-31.  
C. 
 
Gene detected 
Fold change following cytokine treatment relative to media control 
(8hrs) 
IL-31 IL-4 IL-13 
CCL2 12.35 15.37 16.7 
CCL5 0.82 0.67 2.2 
CCL11 0.33 0.38 0.28 
CCL17 0.44 0.65 0.52 
CCL22  0.64 0.49 0.47 
CXCL1 0.93 1.66 1.2 
EGF 1.15 0.29 0.52 
G-CSF 2.16 2.15 2.86 
GM-CSF 1.67 0.69 0.98 
IL-6  0.9 0.24 0.52 
IL-8 1.3 1.96 1.96 
IL-25 sv2 0.47 0.49 0.37 
IL-33 1.54 0.33 0.6 
IL-31RA 0.73 1.12 0.69 
Muc5AC 2.11 0.83 1.13 
TGFβ 1.06 0.7 0.44 
TSLP 0.46 0.96 - 
 
Figure 5.1.5.1Figure 5.1.5.1.b shows the results of a dose response to IL-31 at 8 hours to measure 
the genes, IL-33, IL-8 and GM-CSF. 50ng/ml IL-31 induces the strongest response with GM-CSF and 
IL-8 exhibiting at least 1.5 fold change in expression but IL-33 expression was not induced by IL-31. 
IL-31 receptor expression was also measured but seemed unchanged by the treatment with IL-31. 
Figure 5.1.5.1c. is a table detailing all of the genes tested over various experiments, including 
treatments with IL-4 and IL-13, all with 50ng/ml cytokine for 8 hours. Genes unchanged or down-
regulated by all three of these cytokines were not studied again. 
Further optimisation studies revealed that 50ng/ml IL-31 was the optimal dose. Timecourses 
revealed that 16 hours was the optimal timepoint to measure most genes, with the exception of 
CCL2, IL-6 and IL-33, which were measured at 4 hours. 
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5.1.5.2 IL-31 can combine with IL-4 and IL-13 to enhance expression of inflammatory genes. 
 
 
Figure 5.1.5.2 . IL-31 can synergise with IL-4 and IL-13 to enhance expression of  inflammatory genes.(a)70% confluent 
NHBE treated with IL-31, IL-13, IL-4 for 16 hours before IL-8 expression measured by RT-PCR. Data shown are relative to 
media control and normalised to 18s expression. (b) The suboptimal doses of IL-4 (0.5ng/ml), IL-13 (10ng/ml) and IL-31 
(25ng/ml) as determined in (a) were added in combination to 70% confluent NHBE for 16 hours.  IL-8 expression was 
measured by RT-PCR, data are relative to the media only control and have been normalised to 18s expression. (c-f) NHBE 
were treated for 4 hours with 25ng/ml each of IL-4, IL-13 and IL-31 before RT-PCR was carried out for the genes IL-33, 
CCL2, G-CSF and CXCL1. Again, data are relative to media control and normalised to 18s expression. A paired t-test was 
used to show significant differences between groups. Analysis by Kruskal-Wallis Anova indicates significance 
***p=<0.0005, ** p=<0.005 
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IL-31 is unlikely to be secreted and experienced in isolation by epithelial cells in vivo. We combined 
IL-31 with the Th2 cytokines IL-13 and IL-4 and measured genes known to be regulated by these 
cytokines, in addition to the genes that showed a response to IL-31 alone. In order to detect any 
synergy between these cytokines, a suboptimal dose was used. As shown in Figure 5.1.5.2.a with IL-8 
as a representative plot, a suboptimal dose of 10ng/ml IL-13, 0.5ng/ml IL-4 and 25ng/ml IL-31 was 
determined. Although combining IL-31 with IL-13 and IL-4 did increase gene expression in most 
cases, the only gene where synergy was observed was CCL2.  
CCL2, also known as monocyte chemoattractant protein 1 (MCP-1), showed a non-significant 
response to IL-31 (2.07 fold change ± 0.53 SEM). When combinations of IL-31 and the Th2 cytokines 
IL-4 and IL-13 were applied to NHBE, an increase of CCL2 expression was observed (IL-13 and IL-31 
17.02 fold increase vs. IL-31 alone, and IL-4 plus IL-31 showed 29.54 fold increase,  vs. IL-31 alone). 
Treatment by all three cytokines did not induce the highest CCL2 expression, perhaps due to an 
oversaturation of receptor signaling pathways.   
IL-33 was barely induced by IL-31 alone (1.3 fold) nor by IL-4 or IL-13 (1.27 and 1.48 fold change 
respectively). The combination of IL-31 and IL-13 did enhance IL-33 expression to 2.04 fold change 
but this is not an additive effect. IL-4 appeared to inhibit IL-33 expression as the combination of IL-31 
and IL-4 induced a 0.9 fold change and similarly reduced the expression of IL-33 induced by IL-13. 
For the genes CXCL1, IL-8 and G-CSF, the pattern was slightly different. IL-31 did not enhance the 
effect of IL-4 and IL-13 separately but could promote the gene expression induced by IL-13 plus IL-4 
by more than the fold change induced by IL-31 alone. IL-31 alone induced 1.7 fold CXCL1 but added 
4.2 to IL-4 plus IL-13 induced CXCL1 expression. Alone, IL-31 induced 1.2 fold IL-8 expression but 
added 2.9 fold to IL-13 plus IL-4 induced IL-8 expression. G-CSF was induced 1.4 fold by IL-31 but the 
difference between IL-4 plus IL-13 and IL-4 plus IL-13 plus IL-31 was a 1.6 fold increase. For these 
three genes, the combination of all three cytokines induced the greatest expression.
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5.1.5.3 Effect of IL-31 in combination with IL-4 and IL-13 to enhance the secretion of CCL2 
protein. 
 
 
 
Figure 5.1.5.3 IL-31 can synergise with IL-4 and IL-13 to enhance secretion of CCL2 protein. 70% confluent NHBE  in 24 
well plates were washed and stimulated with  (a) increasing concentration of IL-31 or (b) combinations of IL-31, IL-4, 
IL-31 (all at 20ng/ml) for 48hrs before CCL2  was assayed by ELISA. Data shown are mean ± SEM  of experimental 
repeats (n=3). A Kruska-Wallis Anova with bonferoni post-test indicates significance ***p=<0.0005 
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The studies with NHBE have been detecting relative differences between gene expression. These 
changes may be affected by post-trancriptional regulation and therefore may not translate to 
changes in protein expression. To confirm that IL-31 has an effect on the expression of protein, CCL2 
secretion was measured by ELISA. The chemokine was chosen because it showed the greatest gene 
expression changes in response to IL-31. As shown in Figure 5.1.5.3 CCL2 secretion was detectable in 
the NHBE cell culture supernatant. CCL2 secretion increased with the concentration of IL-31. When 
IL-31 was combined with IL-13 and IL-4 as for the previous gene expression experiments, the 
secretion of CCL2 increased significantly, with IL-4 plus IL-31 inducing the greatest CCL2 production 
of 40.49pg/ml compared with 11.2pg/ml and 22.52pg/ml induced by IL-31 and IL-4 singly. A similar 
pattern was observed for IL-13 with the combination of IL-13 and IL-31 producing 29.67pg/ml versus 
11.2pg/ml and 11.1pg/ml induced by IL-31 and IL-13 singly. In parallel with the gene expression 
changes observed, treatment with all three cytokines did not induce the highest CCL2 expression. 
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5.1.5.4 IL-13 can enhance TNFα induced secretion of pro-inflammatory genes. 
 
 
 
Figure 5.1.5.4 IL-31 can combine with TNFα to enhance expression of pro-inflammatory genes. (a-c) 70% confluent 
NHBE were treated with 10ng/ml TNFα and 50ng/ml IL-31 for 16 hours before RT-PCR was performed for the genes IL-
8, GM-CSF and IL-33. Data are relative to media control and normalised to 18s expression. A Wilcoxen test was used to 
determine significant differences between groups. (d) shows the gene expression response  of NHBE to increasing 
dose of TNFα. After 16hrs RT-PCR was performed to measure IL-33, IL-8 and GM-CSF. Data are relative to media 
control and normalised to 18s expression.  
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Tumour necrosis factor alpha (TNFα) is a highly pro-inflammatory factor with a multitude of effects. 
When treated with TNFα at increasing doses for 16 hours, NHBE upregulate the genes IL-8 and GM-
CSF. IL-33 was also measured because it has been demonstrated that TNFα induces IL-33. IL-33 in 
turn, can induce IL-31 from T-cells (Figure 4.4.1.3) so the possibility of a reciprocal positive feedback 
mechanism of IL-31 and IL-33 was examined.  
NHBE were treated with a combination of IL-31 and TNFα (Figure 5.1.5.4.). The genes IL-8, GM-CSF 
and IL-33 were measured and for each gene a strong upregulation of 5.3, 4.08 and 4.1 fold change 
respectively was observed for the combination of IL-31 and TNFα. These changes were statistically 
significant in the case of IL-8 and GM-CSF. IL-31 acted with TNFα to induce IL-8, GM-CSF and IL-33, 
inducing the genes at greater fold than the combination of the two cytokines singly. 
5.1.6 Microarray analysis of genes induced by IL-31 containing supernatants. 
 
Although a fairly large panel of genes had been tested for regulation by IL-31, they all were chosen 
due to previous literature showing upregulation in allergic disease. The role of IL31 has not been 
confirmed in any disease so we decided to cast a wider net and perform a microarray on NHBE 
treated with IL-31 to investigate whether there is a specific role for IL-31.  The details of the 
experiment are in the methods and materials chapter but briefly, NHBE were treated with media 
conditioned by IL-31 producing T-cell clones (n=3). To find genes specifically regulated by IL-31, a 
control of supernatant plus a neutralising antibody to IL-31 was included. As a positive control, a 
neutralising antibody to IL-13 plus supernatant was utilised, as genes regulated by IL-13 are well 
characterised. Further controls of NHBE media alone and with recombinant IL-31 were included.  
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5.1.6.1 Generation of potential candidate genes regulated by IL-31 
 
 
Figure 5.1.6.1. Generation of potential candidate genes specifically regulated by IL-31 in NHBE. Genes were filtered to 
exclude non-significant gene expression changes of less than 2 fold between media control and other groups. 
Genes potentially 
specifically regulated by 
IL-31
177 
 
The microarray generated thousands of potential genes that were differentially expressed between 
the groups. Through a number of filtering steps, only genes with significant (p=≤0.05) fold change of 
>2 were permitted. The fold change value is relative, not absolute, and generated via the 
comparison of two groups. With 5 conditions tested by microarray a number of comparisons could 
be made, and for each comparison a list of genes (known as an entity list) up-regulated as well as 
down regulated could be acquired. In order to identify genes specifically induced by IL-31 there were 
two comparisons to compare and combine; Genes up-regulated by recombinant IL-31 relative to a 
media control and genes downregulated when a blocking antibody to IL-31 was added to Th2 
supernatants relative to treatment by Th2 supernatants only. 
By using Venn diagrams we were able to sort the differentially expressed genes and exclude the 
genes that had been induced by immunoglobulin or modified by anti-IL-13. As shown in Figure 
5.1.6.1 , there was not much overlap between these two sets of genes so the list of candidate genes 
was compiled from all three sections, with the top 5 genes with the largest expression change were 
included.   
5.1.6.2 Pathway analysis 
The Genespring database is annotated with all published information about each gene such as 
function, cellular location and upstream and downstream regulatory genes. This Gene Ontology (GO) 
database can be applied to an entity list to create a network of those genes called a pathway 
analysis. Genes are connected by such factors as expression, binding, regulation, transport or 
catalyst. Relationships are identified by datamining published literature so are actual as opposed to 
theoretical. The figure also localizes these genes to certain areas in the cell which can help to 
identify the overall function of the group of genes. Figure 5.1.6.2 shows the pathway analysis for 
genes downregulated in the presence of anti-IL-31. The majority of the genes are localized in the 
cytoplasm, with very few localised to transporter proteins, golgi apparatus or the membrane which 
doesn’t narrow down a particular role for IL-31.  It can also be noted that there are very few obvious 
immune system related genes, except for TLR8, a toll-like receptor important for regulating TLR7 
expression and T-regulatory cells (Peng, Guo et al. 2005), may be regulated by IL-31. 
5.1.6.3 Network hubs of genes regulated by IL-31. 
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Figure 5.1.6.2 Pathway analysis showing genes downregulated by anti-IL-31 and how they relate to each other.  
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The pathway analysis figure can be useful to identify hub genes, genes with many connections 
amongst the genes that are in the group. Hub genes may not cause dramatic expression changes but 
due to their influence on so many other genes they are nonetheless very important and were 
therefore included in the list of candidate genes. Figure 5.1.6.2 highlights 4 hub genes that are 
regulated by IL-31: ACTR2, WNK4, CACYBP and Sult1E1. A fully interactive version of this figure is 
available on the supplemental data disc included with the thesis.
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5.1.6.4 Genes induced by Th2 supernatants 
 
 The Th2 clone supernatants induced many genes from the NHBE when compared to the media 
control. 
 
 
 
 
Figure 5.1.6.3. Genes up-regulated by Th2 supernatants. A) shows all genes averaged over each replicate and (b) shows a 
volcano plot, where all red symbols are genes that have a significant expression change, p=<0.05 and >2 fold. 
 
 
 
 
 
Figure 5.1.6.3 shows that Th2 supernatants upregulate numerous genes. Many of these expression 
changes are significant as determined by a t-test. The volcano plot shows the negative log of the p-
value on the y-axis versus the log of the fold change on the x-axis. Probes for genes that showed fold 
A B
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change >2.0 and a significance of <0.05 appear red. The top 22 expression changes induced by Th2 
supernatants are summarised in Table 5.1.6.1. Chemokines were well-represented in the list with 
CXCL9, topping the list. CXCL9, also known as mig, is the ligand for CXCR3 and attracts T-cells. CCL2 
had been identified earlier in this study as being up-regulated by Th2 cytokines and its position in the 
list confirms those experiments. Indoleamine 2, 3-dioxygenase (IDO) was the genes with the second 
highest induction and is also important for T-cell regulation. 
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Table 5.1.6.1 Genes up-regulated by Th2 supernatants 
Gene Symbol Gene name Media 
condition 
Th2 
supernatants 
Absolute 
fold 
change 
CXCL9 Homo sapiens chemokine (C-X-C motif) ligand 9 
(CXCL9), mRNA [NM_002416] 
-2.2591 1.058948 10212.36 
 
IDO1 Homo sapiens indoleamine 2,3-dioxygenase 1 
(IDO1), mRNA [NM_002164] 
-10.6822 
 
0.98199 
 
3245.484 
 
UBD Homo sapiens ubiquitin D (UBD), mRNA 
[NM_006398] 
2195.814 
 
-10.2968 
 
0.803743 
 
CXCL11 Homo sapiens chemokine (C-X-C motif) ligand 11 
(CXCL11), mRNA [NM_005409] 
1372.889 
 
-9.12112 
 
1.301881 
 
PMCH Homo sapiens pro-melanin-concentrating 
hormone (PMCH), mRNA [NM_002674] 
-10.0183 
 
0.288122 1266.357 
 
CXCL11 Homo sapiens chemokine (C-X-C motif) ligand 11 
(CXCL11), mRNA [NM_005409] 
-8.7842 
 
1.390225 
 
1155.602 
 
CXCL10 Homo sapiens chemokine (C-X-C motif) ligand 10 
(CXCL10), mRNA [NM_001565] 
-8.21845 
 
1.034518 
 
610.1279 
 
PMCHL1 Homo sapiens pro-melanin-concentrating 
hormone-like 1 (PMCHL1), non-coding RNA 
[NR_003921] 
-8.98617 
 
0.256284 605.6987 
ETV7 Homo sapiens ets variant 7 (ETV7), mRNA 
[NM_016135] 
-7.20539 
 
0.907959 
 
276.9243 
 
GBP4 Homo sapiens guanylate binding protein 4 (GBP4), 
mRNA [NM_052941] 
-6.85748 
 
1.007046 
 
233.0556 
 
APOL3 Homo sapiens apolipoprotein L, 3 (APOL3), 
transcript variant beta/a, mRNA [NM_145641] 
 
-6.58565 
 
0.943075 
 
 
184.6591 
 
- Unknown  -6.73082 0.382072 138.4187 
XAF1 Homo sapiens XIAP associated factor 1 (XAF1), 
transcript variant 1, mRNA [NM_017523] 
 
-5.00603 1.488415 90.16153 
ICAM1 Homo sapiens intercellular adhesion molecule 1 
(ICAM1), mRNA [NM_000201] 
-5.85693 0.58486 86.93062 
BATF2 Homo sapiens basic leucine zipper transcription 
factor, ATF-like 2 (BATF2), mRNA [NM_138456] 
-5.81497 
 
0.549628 82.40164 
CIITA Homo sapiens class II, major histocompatibility 
complex, transactivator (CIITA), mRNA 
[NM_000246] 
-4.47029 
 
1.892174 
 
82.27942 
 
CCL2 Homo sapiens chemokine (C-C motif) ligand 2 
(CCL2), mRNA [NM_002982] 
-4.65229 1.612596 76.89863 
NNMT Homo sapiens nicotinamide N-methyltransferase 
(NNMT), mRNA [NM_006169] 
-5.99039 0.266576 76.47744 
NLRC5 Homo sapiens NLR family, CARD domain 
containing 5 (NLRC5), mRNA [NM_032206] 
-5.95129 0.250283 73.59677 
BCL2L14 Homo sapiens BCL2-like 14 (apoptosis facilitator) 
(BCL2L14), transcript variant 2, mRNA 
[NM_030766] 
-5.05423 
 
1.132005 
  
72.81867 
 
CCL7 Homo sapiens chemokine (C-C motif) ligand 7 
(CCL7), mRNA [NM_006273] 
-5.75099 0.422254 72.166 
APOL6 Homo sapiens apolipoprotein L, 6 (APOL6), mRNA 
[NM_030641] 
-4.14798 2.014244 71.6169 
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5.1.6.5 Genes regulated by IL-13 
 
 
Figure 5.1.6.4 Mucin gene expression induced by Th2 supernatant is inhibited in the presence of anti-IL-13. A) Genes 
regulated by anti IL-13 filtered on the name “mucin”. (B) Table to show the greatest expression changes of mucins 
regulated by anti-IL-13. 
 
A
B
Gene 
Symbol
Gene name Media 
condition
Th2 
supernatants
Absolute 
fold change
EMR3
Homo sapiens egf-like module 
containing, mucin-like, hormone 
receptor-like 3 (EMR3), mRNA 
[NM_032571] -0.27140284 2.0833666 -2.35476944
MUC5B
Homo sapiens mucin 5B, oligomeric 
mucus/gel-forming (MUC5B), mRNA 
[NM_002458] -0.081753574 1.1499144 -1.231667974
MUC16
Homo sapiens mucin 16, cell surface 
associated (MUC16), mRNA 
[NM_024690] -0.55171233 0.5015707 -1.05328303
MUC17
Homo sapiens mucin 17, cell surface 
associated (MUC17), mRNA 
[NM_001040105] -0.025532722 0.5863538 -0.611886522
MUC7
Homo sapiens mucin 7, secreted 
(MUC7), transcript variant 3, mRNA 
[NM_152291] 0.035125416 0.6079025 -0.572777084
MUPCDH
Homo sapiens mucin-like 
protocadherin (MUPCDH), transcript 
variant 1, mRNA [NM_021924] -0.99373454 -0.45188537 -0.54184917
MUC12
Homo sapiens mucin 12, cell surface 
associated (MUC12), mRNA 
[NM_001164462] -0.42065492 0.045193195 -0.465848115
LOC1001
33790
PREDICTED: Homo sapiens intestinal 
mucin-like (LOC100133790), partial 
mRNA [XM_001719766] 0.06276941 0.50542086 -0.44265145
MUC12
Homo sapiens mucin 12, cell surface 
associated (MUC12), mRNA 
[NM_001164462] -0.21351163 0.2278552 -0.44136683
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A control for the experiment was to block IL-13 in the Th2 supernatants and look for genes known to 
be regulated by IL-13 on epithelial tissue. The classical gene family induced by IL-13 are the mucins. 
As shown in Figure 5.1.6.4 most mucins were downregulated in the presence of an IL-13 blockade. 
This suggests that the approach to identify genes by specifically knocking out one cytokine in an 
array was valid and that genes identified via neutralization of IL-31 are representative. There were 
some genes up-regulated by anti-IL-13 but the mucin family is quite large so these were seen as 
anomalies. When genes regulated by IL-31 were filtered for mucins the observed expression changes 
were very small, with the greatest fold change 0.93 observed for prostate androgen repressed mucin 
like protein 1 (PARM-1), a protein that is only mucin-like in structure and has an unknown function. 
Another set of genes known to be regulated by IL-13 is that of matrix-metalloproteases. When genes 
regulated by anti IL-13 were filtered for matrix metalloproteases there were only two with a fold 
change of more than 1 in response to anti-IL-13 which were MMP16 and MMP8. 
5.1.6.6 Genes regulated by IL-31 related to the epithelium 
The epithelium responds to allergen stimulation in a number of different ways. One such response is 
to increase epithelial permeability to permit inflammatory cells through the membrane. Increased 
permeability can be induced by enzymatic degradation of tight junctions between epithelial cells 
with proteases such as matrix metallo-proteases (MMP). When the list of genes regulated by anti-IL-
31 was filtered for MMPs, only MMP16 (2.027 fold change) was present and no MMPs were found 
up-regulated by recombinant IL-31. 
An additional effect of allergen stimulation on the epithelium is the production of growth factors 
and keratins to induce migration, differentiation and proliferation of the epithelial cells to repair the 
damage caused by the MMPs. Two keratins were regulated in the presence of anti-IL-31 versus Th2 
supernatants alone; keratin 2 (2.5 fold change) and keratin 76 (2.3 fold change). Interestingly 4 
keratins were induced by recombinant IL-31, with no overlap with the keratins regulated by anti-IL-
31; keratin 77 (5.6 fold change), keratin 82 (2.9 fold change), keratin 36 (2.8 fold change), keratin 71 
(2.04 fold change).  
Upon searching for growth factors, fibroblast growth factor) 17 (FGF17) was on both lists of genes 
regulated by IL-31. 
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5.1.6.7  Candidates for genes regulated by IL-31 
 
Figure 5.1.6.5. Candidates for genes that are regulated by IL-31. These genes represent the greatest significant gene 
expression changes observed in the microarray, each coloured bar represents the mean of three different T-cell 
supernatant results and are relative to the media control.  
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The microarray analysis did not reveal a collection of similar genes regulated by IL-31 and the two 
approaches to identify genes regulated by IL-31 resulted in two quite different entity lists. In order to 
compile a list of potential genes that demonstrate the function of IL-31, the top 5 genes, in terms of 
expression change, from each entity list were used. Figure 5.1.6.5 is a heatmap showing the 
expression changes induced by each of these genes. Genes with lesser expression change but with 
lots of network connections or a function that could relate to allergy were also included. The latter 
comprised TLR8 and AdamTs6.  
Primers were designed for all of the candidate genes. In order to validate my analysis, RT-PCR was 
run with the original RNA samples returned from Miltenyi Biotec and primers for the candidate 
genes. Some primers failed validation therefore not all genes in Figure 5.1.6.5 are represented in the 
following figures.
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5.1.6.7.1 RT-PCR of microarray samples of validating candidate genes induced by 
recombinant IL-31 
 
 
Figure 5.1.6.6. RT-PCR of microarray samples of genes identified as those induced by recombinant IL-31. n=3 replicates 
of NHBE treated for 8 hours with Th2 supernatants ± anti-IL13 or anti-IL31 or fresh media ± rIL-31 (20ng/ml).  Data are 
normalised to 18s housekeeping gene and shown relative to one of the media control groups.  
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The genes EBF3, CA5B, TRPC6 and VIP were identified as being up-regulated by recombinant IL-31 in 
the microarray. When the same samples were analysed in-house by RT-PCR for these genes the 
results were a lot less clear cut (Figure 5.1.6.6). All of the gene expression changes were marginal 
but for EBF3, TRPC6 and VIP there was a trend towards a higher expression by the IL-31 treated 
groups. CA5B was unchanged across all groups. There appeared to be a high variance between 
replicates, even the media control and recombinant IL-31 groups which should be identical.  
189 
 
 
 
5.1.6.7.2 RT-PCR of microarray sample validating candidate genes as those decreased by 
blocking IL-31 in Th2 supernatants 
 
 
Figure 5.1.6.7 RT-PCR of microarray samples of genes identified as those decreased when blocking IL-31 in Th2 clone 
supernatant. NHBE treated for 8 hours with n=3 Th2 supernatants ± anti-IL13 or anti-IL31 or fresh media ± rIL-31 
(20ng/ml).  Data are normalised to 18s housekeeping gene and shown relative to one of the media control groups.  
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The genes Glycogenin, FUT9 and SULT1E1 were identified as being regulated during an IL-31 
blockade of Th2 supernatant. They were also subject to the additional filter of being unchanged by 
anti IL-13. WNK4 was identified as a hub gene from the pathway analysis of this entity list. Although 
in the microarray there was a clear difference between the two conditions, RT-PCR of the same 
samples failed to repeat the result (Figure 5.1.6.7). Glycogenin and Sult1E1 in particular showed no 
difference between Th2 supernatant treatments. High variance between samples was again a 
problem. Although FUT9 showed a reduction in expression in response to anti-IL-31, all of the 
expression values were lower than the media control against which the results were normalized. 
WNK4 did follow the pattern predicted by the microarray, Th2 supernatants up-regulated its 
expression to 3.1 fold increase and anti-IL-31 reduced this expression down to 1.8 fold change. 
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5.1.6.7.3 RT-PCR of microarray sample validating candidate genes as those decreased by 
blocking IL-31 in Th2 supernatants and induced by recombinant IL-31 
 
 
Figure 5.1.6.8 RT-PCR of microarray samples of genes identified as those decreased when blocking IL-31 in Th2 clone 
supernatant and increased by recombinant IL-31.  NHBE treated for 8 hours with n=3 Th2 supernatants ± anti-IL13 or 
anti-IL31 or fresh media ± rIL-31 (20ng/ml).  Data are normalised to 18s housekeeping gene and shown relative to one 
of the media control groups.  
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The genes CYFIP2, Greb1L, ZNF 704 and CACYBp were identified in the microarray as being modified 
by both recombinant IL-31 and by anti-IL-31 plus Th2 supernatants and therefore were predicted to 
be the most likely IL-31 specific genes. When the samples from the microarray were analysed by RT-
PCR for these genes there were no significant gene expression changes (Figure 5.1.6.8.). There was a 
trend towards a downregulation of CACYBP expression in response to anti-IL-31, from 0.73 fold to 
0.39 fold change, but the remaining gene expression changes were marginal. In contrast to the 
microarray analysis, none of these genes were up-regulated by recombinant IL-31.  The expression 
of these four genes was very similar to the media control for all conditions with no fold change 
observed greater than 0.5 fold change more than 1.
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5.1.6.7.4 RT-PCR of microarray samples of genes previously shown to be regulated by IL-31 
 
 
Figure 5.1.6.9 RT-PCR of microarray samples of genes previously shown to be regulated by IL-31. n=3 replicates of 
NHBE treated for 8 hours with Th2 supernatants ± anti-IL13 or anti-IL31 or fresh media ± rIL-31 (20ng/ml).  Data are 
normalised to 18s housekeeping gene and shown relative to one of the media control groups.  
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Preliminary experiments prior to the microarray had identified CCL2, IL-8 and IL-6 as being induced 
by recombinant IL-31. When these genes were screened by RT-PCR on the samples used in the 
microarray results were hampered by high variance. Despite this, CCL2 was significantly up-
regulated by TH2 supernatants to 3.9 fold increase relative to the media control (Figure 5.1.6.9). 
Blocking antibodies to IL-31 and IL-13 had no effect on the CCL2 expression induced by the Th2 
supernatants. IL-8 was induced by the Th2 supernatants and also not modified by either blocking 
antibody. IL-6 expression was not enhanced by any of the conditions over the media control. 
Recombinant IL-31 did not induce any of these genes in these samples.
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5.1.7 RT-PCR of NHBE treated with Th2 supernatants measuring genes identified in the 
microarray as being regulated by IL-31 
 
 
Figure 5.1.7.1. Repeat of microarray experiment. RT-PCR of genes regulated by IL-31. n=3 replicates of NHBE treated 
for 8 hours with Th2 line supernatants ± anti-IL13 or anti-IL31 or fresh media ± rIL-31 (20ng/ml). Th2 lines (a) 153 and 
155 were diluted with media as to contain equal concentrations of IL-31. (b-d) RT-PCR of CCL2, AdamTs6 and FUT9. 
Data are normalised to 18s housekeeping gene and shown relative to one of the media control groups.   
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In order to validate the microarray analyses further, the experiment was repeated. Unfortunately, 
there were no more Th2 clone supernatants so three Th2 lines from different atopic donors were 
generated by culturing T-cells in Th2 polarising conditions for 4 weeks. As shown in Figure 5.1.7.1a, 
the IL-31 produced by these three lines was quite varied ranging from 34pg/ml – 490pg/ml. For the 
assay, T-cell 153 was diluted with media to 161pg/ml to be equivalent to T-cell 155, not T-cell 154 
which was considered to have too low a concentration of IL-31. The only genes measured were 
Adamts6 and FUT9 as these had shown some degree of IL-31 specific induction. CCL2 was measured 
as a positive control as NHBE respond robustly to most stimuli by producing CCL2.  
The Th2 line supernatants did induce a strong CCL2 response (59.1 fold increase over media) that 
was unaffected by anti IL-31 and anti-IL-13. The media control showed great variance which 
accounts for the very low media control values. Relative gene expression of AdamTs6 and FUT9 was 
equally low however, with neither gene induced by recombinant IL-31 or IL-31 containing 
supernatants. 
5.2 Discussion 
This section examined the effect that IL-31 has on T-cells and lung epithelial cells with the aim of 
elucidating its function. 
5.2.1 Effect of IL-31 on T-cells.  
Very little work was carried out on the effect of IL-31 on PBMC due to published studies and our own 
work failing to detect IL-31RA on T-cells and other immune cells. However, to confirm IL-31 has no 
effect on PBMC a proliferation assay was set up. Surprisingly, an increasing dose of recombinant IL-
31 had a marginal but significant effect on the proliferation of PBMC albeit much less than the 
proliferation induced by the lectin PHA. The proliferation observed may have even been due to trace 
LPS or other contaminants in the recombinant protein.  The reverse experiment stimulated PBMC 
with allergen and then blocked any IL-31 produced with an antibody. This was unable to inhibit the 
proliferation induced by the allergen. Although there may have been compensatory pathways with 
other factors promoting proliferation to hide the anti-IL-31 blocking effect, these two experiments 
imply that IL-31 has very little effect on PBMC.   
5.2.2 Effect of IL-31 on normal human bronchial epithelial cells (NHBE) 
The airway epithelium is the point of contact between our body and aeroallergens. It is an important 
co-ordinator of the allergic response releasing chemokines to attract immune cells, permitting 
access for these cells and providing mucus to trap further aeroallergens. The function of IL-31 is very 
poorly understood and the following set of experiments aimed to identify the outcome of IL-31 
receptor signalling.  
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The only experiments that had been carried out prior to our studies were performed on the 
immortal cell line BEAS-2B (Ip, Wong et al. 2007).  We used cultures of primary NHBE from a healthy 
donor that were only used at passage numbers less than 6 so that the cells were as similar to in vivo 
conditions as possible. However, a caveat to these experiments is that the cells were not fully 
differentiated to mature cilia coated monolayers, nor were they grown at an air-liquid interface. This 
was due to the fact that during optimisation experiments we found that gene expression responses 
were much greater when cells were proliferating, so all experiments were carried out on non-
confluent cultures. Importantly though, these cells expressed IL-31 receptor and were able to 
respond to IL-31. 
Before embarking on the large task of identifying genes that could be regulated by IL-31 we first 
investigated whether IL-31 could affect the physiological function of NHBE. Many cytokines act as a 
growth factor on their target cells but IL-31 had no influence on the proliferation of NHBE even at 
very concentrations of 100ng/ml. To account for the epithelial growth factors that were present in 
the proprietary NHBE growth media, this assay was also performed in serum free AimV media. There 
was a marked difference between the proliferation of the cells in the two media types which 
confirmed that this assay could detect differences in proliferation.  This complements published data 
(Chattopadhyay, Tracy et al. 2007) showing that IL-31 could suppress the proliferation from similar 
alveolar derived cell lines.  
The wound healing assay is another technique for measuring a response to a cytokine by epithelial 
cells and has been used in our laboratory successfully to demonstrate the effect of IL-22 on cell 
migration and wound healing. IL-31 however, had no significant effect on promoting the migration 
of epithelial cells so further work in this area was not pursued. 
5.2.2.1 Effect of IL-31 on gene expression 
Our preliminary studies did not suggest that IL-31 affected the physical properties of NHBE. The 
focus of investigating a response to IL-31 then shifted to identifying genes regulated by IL-31. A 
panel of genes involved with allergy, inflammation and growth were all measured (CROSSREF) in 
response to IL-31, as well as the Th2 cytokines IL-13 and IL-4. We found that IL-31 could induce a 
range of genes from NHBE, in particular CCL2, GM-CSF and IL-8 which all attract and promote the 
growth of innate immune cells such as monocytes and granulocytes. This would support the 
hypothesis that IL-31 is a pro-inflammatory cytokine, although it should be pointed out that IL-4 and 
IL-13 nearly always were more potent inducers of these genes. The experiment was developed 
further to include combinations of IL-4, IL-13 and IL-31 each at a suboptimal dose. Epithelial cells are 
unlikely to experience cytokines in isolation due to T-cells secreting a range of cytokines so this 
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combination would represent the presence of Th2 cells induced by the allergic reaction.  With the 
exception of IL-33, which is starting to be shown to be inhibited by IL-4 and IL-13 , all of the genes 
measured showed an upregulation when treated with 2 or more cytokines. IL-31 at the suboptimal 
dose had a minimal effect on gene expression alone but was able to boost the expression of IL-8, 
CCL2, G-CSF and CXCL1 induced by IL-13 or IL-4 and IL-13 together much to a greater extent than just 
adding together the fold changes induced from the separate cytokines. The signalling pathways from 
IL-31 receptor involves Stat3 (Dillon, Sprecher et al. 2004) and IL-4 and IL-13 use Stat6 (Kurata, Lee et 
al. 1999); having independent pathways with the same target gene may interact and enhance each 
other. IL-31 did not have a consistent effect of boosting expression of genes. Most commonly, IL-31 
worked in concert with IL-13 only and could not augment gene expression induced by IL-4 alone. 
Treatment with all three cytokines rarely induced the highest gene expression perhaps due to an 
oversaturation of signalling pathways. A preliminary experiment also demonstrated IL-31 could 
enhance the effect of TNFα at inducing genes from NHBE. This was investigated because of the 
result that IL-31 may be able to induce IL-33 and TNFα has been shown to induce IL-33 (Prefontaine, 
Lajoie-Kadoch et al. 2009). As mentioned earlier, IL-33 can induce Th2 cells independently of IL-4 
(Lloyd 2010) (Schmitz, Owyang et al. 2005) and can induce IL-31 from T-cells (Figure 4.4.1.3). 
Although it requires further optimisation, these data could provide a means to amplify the allergic 
reaction with IL-31 and IL-33 being induced by each other and IL-33 enhancing Th2 polarisation and 
IL-31 enhancing the effect of the Th2 cells. 
 
Figure 5.2.2.1 Positive feedback mechanism between IL-31 and IL-33 
Together, these data imply that IL-31 could have a role at enhancing the effects of other cytokines 
and indirectly promote inflammation 
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5.2.2.2 Future work 
All the work carried out on NHBE was performed on cells derived from one healthy donor. A 
comparison between the NHBE of healthy and atopic donors should be performed to identify any 
differences between the IL-31 responsiveness of different donors. As mentioned in the 
immunohistochemistry section, a wide range of tissues express IL-31 receptor, all the experiments 
that were performed with NHBE could be performed in parallel with alveolar epithelium, 
endothelium, smooth muscle or fibroblasts to compare the effects of IL-31.  
5.2.3 Microarray study of genes regulated by IL-31 
The investigation into genes regulated by IL-31 has so far been biased towards genes up-regulated in 
inflammation, particularly asthma. We decided to carry out a microarray analysis of NHBE treated 
with IL-31 and IL-31 containing T-cell supernatants for an unbiased search of genes regulated by IL-
31. As described in the results section there were two arms to this experiment; genes up-regulated 
by recombinant IL-31 compared to a media control and genes downregulated by a blocking antibody 
to IL-31 when NHBE were treated with supernatants containing IL-31. As shown in Figure 5.1.6.3, the 
Th2 supernatants were very potent and up-regulated many genes from the NHBE when compared to 
NHBE growth media alone. In particular, chemokines were among those genes with the greatest 
induction, highlighting the importance of the epithelial tissue in promoting inflammation driven by 
T-cells. IDO was the gene with the second highest induction and is also important for T-cell 
regulation via catabolism of the essential amino acid tryptophan (Mellor and Munn 2004). 
The original experiment design proposed that genes that were regulated in both arms of the 
experiment would be the genes that were specifically regulated by IL-31. However, we found that 
there were few genes that were identified in both groups and the ones that were had marginal gene 
expression changes in response to IL-31. The reasons for this disparity are unclear, although the 
genes induced by the Th2 supernatants may have been induced predominantly by factors in the 
supernatant other than IL-31 which was then slightly down regulated by the removal of IL-31. 
Although the two pairs of conditions were carried out in different media, with recombinant IL-31 
being added to NHBE growth media and both of the Th2 supernatant groups using T-cell clone 
media, this would not fully explain the difference in gene expression within the group. An isotype 
control was used in all of the conditions without antibody so results cannot be due to presence of 
immunoglobulin. 
We therefore decided to keep the two arms of the experiment separate and validate the top 5 genes 
from each comparison in addition to the genes that were present in both lists. A gene ontology (GO) 
analysis of the genes regulated by IL-31 revealed many different areas within the NHBE that could 
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respond to IL-31 with no obvious bias towards, for example, transcription factors or cytokine 
receptors. The GO analysis linked up each gene, wherever possible, by known regulatory networks 
and highlighted genes that may have only been slightly induced by IL-31 but that play a vital role by 
being a hub of regulation for the remaining genes. Our GO analysis identified ACTR2, WNK4, CACYBp 
and Sult1E1 (Figure 5.1.6.2) as hub genes in the network of genes regulated by IL-31. These genes 
have various functions; ACTR2 is involved with actin polymerization (Welch, Iwamatsu et al. 1997), 
WNK4 is an important regulator of sodium and potassium ion transport (Subramanya, Yang et al. 
2006), CACYBp is involved in ubiquitin mediated protein degradation of beta-catenin (Filipek, 
Jastrzebska et al. 2002) and Sult1E1 encodes an enzyme that modifies freshly synthesized hormones 
with sulphate groups (Weinshilboum, Otterness et al. 1997). Although not classic pro-inflammatory 
genes, these genes may be equally important for NHBE homeostasis. IL-31 had no effect in the 
migration assay; however, the induction of an actin regulating gene suggests that IL-31 could have a 
role promoting a healthy epithelial barrier. A number of keratins were also shown to be regulated by 
IL-31 which would support the idea that IL-31 can regulate the structure of the epithelium. Keratins 
are also markers of epithelial cell differentiation and IL-31 has been shown to interfere with correct 
epidermal differentiation (Cornelissen, Marquardt et al. 2012). The proteases MMP16 and AdamtS6 
which are used to cleave tight junctions between epithelial cells were regulated by IL-31 and help 
modify the epithelial cell monolayer to permit access of infiltrating immune cells.  
The approach to blocking certain cytokines within a biologically relevant supernatant was validated 
by including an experimental condition with anti-IL-13 plus Th2 cytokines as the effects of IL-13 on 
the epithelium are well documented. The classical gene family induced by IL-13 are the mucins 
(Whittaker, Niu et al. 2002) and the majority of the mucins were regulated by anti-IL-13 in the 
microarray albeit.  Previous experiments in house have shown that optimal mucin expression can be 
observed from fully differentiated confluent NHBE, therefore it is significant that we could detect 
differences from the subconfluent culture used for the microarray. Another set of genes known to 
be regulated by IL-13 is that of matrix-metalloproteases (Zheng, Zhu et al. 2000) and the microarray 
did identify MMP16 and MMP8. 
The microarray results were validated by RT-PCR on the samples that were used for the microarray. 
A caveat to these experiments is that the RNA samples had been shipped to and from Miltenyi  
Biotec in Germany. Although they were sent on dry ice and returned on dry ice, how long the 
samples were kept at deteriorating room temperature while at Miltenyi Biotec is unknown. This may 
be the reason that the gene expressions determined by the microarray were not always replicated 
by RT-PCR. There was high variance within the groups, even from the media control and 
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recombinant IL-31 replicates which were identical during the microarray, suggesting some 
degradation of samples occurred. The variance between Th2 supernatant groups was expected to 
some extent due to the varying concentrations of IL-31 from each T-cell clone but again, this 
variance had appeared to increase when compared with the microarray results. As a result, we were 
unable to fully validate the microarray analysis but some genes did follow the expression pattern 
predicted by the analysis albeit without statistical significance. FUT9, an enzyme for modifying 
proteins (Nishihara, Iwasaki et al. 1999) was specifically regulated by anti-IL-31, as was another 
enzyme WNK4. To investigate whether these genes played a role in allergy and asthma, another 
gene expression database was examined. The study, of children with allergic asthma or healthy non-
atopic, measured the relative mRNA expression from airway epithelial cells (AEC) by microarray 
(Kicic, Hallstrand et al. 2010). Although WNK4 and IL-31RA were not detected, FUT9 was significantly 
up-regulated by the AEC derived from children with allergic asthma (Figure 5.2.3.1) which we could 
postulate was part due to an increase in IL-31 in the tissue brought on by the allergic stimulation. 
 
Figure 5.2.3.1 Relative expression of FUT9 in airway epithelium from atopic asthma and healthy non-atopic children. Figure 
from the Gene Expression Omnibus (Geo) series GSE18965.  
 We analysed these samples for genes that are robustly induced by Th2 supernatants, CCL2, IL-8 and 
IL-6 and found that the expression of these genes was slightly depressed when compared to other 
experiments that used Th2 supernatants, in particular CCL2 which is usually induced by a factor of 
ten even by recombinant IL-31 was only induced 4 fold by the T-cell supernatants. CCL2 expression 
when measured by the microarray was very strongly induced by the Th2 supernatants which may 
confirm that the samples were in some way degraded. Overall, we were unable to show any 
significant gene expression from the samples used in the microarray. As an attempt to validate the 
microarray results again, we set up a repeat experiment with fresh IL-31 containing supernatants. 
FUT9
A
to
pi
c 
A
st
hm
a
H
ea
lth
y 
no
n-
at
op
ic
2.5
3.0
3.5
4.0 *** p=0.0009
S
in
g
le
 c
h
a
n
n
e
l 
tr
a
n
s
fo
rm
e
d
 c
o
u
n
t
202 
 
This time the CCL2 showed a characteristic strong expression which was uninhibited by either anti-
IL-31 or anti IL-31. The candidate genes AdamTs6 and FUT9 were also measured but did not show 
any regulation by IL-31 which weakens the microarray analysis somewhat. Further replicates of the 
microarray may reveal genes regulated by IL-31 with a greater statistical strength, but the costs of 
large scale studies are currently prohibitive. 
To summarise, the microarray experiment worked correctly but did not identify any standout genes 
that were strongly and specifically up-regulated by IL-31. This does not mean that IL-31 is not pro-
inflammatory but it is likely that genes associated with inflammation are induced by a number of 
factors which are able to compensate for each other if one is blocked. Those genes are very 
important so it makes sense to have a number of pathways to activate them. As shown in the 
preliminary studies, the microarray confirmed that recombinant IL-31 has little effect by itself. The 
IL-31 containing T-cell supernatants had a strong effect on NHBE gene expression suggesting that the 
Th2 cytokines may synergise to have the greatest effect. Another cytokine that has a greater effect 
in combination with other cytokines than alone is IL-22 which can amplify the effect of TNFα (Cavani, 
Pennino et al. 2012). These data support the observations in Figure 5.1.5.2 that IL-31 may have a 
more important function as an amplifier of gene expression induced by other cytokines than having 
a specific function itself. Whether this effect is restricted to amplifying Th2 induced genes is unclear 
but IL-31s dependence on IL-4 would suggest this is the most likely scenario.  
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6 Conclusions 
 
This thesis examined the potential role IL-31 may play in allergic airway disease and has identified a 
number of features of this cytokine that suggest it is a vital player in the immune response. Firstly, 
we have shown that IL-31 is strongly associated with allergen stimulation and is over-expressed by 
atopic PBMC compared to healthy non-allergic donors. Although not restricted to T-cells, IL-31 is 
produced in response to the IL-4 and IL-33, both cytokines that drive Th2 differentiation. However, 
we have shown that IL-31 is not restricted to Th2 cells and exogenous IL-4 can drive IL-31 expression 
from Th1 cells, without modifying the Th1 phenotype. This effect is temporary and we have shown 
that IL-31 requires a constant source of IL-4 in order to be expressed which may explain the previous 
association with Th2 cells. IL-31 is likely to be expressed at the site of allergen challenge where it 
could be induced by activated dendritic cells and epithelial cells producing IL-4 and IL-33. Also, IL-31 
positive clones potentially over-express CCR8 which is also linked with lung homing T-cells in asthma.   
The function of IL-31 was a little harder to elucidate but the results acquired so far suggest that IL-31 
acts in concert with the Th2 cytokines IL-4 and IL-13 and amplifies genes induced by them. Normal 
human bronchial epithelial cells are responsive to IL-31 alone and when combined with Th2 
cytokines can induce a number of chemokines, growth factors and cytokines that would strongly 
suggest that IL-31 is a pro-inflammatory role to play. Although IL-31 could not induce cell migration 
or proliferation, there was a suggestion that IL-31 could regulate genes involved with actin turnover 
and keratin synthesis implying that IL-31 may promote repair or maintenance of the epithelial layer.  
Interestingly, IL-31 was able to induce IL-33 from the epithelium which in turn can induce IL-31 from 
T-cells. This could be a positive feedback mechanism for maintaining and amplifying the allergic 
response. As a target for an asthma or allergic rhinitis drug, neutralising IL-31 may provide a means 
to minimise a chronic Th2 response without compromising T-cell immunity in other areas. 
Alternatively, a combination drug to block IL-4, IL-13 and IL-31 simultaneously could be the solution 
to stop Th2 driven inflammation in its tracks and allow lung tissue to recover and improve the quality 
of life of those suffering with allergic airway disease. 
This body of work has combined to prove the hypotheses set out in the start of the thesis. The first 
“IL-31 is a pro-allergic Th2 cytokine” is partly true. IL-31 is certainly closely linked to allergy and is 
highly expressed by allergic subjects in response to allergen stimulation but it cannot be considered 
a true Th2 cytokine. T-cell clone studies revealed that IL-31 was not restricted to Th2 clones and that 
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IL-31 could be more accurately described as an IL-4 dependent cytokine. The study suggested a new 
hypothesis, any cell that can respond to IL-4 can produce IL-31, and work is ongoing to prove this. 
The second hypothesis, “IL-31 affects the function of airway epithelium” was demonstrated but the 
results were not dramatic. Recombinant IL-31 had no obvious effect on the physical appearance of 
cells nor did it affect proliferation or migration. A genome-wide search for genes regulated 
specifically by IL-31 did not reveal a clear role for IL-31, with a few disparate enzymes, transcription 
factors and keratins with minimal fold change of expression being the result. However, the third 
hypothesis “IL-31 acts in concert with Th2 cytokines to induce airway inflammation” proved to be 
the primary role of IL-31. Alone, IL-31 has minimal effect on the gene expression of NHBE but is able 
to synergise with Th2 cytokines, particularly IL-13, to amplify the pro-inflammatory gene expression 
such as chemokines, cytokines and growth factors.  
A cytokine that could be dismissed if studied in isolation, this thesis has demonstrated that IL-31 can 
enhance an allergic response by promoting the effect of Th2 cytokines. The observation that IL-31 
expression is not restricted to Th2 cells but any T-cell responding to IL-4 proposes IL-31 as a means 
to positively regulate and maintain allergic inflammation. 
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8 Appendix 
8.1 Primer sequences 
Gene Forward Reverse 
Cytokines   
IL-4 5’-AACGGCTCGACAGGAACCT-3’ 5’-ACTCTGGTTGGCTTCCTTCCA-3’ 
IL-6 5’-GGTACATCCTCGACGGCATCT-3’ 5’-AGTGCCTCTTTGCTGCTTTCAC-
3’ 
IL-8 5’-
GAGTGATTGAGAGTGGACCACACT-3’ 
5’-
GCTCTCTTCCATCAGAAAGCTTTA
C-3’ 
IL-17 5′-CTCGATTTCACATGCCTTCA-3′ 5′-GAGGGGCCTTAATCTCCAAA-3′ 
IL-22 5’-GAGGAATGTGCAAAAGCTGA-3’ 5’-GCTTTGGGGCATCTAATTGT-3’ 
IL-31 5’GATGATGTACAGAAAATAGTCGAG
GAATT-3’ 
5’CTTCTCTTCCTCCACATCTTTCAA
A-3’ 
IL-33 5’-
AAAGATGAAAAGAAAGATAAGGTGT
TACTG -3’ 
5’- CACCGTCACCTGATTCATTTGA 
-3’ 
IFNγ 5’-
TCTCGAAACGATGAAATATACAAGTT
-3’ 
5’-
GTAACAGCCAAGAGAACCCAAAA-
3’ 
Housekeeping 
control genes 
  
EF1a 5’-CTGAACCATCCAGGCCAAAT-3’ 5’-GCCGTGTGGCAATCCAAT-3’ 
18s 5’- CAGCCACCCGAGATTGAGCA-3’ 5’-TAGTAGCGACGGGGGGTGTG-3’ 
Chemokines   
CXCL1 5’- CTTCCTCCTCCCTTCTGGTC – 3’ 5’- GAAAGCTTGCCTCAATCCTG -3’ 
217 
 
CCL2 5’- AGGTGACTGGGGCATTGAT -3’ 5’-GCCTCCAGCATGAAAGTCTC-3’ 
CCL5 5’-TGTACTCCCGAACCCATTTC -3’ 5’-TACACCAGTGGCAAGTGCTC -3’ 
CCL11 5’-AGTCCTGGACCCACTTCTGTGT-3’ AGGAGAATCACCAGTGGCAAAT-3 
CCL22 5’-TCCTTGCTGTGGCGCTTC-3’ 5’-
CAGACGGTAACGGACGTAATCA-3’ 
CCL17 5’-GCTTCTCTGCAGCACATCCA-3’ 5’-
GGAATGGCTCCCTTGAAGTACTC  
-3’ 
Microarray 
genes 
  
FUT9 5’-TGCATTATCCTGGGCGTTTC-3’ 5’- CCAGCTGTTGGTAGGTTTGATG-
3’ 
Glycogenin2 5’-CCACCTCAGCCTCCCAAAG-3’ 5’=TGGTGGCTAGTGTGACAAAAGC
-3’ 
LTF 5’- 
CCTGTAGCGGCGGAAGTCT-3’ 
5’-
ACAGCCACGGCATAATAGTGAGT-
3’ 
Sult1E1 5’-TTCCAGGCAAGACCAGATGAT-3’ 5’-
TCACTAACCCAGGTTGTACCAGAT
T-3’ 
TCF23 5’-CCGCTACTTGCACCCTCTCA-3’ 5’-CCCAGGCCTCCAGCATAGA -3’ 
CA5B 5’-CACCGTGGACAGCAAATGC -3’ 5’-GACTGCGTTCCAATGCACTAAG 
-3’ 
Cytohesin 4 5’-CTGCAACCCAGGCGTCTT -3’ 5’-
GATGATGGAGAAGGACAACACGT
A -3’ 
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EBF3 5’-GCTCCTGGGCGCTTTGT -3’ 5’-
GAAAGCCGTAATCTATGGTTGGTT 
-3’ 
TRPC6 5’-
GGGCACAATAAACAACCAAGTATAA
G -3’ 
5’-
CATTATTTTCTGATATTGTCTTGGA
GGAT-3’ 
VIP 5’-ACTTCGGCATGGCCTCTTTA -3’ 5’-
AAGGGTATTCTGTCACCCAACCT-
3’ 
ACTR2 5’-CCCAACCAAAAACAGAGAGAAGA-
3’ 
5’-
ATGGCTACATATACACCGGAAAAC
T-3’ 
ADAMTS6 5’-TGCCCTTCAACAACGACATC-3’ 5’-
CCACTTCTTGTGAAATCCGAAAC-
3’ 
CACYBP 5’-ACTGAGAATGTGCAGGTGCATT-3’ 5’-
CTCTTCCCATTTAGATTCTTTACCA
AA-3’ 
CYFIP2 5’-GAGTCGCAGAACCTTTCCATGT-3’ 5’-TGGTGGAGACACTGGGTGATC-
3’ 
GREB1L 5’-CAACTCCCATGTGGAACTAACG-3’ 5’-CATGACTGGGTTCGCTATGTGA-
3’ 
RTP1 5’-GCTGAGCCCTGGTTGGAA-3’ 5’-AGCAGTGGAACCTGCCTGAA-3’ 
WNK4 5’-CGTACTCCGAGTGCCAGAATG-3’ 5’-CGGCTTTCTGCCCGAAGT-3’ 
ZNF704 5’-TTCCCCATCCCAGATTCAAG-3’ 5’-
TCATCAACTTAGTCTCCGTTTTGG-
3’ 
Transcription 
factors 
  
AHR 5’-ACTCCACTTCAGCCA CCATC-3’ 5’-ATGGGACTCGGCACA ATAAA-3’ 
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ROR CT 5’-
CAGTCATGAGAACACAAATTGAAGT
G-3’ 
5’-
CAGGTGATAACCCCGTAGTGGAT-
3’ 
GATA3 5’-GCGGGCTCTATCACAAAATGA-3’ 5’-GCTCTCCTGGCTGCAGACAGC-3’ 
T-BET 5’-GATGCGCCAGGAAGTTTCAT-3’ 5’-GCACAATCATCTGGGTCACATT-
3’ 
GFI-1 5’-TACAAGTGCATCAAGTGCAGC-3’ 5’-TTGTGAAGCTTCTCACCAGTG-3’ 
IKAROS 5’-TCGTGCTGGACAGACTAGCAA-3’ 5’-AGCTGGCGCTGCTGTCGT-3’ 
FOXP3 5’-GAAACAGCACATTCCCAGAGTTC-
3’  
 
5’-ATGGCCCAGCGGATGAG-3’ 
Misc. epi. 
genes 
  
VEGF 5’-CACAGCATGGCTGCATTCAG-3’ 5’-GCGGATCAAACCTCACCAA-3’ 
TSLP 5’-TATGAGTGGGACCAAAAGTACCG-
3’ 
5’-GGGATTGAAGGTTAGGCTCTGG-
3’  
IL-31RA 5’-TGGAACTGTGGAGAGTCCTGAA-3’ 5’-CAACCGCACTGGCCTTCT-3’ 
